var title_f39_34_40480="1st incision simple vulvectomy";
var content_f39_34_40480=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Incisions for total vulvectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 242px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Clitoris to be removed and (B) clitoris to be spared.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_34_40480=[""].join("\n");
var outline_f39_34_40480=null;
var title_f39_34_40481="Acrodermatitis enteropathica";
var content_f39_34_40481=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Acrodermatitis enteropathica",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 224px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Acrodermatitis enteropathica in an infant. Moist erythematous plaques are present on the cheeks and buttocks. The buttock lesions are typically symmetric.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     (Panel A) Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"     <br/>",
"     (Panel B) Courtesy of Robert Sidbury, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_34_40481=[""].join("\n");
var outline_f39_34_40481=null;
var title_f39_34_40482="Vaginal transection";
var content_f39_34_40482=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transection of the vagina during hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 385px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With the ureters retracted laterally, the bladder is reflected inferiorly so that at least one-third to one-half of the vagina is visible anteriorly. The posterior rectal space is developed so that at least one-third to one-half of the vagina is visible posteriorly, the operative specimen is resected, and the cuff either closed or dealt with by running the edge.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_34_40482=[""].join("\n");
var outline_f39_34_40482=null;
var title_f39_34_40483="Terconazole: Patient drug information";
var content_f39_34_40483=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Terconazole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/15/26867?source=see_link\">",
"     see \"Terconazole: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F225766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Terazol&reg; 3;",
"     </li>",
"     <li>",
"      Terazol&reg; 7",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F225767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Terazol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692122",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat vaginal infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to terconazole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701537",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to any type of nuts or seeds, talk with your doctor. Some products have nuts in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696941",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug if you have belly pain, fever, or bad-smelling discharge. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect clothing and fabrics from staining.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698702",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If the yeast infection keeps coming back.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696196",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use suppository or cream vaginally.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11080 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-9EF4B3CCD6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_34_40483=[""].join("\n");
var outline_f39_34_40483=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225766\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225767\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018817\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018816\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018821\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018822\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018824\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018819\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018820\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018825\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018826\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/15/26867?source=related_link\">",
"      Terconazole: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_34_40484="Breech2";
var content_f39_34_40484=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Delivery of the lower limbs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 294px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEmAh0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKp6xqEGkaRfaleFhbWcD3EuwZOxFLHA7nANed2/xo0a5t4p7bw/4vmglUPHJHo0rK6kZBBHBBHegD1CivM/8AhcWl/wDQteM//BJLR/wuLS/+ha8Z/wDgkloA9MorzP8A4XFpf/QteM//AASS0f8AC4tL/wCha8Z/+CSWgD0yivM/+FxaX/0LXjP/AMEktH/C4tL/AOha8Z/+CSWgD0yivM/+FxaX/wBC14z/APBJLR/wuLS/+ha8Z/8AgkloA9MorzP/AIXFpf8A0LXjP/wSS0f8Li0v/oWvGf8A4JJaAPTKK8z/AOFxaX/0LXjP/wAEktH/AAuLS/8AoWvGf/gkloA9MorzP/hcWl/9C14z/wDBJLR/wuLS/wDoWvGf/gkloA9MorzP/hcWl/8AQteM/wDwSS0f8Li0v/oWvGf/AIJJaAPTKK8z/wCFxaX/ANC14z/8EktH/C4tL/6Frxn/AOCSWgD0yivM/wDhcWl/9C14z/8ABJLUN58bNDsrWW5vdB8XW9tEN0ksujyIiD1JPAFAHqVFeVD44eH2VWXRfFZVsbSNIkwcjIx9RzQPjh4fZlC6L4rJYblA0iTkeo9qAPVaK5TwB470nxzb30ujR3sX2KUQzJdwGJ1YruHB9q6ugAooooAKKKKACiisrxTrtn4Y8PX2tamZBZWcfmymNdzYzjgd+tAGrRXmS/GPSXUMnhzxkykZBGiSkEUv/C4tL/6Frxn/AOCSWgD0yivM/wDhcWl/9C14z/8ABJLR/wALi0v/AKFrxn/4JJaAPTKK8z/4XFpf/QteM/8AwSS0f8Li0v8A6Frxn/4JJaAPTKK8z/4XFpf/AELXjP8A8EktH/C4tL/6Frxn/wCCSWgD0yivM/8AhcWl/wDQteM//BJLR/wuLS/+ha8Z/wDgkloA9MorzP8A4XFpf/QteM//AASS0f8AC4tL/wCha8Z/+CSWgD0yivM/+FxaX/0LXjP/AMEktH/C4tL/AOha8Z/+CSWgD0yivM/+FxaX/wBC14z/APBJLR/wuLS/+ha8Z/8AgkloA9MorzP/AIXFpf8A0LXjP/wSS0f8Li0v/oWvGf8A4JJaAPTKK8z/AOFxaX/0LXjP/wAEktH/AAuLS/8AoWvGf/gkloA9MorzP/hcWl/9C14z/wDBJLUN18bNDtBEbrQfF0IlkEUfmaPIu9z0UZ6k9h1oA9Sory8/GjRRJsPh/wAX78E7f7GlzwcHj610PgTx/pPjW51K20y31K2uNO8s3EV9amB18zdt4PP8JoA6+iiigAooooAKKKKACiiigAooooAKKKKAOb+Jf/JOPFX/AGCbv/0S1R/Cz/kmXhL/ALBFp/6JWpPiX/yTjxV/2Cbv/wBEtWb4LlvoPgtoUukQfadRTQIGtodyr5kot12LliAMnHU4oA6jSdW0/WIJZtKvbe8iilaB3gcOFkXhlJHcelXq8m+A3g7xD4FTVtL1qKBrG5S3vIpoJAV+0GPZOrAktuOxGJxtJY49K9ZoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiimyOkUbSSMqRqCzMxwAB1JNAEOo31rpthcXuoTx29pboZJZZGwqKBkkmvFnuZPipdQ6vqcckHhC0fztO0ubMbaiw4W4mPQJkHYh69W4p2rarH8TtZjEkkf8Awg9pPthtmJzrEynPmMOvkKQSo/jIyeOnQQJbWltaPI5JZWRZA2CBnAwzANtAHTABCjGQDTQ0ia5nneE7JFMqTiV2iYbQV4weCxHIHPPT05dawXQLxXKRz7VB24LuwGe+OcZODgck+lVrlEm06S2RJpY2jIk82YliSMKV2gsSOOnTjkmqkNhDHDjz5VkcB5JRI27jLcAZO0A47AbVx1xSGP8Agozv4r+JDSkmQ6tHuyMHPkLXrFeQ/AmB7bxH8RYZcb01aMHg/wDPFfXn8+fr1r16gkKKKKACiiigArz/AOP3/JGvFn/Xkf8A0IV6BXn/AMfv+SNeLP8AryP/AKEKAOwsriG08PwXN1KsUENqskkjnARQmSSfQCo/D3iHR/Elo91oGp2eo26P5byW0qyBWxnBx0OCKoa1Zz6j8Or+ys4/MurnSpIYkyBudoSFGTwOSOtcd8BvDGueG7LV/wC3rSe1+0m18tLqaGaYtHbpG5LxEjZlQEBOQB70AeqUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRXP8AjLxTa+GLGJ5IpbzUbpjFY6fBzNdSYztUdgOrMeFHJoAPGXim08L2EMs8U13fXUnkWVhbgGa6lPRVHoOpY8KOTXnelWt9qOuXGt+LJEuNctoy0FrDcD7NpsbcFY+mZMH5pOSeg+U4MGgWFze6veav4ruvtusXUJjKQRtttYTnEUI4JQN94j5nOCeOKv30NrdQSpFBKx87nyfMDNwAApDAvj5jjofXnkQG2l3c25gQn7M5dQJEdpwmeQpVSMhiDzwM4+lc98HoJLb4pfESKbdvEWmHLdSDFIQT74NX1sJbm73i3dArHYQxjLsDkAg4JALH2IKYPNZ3waZm+J/xD3o8bCHS12OMFcQvx1PFID2SiiimAUUUUAFFFFABRRRQAUUUUAFFFFAHN/Ev/knHir/sE3f/AKJao/hZ/wAky8Jf9gi0/wDRK1J8S/8AknHir/sE3f8A6Jao/hZ/yTLwl/2CLT/0StAHUUUUUAFFVtR1Cz022e51G7t7S3QbmlnkCKo9STxXJj4laBcDOkpq2rrnHmadps80ZPtIE2H8DQB2tFee3Xxe8MadeLba4NV0iZhuC3unyrx6kqGx+OKvp8UfA7ED/hKNKXIzl5wo/M0AdnRXO6b448KapMIdO8S6LdTE4EcV9GzE/QNmuhUhgCpBB6EUALRRRQAUUUUAFFFFABRRRQAV414r1Wf4k6pJomkzSReEbeQrd3UZK/2rIh+eCNh/yxXgO4OWJ2r3NT+PPEN94rnutE8OzvDoUJaLUL63YiW5dc77eFv4VGMPJ6naOd2Hwy3WmTQpBoq6fZiNLdA9tGDGm1Sq7lb5VwMAY6igZoxWlxZW0FvbxxwafvRBFGgwjcbQqggFMYABHAXB5ps1pLfOjC5t3O8FtxCFssSuQSfnB3c9GGO+axlulSVZYbSFXX96ZnAJaM43qMM2Sdp98MvTANXYGuZEVHht/sqjyxHJGI2BB24ADFQrZyMn+L2NMCK5tZQQyNMxg4R4JCSvXJAByeTjAPXPTNaUBuiZxDeKXVCIxIhZwDnBIY54IwemD0wBWDPsfRJ0k0uUWYkBw2Hyd2Dt+Y7SG9PQd6qxCEOX+wW037rCJEmRCASN2xicE47Buh6Ak0Bc1fgTn/hIviICqjGqxfdYsP8AUL68/h26dq9eryT4HLs8SfEJSVONThHy9B/o6ccdfr3r1ukIKKKKACiiigArz/4/f8ka8Wf9eR/9CFegV5/8fv8AkjXiz/ryP/oQoA7XR/8AkE2X/XBP/QRVuqmj/wDIJsv+uCf+girdABRRRQAUVl614h0fQ0DavqdpZ55CzShWP0HU1m2Hj3wpfzeVba/pzSHorTBM/TdjNAHTUUisGUMpBB5BHeloAKKKKACiiigAooooAKKKKACiiud8aeKrbwxYxFonu9Rum8qysYj+8nf/ANlQdWc8KPwBAG+OPFtp4V09HdRc6jckpZ2SyBGnYdSSeFRRyznhR+APDaXp179qufEHiDUI7rVLyAJ51u+2G1jO1kSHdhkTJ5JBZmUMewFfTLa7/tG91PW5LXVNTvUCPJImyNQh/wBVCpztiXIIGd7tktjGBowSOLiR3t7ZIdu+3MRBJ+b7jd15Hrjj0GKALNtNLcXlvM0k0MjBo4Xc7mc8lSRuOGwSvPf1GKq6hZ3zzxorrHE0xkJhVdzqOpAJ5JDAgen0qe1eU3b+dbQlo1CxPDGTlmGPmYgKThvqOep5qyuy5tXkktIluMgfI8vDqd3zHGO3UAdMH0pDKk7qkTLPcQ2cg8x3CyebxjduJOSv3mAHH41mfB1t/wAVPiPJujYummktGm1SfKkBIG5uDjPXvWzKtzeTTW9mYXhWUq7MDEWRxy28Id2MgZ7kYPrWT8IUMXxT+IaGMIFg0sKBjG3yZMdOOmOnFAj2CiiimAUUUUAFFFFABRRRQAUUUUAFFFFAHN/Ev/knPir/ALBV3/6JavOvAnxIZPAXhyw0Dw5qup3FtptrDLPOBZWqOIlGPNlwWGQeVVhxmvRviX/yTnxV/wBgq7/9EtXAfDd7h/h/4eaQMziwtFjBmJCnylAJOAUBHHAI5PvQBcudT8bXod77XNF0GAAnydOtmu5uATgTS4TJAJ+4eOmay20e2ubsW2seI/E+qTS7WZDqr26DdkAAQBF9B6dfUVts0FkXvNUC2SmLbPcu6CMsMLkGQgc/QnBrJsfE+gJfwm21Vb1oQq7dLtZbw4G4/wDLNCOSwzjjjpxwDILTw94RtbFbmPRNNOCoW6ujDNI/OCd0hfk5UdgC3XtW7b3Ny4kDXXnrK++Imb5c7yMcHHO37qjIHqelCLWbdLqM2nh7xeRHlmI0mSMtg8DDMvy89O+B1pYtUuIo0kTwt4mdYzks9rGmOeW2mUckEjPYAdMZoAvyahqUCtJLqPlIkhyCxyT90Bs/dBCMQc4JOOvBfFrcsq+X9tbz3CpHbiYEFgMnAYZ6D/6xOaxf7Qt7ffM/hjxBJ5hAmeGCEmQBcfdRznjd+XbJqyNasnVVex1qCIKFIutGulAOAM4SM8dehHXvQBNr1voOszvDqWlaHcysgAF3DEwLbiN2QMnPHftjByDWHH4P8I29yv8AZ73Og3IOzztD1SWFQeDjbvKnqOAp7fhck8Q6CJHePWtNhuZAC0Ms7WxJyecSAfN90kHp79DcuFmXTg1gjzxhUdWt2SURe+4LzwGJz03Z9KAKK2fi/TGf/hHPiH9sVc4t/EFikqFhnKm4jwQeOnWr1t8UNe0fcnjXwdeLHHjff6FIL6ADuzIDvjA9wTVmQm3uZ2b5XZfNcZ+Qyc73HXgY+7xg4I75igv57a4kP2NYpgBG8gOEJUYPKqTjvnAzgDHQAA7nwr4v0DxZafaPD2rWt8mMskb/ALxPZkPzKfYgVu14f4h8KeGtbuIru8gisdU2gw3+m3HkXKyE8/OMFsZ3bmB4H4Vp6Z4p8V+EgkGtQy+LtIXAF/Yw7L6JfmwZIc4lGEPzIQeMkHNAj12isrwz4h0rxPpUeo6HexXdo/G5OGQ91ZTyrDuCAa0bieK1gknuZY4YI1LvJIwVVUdSSeAKAJK8r8W+JZfFMtxpWg3n2fRInMN7fQtiW7YfehtzkfKMYeUdM4XnJWvrOuTfEJ1tNPeW18JHJlk+aObVVGMKmMFLc55bIL4wMA5OrbLb29tHb2McUNqI1CRuVUKoGNuBwqgDgjtxxg0DRm29ra6bZLY2kdpa2UcQKJuKqm1SGCjoAAfXHXoRSzXsDXP2Y+fvbCnzUVlQE46KwwAVUFmyMAd84V4ZbzynmWU8FHO5CvIDH5iAcDnjpyOtWLqUySSwiQDbuZAJSY88MA7YJ52tkkED8sgzMt3tZBCY54XCeYxmYLkAYwBgKhwBkEjPUVK8iv4f2xXOEldUB8jzSCR82DhucYHTC4Poasie5CxWltcqkrFtsfms8ZwR1O05HboMZx3FKHu986ywwM0zGQGWRkEgG48/KeQArZzjlgQOMsRnM8DRxRWU2yFWfaVKx/ICCHJIHOVUEcZwuR0xbs2tWWNbi6WN8mOFdixK/PQ8lf4mzgjqeuKiibyLTzvs6RsIg4myyDshDAjsoyuW6H8Ro2UrXEDNbfLGFWEfZuSpDYO4AcADnPpu9sICn8EijeKPiMYc+V/asWzJz8vkJjn6f5PWvWa8o+Cu4+KviLvADf2pD0XaP+PdMYHavV6BBRRRQAUUUUAFef8Ax+/5I14s/wCvI/8AoQr0CvP/AI/f8ka8Wf8AXkf/AEIUAW3+IPhbR7WysrnWIJtQ8hB9jsw1zPnaOPLjDMPxFVZfG2u3uP7E8I3UaMQFm1edbUdCc+Wgkk7dCFrG8PWVhp2l2dho0Flp8hgiyLSPydzkA7mAHzZA65P5E1dmkuZLlxHPbwyGUANG3cHktntwwzx0HryDsVrq78YXMLXGo+JINKhOMQaVpRkcKRnJeXdz/wAA/CoLjRYL9XTUNW8XanGFw4N88SbzyysIFQcAN7Z4rWisb24uHnZpPJ+6xQJ5MmA524zgDkc/SqFzrOi6ZcObzXdLtmZ8vHPeoHVg3HyhuuTkdjj06g7DdJ0TQPCwF7pmgw2t1JkNcBHEhPzdXyzEkZxn+tW9QsdO1uwB1bTLXUUVwVSeHzd2VUAOrjHbqMfd+tUNL17RIFRINaiuI43xElvbSTbSRk42I3f8MH1FOl1rT5Ji73OptbyvsTfpN1HjphdwiGOePbJ+lAaBpnhXwvDJJDbaK9ohHENpNLBg9gDG4B6HJHSli0KB4C2n6h4r06WM4kRNVmcIemEWUurD734igapoNrHKJfEcMFywyZLlWtSeDyUcAZAPXGcnPFaYdNQhTytV0+48tPLd7ZllB6jcOTwAefU+lAbmVat4w0+MPp3iv7ZCgwsGvaYMsdxGPNhKNnp1U9a1NP8AHmt22xPEXhO5G44E+j3CXiMOTu8v5ZQMKTjaTway0hZpVS2uIoJra6aeRGkBI2tj51IzlgAe4BCnPrAtv5Kkw34itfvRmQpvQDIxuPzAjJyM4GDzzwCZ6J4b8WaF4lVjoupQXMif6yHJSWP/AHo2wy/iK3K8p1LTNP8AEIgfV7eG5SJQFZGWKW3KjmQTgh0wegBHvgVXS48UeGkjm0PWj4gtCzA6brRCzHHOIrlRnOMf6xSCe47AWPXqK4zwj8RNJ8QXY025iutG10A7tN1KPypWwcExn7sgz3Un3Ars6BBRRXOeNPFdt4atYUEf2vVbsmOysEcK87dyT/Ci9Wc8KPfAIBJ4w8SweHLKMiJrvUrkslnYxsFe4cDJ5PCoo5Zzwo59AfKpkuy9xqet+ZfatOQJbmBGZERSHEEQxgRAjjOd5O5uRgaGlQi8vL7WNW1FbvVJUEE0xiRYYRnPlRZO5IhwcD5mIJfsBa124Mh8wTwqhlym1kIcFtu7oPXbjP4cUBYdbPA8aw3PnpJHK+1Y2DRKuc85OB8wzwQOe3SnPN9njjEhhgSZl8l5JfmY7TwWU53YPHJxtOTVeC8itVM7BhGDtjLygL8nIPGDyEHGOuc+164jUxmO4mj3ylnUEfvA4VV+Q7s5IGR344zjNIZLjzp1jH2n7RFG0qs0hYP/AA5IVyTn5+h6dR6Vrcl79nVZvPjznzY9gWPd8oAY5PRQOoJGD60s80rzqUkmS6jzIuyQJIFABPAyDwzkcc45zUkEUDrBFDPEsjMWXeQk0YOcA84PJxuGOTg4zigRLeB7m2WScNFYmJnUK7ibp82VDLuGQTznrxWR8IQF+K/xJUGTITTMrIcsh8l/lPJ6Vv30Z89riOW1tJEw8n2cKxdsg7T3zjI/A+grD+E7I/xb+JTR/cMemEH1/cvz1PfNMD16iiigAooooAKKKKACiiigAooooAKKKKAOc+JX/JOfFX/YKu//AES1eVfD6DUb/wCHmiRXetCxslsICkGng+eyhFxmeQMQeW+VFGMgBsYr1X4lf8k58Vf9gq7/APRLV5v4DCz+BfC/mtcrJBplu3mIzbY28tdu4K4JyMcdeO2aaAuRaLolrJNdtolveXsbszXt3LJcSEEHlZCzODhWJHHTt1rUmvbkPasd0vzlo5leUKYiu4/LGSD/AAgBsHJx6ZQW4it0tI9ymIFmVJRsLHgMx9CuDs9wO2TXs87ZD9mCui/6tmKmQFPlHTHAA4GBz0zSHYsWMVz9rIYrNLbvnzHuHCklW5ZcYIG4nByeR0xVAzxWhecpKluGEpQlkAQLk4VjgA5PJ54A4q39iaa4tjbR5DM2638wI0oAx0JHzEZ9/lB46CppUAktZUkjLMhEWyVgN2FB2hgdo+Xjn09ySAPN+WnuILSO2KzOVkmDOiDGDuIzwdu89icY55qaCb+z7hJIJFzOzQnIl2hsjCE5xxlhkf1xVOTUWt/tCvH5U6qzeXEwYAEL0IbBLEY4+nGaebPMaytMRAQn7tTkBgwc/NnBHy4z2688CgCS/uJxp7RRLFIr7iyXDSMgUHHmfOfm456jOR2rKfRvDVxEZE8OaXC6MiCZYWtZS7ccMhBHOPU9/etgWTKk88sRuliKl5biQIh4YbmHGOGxyfQ9qyE1zw9cwRppd02oSRJtP9j2cl0o4fOWQFP4icF+/bigCaTSHdZbfStYuRHFKTPDfbb9FUdsSAyZIyMB/wCGoLrUNbtbOOTVdBW5gGQ1zpbyeZwVBD27Mr4x8pwXPSiHUGNuWufD3iZW8z5nbSTLt68ALKSowxwOucc4q3Y+MrCG6+yPqlpaXIAZYdWhezk3gHkJLtDc8ZU9vxIBa0+/0/VLObUNO1C3vIQwBW3WVioY4ZMA43MQfvDIzg461ftrqeygNvJFbxZhwDDblUBzhVYH9O/Tgk1gX/hiz1jVIdS0+UaLqhCOuo6ZuSSYEjiRSAsgORw6txgEjJNV7XxHJpdzFb+MzZ2rXE2Y9RSLbaXxAx8znIhfp8rDB3ZUngAAtav4UuG1mPxB4J1WPQtbkT95JNEXhvFBA2XIB2k5/iGWFc9oGp3HjDWZLH4n6iINatXEkOg+UYrF4/4bhRkm49csSF/u967h03MvmG2ZUViq+U7ZZlVsgkZH4j+7xxWd4v8ADul+NrL7NdNPZ3cEmbO4tyUlt5VHMiseRnnIGc7RzkHDA35by2gkkigaL7PLGD5g4iPf5WwAeg7gcVn5s2nMUpeQpIWYhchm7gAkYwAOAOv0rmPC3ie/s9dl8L+NPsn9oi3L2lzEgWLUogSDMo5xIACGTjABI44rqNSSee+ZGj8wtGAxiiEnfOOvcE5OO30pAR/uWtpEhgljKP5eGtmUgdjg/e4+UkZPK9OavzXFubeZ5GDrGAJAXZNqBu4bGCD17g8Y4wKUNm8bNOI4YC2QVWEpI4wfmIzg/dHTrgduDLfKLqCRERLiGRQjtPErbxnk7TjdjI4J9D1OSDIjYxLZ23kRSCcA7IYR5buW3MWwuGI+8Npx1yecVntcWhh8nUcyTZ8xRJvkYfe2kKBngnBGDnYwI441VikuII5ZwyeYrfvXsy4jGWyQQQQDhcAE5Hs1MuFktIFK+XFsYboWUqUbgfxEqOC2MYX5sZ6UAZ9lEnlsYhLK87bD5LhMZXJJGSAAGUgbcdOR0Nuw1IWk0wit544bqPcHlXEZcDACg4HbJPGCfYVVvEjWLzpJ4J1kQBd0YJMhYjKsG+XBAPI5xz1wZ9ODPEZbiZlG9GCNnCoqjJDbuSpzyuPpwaBCfBSR5vFXxGkkVFZtViJCEkD9wnrXrFeUfBYOviz4kLK6yMNWjG9RgMPIXB49sV6vQIKKKKACiiigArz/AOP3/JGvFn/Xkf5ivQK8/wDj9/yRrxZ/15H/ANCFAGNZ3t5caVYx2vhmSECBVjm1OdbdcgKTtRAzkfL/ABBck8Y7PuYNenSUprmnxbCS8GlWyq+4c7fMl39TwTgY64o0ixhaxiSKa+dGij3NO8pLbgcbVJOcbSNwxgZqxbtHarbxwQyhZ8sFEz7guQGBBzt5wcDpk9M4IUZl/wCG/D0ahtaspdTcAOst7cS3BRienlH90OA33RjjpzW7aW8mktImladb28BdHiS0gWNWC8MOAoHUEfN/D060ya3jtlVMTvA5ZWiUl8hm4+ZW3D5jjIGOT0AAqg1iXkEMwvTExyqyynDsGPyK2Mg5KDGeQeny8gF+C41BFQRkiL5w0bRkOmevOeG+XPpk5B7CwbmVoFKTyKkcm8wsSwcDBKlu+QM4x1B9aqxiN7lWaGXyZ4WBkBkwMvlV8wEYwVOQTz9AaablLoPNEkyyIPPaSQvtMZO44wwGckA5/HryAakl7dtaOPOjOAyskg+QfL1OBk8E9M8CueuLLR55IjqWn6TPdMF3nyNjpyPmWTZuztz/ABHnAFXXEUESx7bu2VJHiACfOTsbOMnB49uoHI5xAB5uoNNJpsscR+YsFPnEZADBRgA43ZI5zz0GSAU73R1QNc6dqGo2aQSHAMouUQqQq4WcEgEY+664yKrwy6hZ28gl0mw1GzdT8+nMLeQEnI3RysVJBYn/AFg59atyLthjmlgmEYeNvlaUYU5BLYfOQCuRx1HPpFbwRWltBCbm+mb5lR5A6qMPtCs2cgZ6c9T3oEWbHV7fUnawjKRXr/KbW7T7PK4wwYFGUBh2JXPPfni9Eb6NvIuY4Gto1UoI3IjJwSxH7vGPu/jxUepT6ffaaset6dFqVrGVKCQF1XPUq3UPtKnj+97VkQ6ZqNrBLLYSXd5FhAbDVJnZXU4H7uVfmGf9reufQ9ADR1zRNO13TorTVbeC4iEn+qLmMLJyARIBuRlYH5lxjA6AGqmj674j8GW+bxNR8TeGUbaJypfULUdyflHnoMHJwHGDwwxViz1C0vZzFuurPUULNd20rPHIE3MCQAcOpIbDpuBPfk1bh+0RGSS2WaRgoLotw6PkYAPLlQMjkYyc85zyDGr8R9Q8R2KzeBtCuJbWQZGq6kBFbKMjJVAfMkPthfqKqWOj+VNJfXjTX+qXORcXVxKUknVGyqqowsaA7tqg4BwTuzurJ1vSLjTLmXWfBv8Ao97dZa+sZVYWd/gDer7RkS4yQ6jP94EdLfh/WdO1+Ga3lhn02eKXbc2FwWE1u38Ktk7sEfddeDjjpQI3bi1WZxGGeVPmy8bGYh2JVhhgRjDKQCf7oPHWIExzTpK80SwyZWQDMeVwAcgcDnHHTDdagl06T7MbFBNGty4XiRgD8oGNw6nkn0GM+wbNKlxfPp4huZW8sS+bFE6DDNt5OCASo6+nTjkoCyXngWLzPssNxsZIcSl0c+Z8rYb0BOcjPB61HcCdEEsSxHPzCVGdRjGeTt6nCgjPA6Uy8hWSONGXz5ZGA5GxWyCFBxyxAOOvX15qNmjWNXuEZCEbKTnyyxA5AXIySckFj1XtngAstaSGbfdLE3mKn7kTOgwAOmCQSMY5AyPQUgso4ZYJruO3CrLslMch8tFLH14yflBzjls9cUy8+yjEy6ffJcRqU8nAUudvHyhuRnGD7Y9KlsJ/MukuYtOkhXeYxu3MyBhtzs3HIDqvIGPfgksDTvJHW/DxGCGV1d0EqkDaygh9uAGI2NkdeR9a5v4UJ5fxa+JCeaZsR6YN5csT+6k7mt6R7eORZmiuHkZW3RurA7VIAZc84BJGAOjfTOD8JlgX4q/EIWqPHD5Gl7UcEEfupMj86QHrtFFFMQUUUUAFFFFABRRRQAUUUUAFFFFAHN/Ev/knPir/ALBV3/6JavPfh1GP+EJ8OBoIvsi6ZbSsjZ3sREvPXAORwTjAOcHrXofxK/5Jz4q/7BV3/wCiWrzr4ZuE8CeHGW5diNOtQTvBJOwDysZGMBg3XuKAN+fScgqRLaSMzALCuDktjPynGTjqepxThbxvFEn2V5TCpTy2w6nrgSKzDPt0OfzqWJIcm7a5tzC+BJmUDeBhTg7uo9OTkDkg1UumLkfaNQnSONnKXG/aqAOCA2Fx0IAPA4IB9QY2OHTXgW1+yxyoY0QOw27T/C3LAjg9evByahYxQN5sNjdpZxbC+Y1JjZdiZCjlWAUcYPC/m2UyTeSgvRGVMZRogI2fk8OXBHrkgLxkYANWbSFLaSK3ickRZbcQu2Taw3/IBkZBUhhwDn2FAFXT7ITX5WRo1hs97fajJnYRtDbssxJ+Yccd84zVPUPEBtdWNloOni+1VYkkYSv5EUG7YA8hIZkUnYAgXcxAwMZNVfFGrXUd/wD2LoNzPNfSBvNuXIY28eSpZ1bBLOQyouQCwJPyitDwzptrp3meTet5shMp83DvM7D5nkPJds8FhjGeAAAAAVtP8IWmo3z3viowa9qTqriMqqWqdeRAjEEjJ+aTcxKnkdulbFhaRmS0kt5CRDtRlIjRtwUjtwXB25xyfTFV57mysdkFqxa5QCcnawhViG5Leo5GAc45xis6Sea8mZWa5kDykERybUKkBhkgAtt34OcenBFAGr5d0ivKZL1TIQgKFYzkNj0xnIGexySD0w11ln0uBby1a6twd7wzLHJEFbsQzf7TLnGMgduuW8s8MjRwrsHERBUhiME8sMFjwMnO3IHOc5ZLcXQcLDcTsjJtWMsreUwyo5IO0jC9QeR1w2aAGx6G1uhm8KTvYy26Cd9Mc+fasSvaMkbCcAYiI68g9Kvadq9teCfStb0UW+omFo5oJJI5InC8uYzJw685xjd6qBg0abNvha0vBKSrMRIygiQ7jyHJPqM54O4Yz1q5rVlb39k1hqtwstsyqYFTIdJM7g6suCGBU4deQPrigDmGEfgfUIINQEl14eZy0QKb5rV8j/VAbmkgwNxABaMdMqAB0NqNOvGhu7AmWO5dZElikDqB3O8eo5Hb5gcjOa42+1C/svE/hvTNee4N1M81rY6gp2xzrIiyICyqNsqvEgIIG7IZe4HVeHJ0LtazeZpk9pdTQy4kDqXOTlRtB2su2QYwOcnvQAzxH4VtPF1jPDc2VxbTNKJI7pXXz7WcNgOj7shgx+7gAjI71meAtbvJ7y48OeJrCCHxBYW+6W4hULFcwKeJo+g2kn5gMAN1xuAHQ308f2m6ilu7zzIsCZre2mlSEqSwZisZG/lThjyAOgJzg+I9GtdWt477Tr+IXqyGezvBIhWKTGDvUDLRsoKyKOD1wCuQAbepWSzxCGSF7eB3AdUSNlKYJ3DGeCSeMZzgdKTylYysunOIgwZmlwqucfMAmeAAO+e3HWszw7qg8Qae5u3kttqlLmyldRJBMvEiKUCZA+VlYk5G1q1ndrqwWKG8K8hijtsCcfMd3GAcjg9sg4zQMmMlvbQ2yQ2czs8KOsccY++MbiwJwo56cD096eqWv2yTNpDc7lcpsLAh8Ngg9M569e2fXLDtUwSXcktw4RI9+5YxnKkMpIIPUc9Pz5tSRwHLR3dzbSklEEkasoXd1YgevfPVh7AADGih8wQXtsFMjKAxywU7S2TgHk7V3HOM854qUQxSpc/arFBJmPc7svznHUMVJz0z0GTjGRVS4sZPMt7hbu5CRYKus4KI/JZQWPJ+6enQHp3SFAryT3mo3zXJQSbYcKF2jAZyCQc5I6+vtgAi+CQI8UfEYvnedViZsrtOTApPHbk16zXlXwaKt4w+JJRtwOrRc8Y/1C9Mdq9VoJCiiigAooooAK8/+P3/ACRrxZ/15H/0IV6BXn/x+/5I14s/68j/ADFAFTSriKTR7B5ZVmtZ7aMQ7iAEIQ/xjnjj1/UmpfMguLRlknURhNmGZSYywxggKeSQ3GO2Kl0d5VsLKeQSovkorb5AMgR4GduSxyfwGetLLeSiQTMGiV0kYAP94KAc8jnOX6kY9KChloSJoxPNuEjkwrK4Xy0D4bAxtyewAB6expmpW7RQz+TMYW2q8LLhCucDGGwDx175TJFPRpUMqTJaiYnzT5T+aS5ZQFzsGQO/ORx0HSO8nCRqyJ5wilMbKRhnygGZMkKcgdORx14IoAX90scMUVu0rxjy0Kxg+YSd/IzkA/KfT5selNWzEZWX7QByA5Xq2Qc+YmCQB0z659ant55DE7KUXyvnkYMGwoAIc7cFSR2556jkVIkTxWZldTDFsLLH5rkg5Lkh+SRhye3TGKBg1vbTCSXzRcW6b9yIS2FbBb5l5zlWbt1PGcVkeIdY0zSJnGqasIXkVPKgBkaRgpUnZGmXbIHBHHPJqjq3ifVdV1N9G8LxR2rxFRdajMvmxWm5B8ix8B5tpBKkBVyC3JAqxoOl2nhtLya3iWW/vCxu7i7lJuJuoBkcZO4jOAcKOAAM4AIr22oai1msll4b1KRUJlim1K7trEEZ3ZC7mZRyeqZwagXU/E0cH2aXwlZbiNu+2122d/vEltkkarnI+nFb91K13BMzBfLiUrK3mMxTaVyiqAQynaevPp1BpY5ruW2KK2IlmMUQLP8AOqEjGCvAzj145yKBHN6p4yjs4w2uWPiDS2QuwuLu3SWANjGfNiLoB2y2FGckenS24t9UsorrStTsb6Fgp823Ecw2nBYbhk+mBkHg98ZWDU9Rjjee4tpX8ovuhjkAjkG3Jydg4zkd889TWPqXgzQtVm/tXTFPh3WZBn7RosqpuOT/AKz5dkisMEhlP165AL/iKzsNaslN5NLHLasZ4J7V0Z4nII8wFeVAwuex3AEEcVUsrrULKfbq92XW7AW1vjAiwOzMSIpAB8j8gZJ2kEYwSFrPl1vxR4PjjHjTT4tR0gEIusWK+WIUxjdPCuWTjB3rkDjIFReL4oPFGo+HxJPNd+HLq6ljlCTKYrzfAWgcsp27dytjPRsdxQB0svm+bLtlkiCyFdhCKoAO/wCXnkHK89sAc8k53jDw7bagtrd201vYeJbcFbbUHZWRhuw0ciHIkjI5x1GMghus2m6fdWItbO4u7zVwqOEnuwBKFJygZ1BDbQGBYkZwOpINW47xNIligu9Ult5d5ZIkTzmdQqqTsRTheB8xPUkcYwQZz/h/XhrUc+heJootO1uxP76F3+QRSABZIm5EkTseD2O1SBXU35kiuI4l1BUupERo1VQCOR8uSMYLZGMDhu3GOd13S4fFljb6jpT2tvqVi7vaX0a5WNjjfC6dTGcnchzxlhzipvDuvfaIbq2uYf7N1i1nFvPZspkMUhXIYttw8bASMjc7gx6EcAjdsLJNOkeziSTgoHkdBhupXLYOeD1wOh9MU8h1vZy98rIsp8yN0RomYnGBkkjuT2GOw4qC7tLoBY/OXJZWjSaQbY8sSNqgA9FB6ZGODycWF+0zWsibo1YqVXceHAOT1GQv3uNvPtmkAwQQJfXC2TxLDGuyZFhDIRyp6DKnhh1IwelLI8ypb3BvLcByziK4KqULAbVXHygbwec9xzUl2bl2iaErPiPZiKZkYow2t84Bycr69QOnWr8TCArFDLM/7xothlPmFix+Y4+mM5HHWgCGeUxo6MPki/dHzSiq2AOgHTIJI6dvauU+FLFvi18Rw8hlkSLS1dyAMnyX7DgfhXT2rTrOphX7PFHGwlkMnzAZUnA2kkke4wR36Vzvwyz/AMLg+JBeRZXaHSyzqAAx8l8nimI9YooooAKKKKACiiigAooooAKKKKACiiigDnPiX/yTnxV/2Crv/wBEtXn/AMNheP4F8PobYW0CadbksWR0f9xgFuhAIKkr/wDXrv8A4l/8k58Vf9gq7/8ARLVw/gYTWvw28IETymKbTYGdpCcpiNcYbGV5wo5wMjg80AbcVzPMsqu8AuIyEjJC/eYsN3GNoGD1HOT61BfJdwxyC3gZcJ5G44RGBU7eg3YBA4HTdnpjA16qac6tHLsEnlnJ3Z3DqGVWbLD+9g/N3xUM9zb2UUa+VcyQSRbmRYyA+1dxyAM/dXPzdc4x0wDHJdXkQS0FszPIqKYZAQREMq4DDAG0Dk45zxzgVD4o1SPR9Ju765hja1gjNxMZFVZCqj7vQ5Y8DPuOPW/YCb7RlYpNskLNJ5VwcjaTgqcctgHJ4wfriuL+IzG8n8PaMkYYXmoxtLFLcciOFGuJgdy4GdqjPOQcUAXPAdldLZ3s+rRQXF9dP9pvHAJ3S5A2KMY2IFMYORwM85rbnu7iKZLclSzqHJjYJtO7PBPCnaTtOMYU54GKr+Gnhh0hVuorkffuJHLEKeMk4wF4wT9ck4zTGnudQuZJ5hOFly67I3QBVYZ2uDtC4XGAWz83BHUArWkU0EBNvazs8ahQ025QSSB7E59uysehNWbydLdJrjVLqW1UOC5kkC7VBJ+bPGBzge5GTkYyX1HUbvUBoHhm3lvNS8tVZpztjtYuR5szgsQDzhR8z7W4AJIsav4M/syIXWp29rrN5CQTfXcIljgJycQWw+SNR0DOST3J4oEczqXxQ8IafiP+2EnjBAkktI5ZkbGBjIUjPAPUdOh4p1v8UPA1+mU16Nzu/wBVOkkQC5B2jcBxkZGScbQO5rr7S68VXMKS6X5EkCBtscUkT5GOrRRlAM5zgsTn6VU1nS9F8QQGHxRp3hi6n3+TIJbA2lwcAZZX8zIHUbuBkUASLtvbVXsZYJVkYkOY1ePjj7ytgkkE4yCN+SBnnS03V5baRo7pdqpzvlZ0jAUnB44CgbRn05Hyg58M8RfCXxD4bgu9b+FGralLaKGM2nFwLhEJzhdpKSrgDIHOMcHNZPhD44kSQWvjCyO4SkyX1qgDc9S0ZHXOSSPptNAH0T4k0CPxbYx2F9PDMlwgkinjnKMkgOY50Gw8gjIOecMOjGszdNpvinSm1CFoZNaxZToqukcNzC7bZFbI4dSSORnYvryngnxDbaykUtlrJls5gXSRZhtRn7MD0O4HrzuPHUY0fE2j3er6eY7YhLxpBJDMW2iKRASuWHyjkhfXn6GgZ2vw+GfBulyElpZovOlZjktIxLOTyedxPeqPinw88bT6toiMLnazXFpGxUXQIwSMcCXHQ4O7gHsVzPhT4hhvbD7HIj28kzPcxRsMKrsd00IPcpIX4/uFSM849CoEeE6rFJYOPEkMi3EckEf9oJDCSZbYgESkYyHjY8hckx7gRlQB1sGqXM2kvJDf2bKMFj5zyg5G45cD64P5ZzUuq20ek+Kr6MK5ju4vtlsse7KSFwsoG3nlmVuO8j561ydndv4elj0bUob2SzZHlsYxId8VuxwYBwHPluQMn+CROcDNAzqFW+/s6SOXyUnUxwiLzMIzhtu0f9MypOG4PbBI5demTTppwkxVzLHGEkLorF8qMsPXBGcdADweaj1GQSWktwQIreQw741aRpASQCHIIIG7OSeMZNLqsVyL2KT7TclUdmHlx8s2CAWI5IA5z1GAccGgZWNvfxufKCDy49ojlAjRiFyAGQ4wRjg4ye/ounGSK5heMwiBVIZRARyWIBOAQVxnGSSflOapwMqmGVlmtS0iqHDOiowTbuIb5Xxs6fjzzm6E1KWyaLSTa/bWliVrmaM+WY+zld21iqE5HGW75FAEHwXDjxb8SRKQW/taPlVCj/ULjge1er15H8DVuV8S/EUXzFrkarFvJABP7hfTjpivXKCQooooAKKKKACvP/j9/wAka8Wf9eR/9CFegVwHx+/5I14s/wCvI/zFAGXYpbS22w3M/wAlqkUuxSEUsm4ZJ5UdO4Gc+2LTSoZlt7i4uHaMq63G0qMYZjhgSCMg9zww9BnK0+3txo8MEElnDcTW4G0MPMGV3bMEdcP3OAOncUJLJEsVu8nzuUWT5Uc7hyqgDPIYH8/rgKNKNFuJBva8dYdyRZjCbCxI2nPBODtyc/mOXQGG8dmuJdTt7oLscRxyRIdxyNnbgEHjJ+UfiWF4lvai2udQguWjUxrNFGCU2jPzHdjnaT2PXoSM0bq+ivLCRXkmxallmkiAcPhjvYjfwp4ODjJyBkjgA12+z3xJtruOGWOMxLvhCseATu3HnHPVTgr7YrB8Vazc2lpBp+iOw1m9nNvZ/akDmMAEyTOh5URqQcAclkA6kU9dSW4aWGK6t5GIKmYglVTOdp5xkh8ZzjJ/CsXw4suq69ea8ssNrH9p/s608+RcG3iZi77jkhpJlkbI/hjQehoA6bw3oS6LoyW9tHdwRkEKs6/vVBXLO5HLM7YZskH72egqqJrK1vrZphLM0gbykjbPzKSN5DOWz/MkjkgCtGSSa3a4mWeOCRo2LQzbUHm8gsAPmKY3EhWBwOBk85AdvshWeEzzEDcyhR8wAJBCcYwq9ScgkjnqBsTiS4uhDl2+ygIscVu8jEKBx8wYMQDnA4BCgkA8FPN/dRypIzSSL5iqpVRu3dtwIOdqnj0HvinqmqadpenJPdXUNgjLgmW4ijRumAd2S2GC/dBILE44FYsvjQ3UcjaTouvazOrswaz0yd4T14EhCgjJzkYznNAjoYrueGKR1gidcCPy2ZwvPDE/MB0wSc5+Xr8wNX7K9iEMshZkR+CLdcjZnjJHPygY4yc8ZxXJHxm+mea+teE/Flqqkslw+kl0+pKscZyeMDrzwMUmlePPBeq3LwWmt2bykgCOZfs7YxgjLhecBck9CM+pAxJnosN5dHy1dpBErNHmPErDksVJ7jaG428YHPXPBeL/AApeabYajP4IIhtG2zz6ZAitDcOuGE1uD9yZHGSgwr7QMAnNbqXgSMTK8E9ruYuIQzpnBXPyjjliuRj39K0LG4S+t5XN2oLOMJFt82Mf7IADbiRj0IzkA5ABnn3h3Wo9U1DS763J02215kM0EKFFW5AKOh/utlGXHU9TwBj2D4cRxSaAdRC/6TezSPKxBzhXZFTnnCqoAH1PUknh9U0K2ltr9HMNreXkwuRHMQBLNgkttUfLu2qCQf7xHzHLW/hj4ka0IstQaQw3VwyEyDDW10WIZG9pCN2eMOzD+JaBHb+JfDMGrH7TbN9l1NBhbhCV8xcEbJNpBZcE98jqpB5rynxakq6nFrFnC9t4h0qSOC5smkLC8h+81uC33s8vE+MZJHB3Ae7VxvxC09VW01dIkdoXWCdWwN8bthDk9CkhRgew3epoAxtHvNO1fT7fWLG6e6srkJLEDLgyn5gMDGQd2cg85VvfN6RLRrZkd1humwy5JDSIHyeA3zdCMY7kiuEjtbjwjr9kbOcx+H9WkDMItrRw3/G6POSFEmH7j94pAI3iup1ILPaRTJqFuUExaHztrrllOFLFfQ5A9fcAUDFiiazVhbW10LxdsvlR5LqScljliFU7gCAOgIB4BN147MmKD7A+wptKxXRjKJwcE7/944Jz0HtUXnskcBhVknjCLGJlUbdx+ZiSSWOCcjJJwT2NLZpa3Uwid4vNBYRBnRDhefMQY56qDkYBOOR1QAkcU8sU87JLDC+4xsA4PKFV3Fjz8qt7FCeaxvhMgj+LHxHjVZF2x6aCH658uTPc8ehBxWzCkAv5LOylgfY0mCYViKZQgIQCCc9zjsCMAisv4YMrfF/4lFZFkUR6YMrjA/cycDHT6UxHrNFZV/4i0bT4nkvdVsYVU4O+dc59AM5J9hzWdb+NdNunxZ2us3CHgSR6Vc7D9GKAGgDpqKwv+Elg/wCgdrP/AIL5f8KX/hJ9PQZuUv7ReMvc2U0aDPqxXaPzoA3KKZBLHPCksEiSxONyujBlYeoI60+gAooooAKKKKACiiigDnPiV/yTnxV/2Crv/wBEtXnPgF78/Dzw2SJdsWnQSFInKK37gY3Y65AU4/yfRfiX/wAk48Vf9gm7/wDRLVxngZbhfhxoAWwupAdJt8MI1KsGhTnPsckZHegB/wDaF9CbdbuLdePMjI0hWPapYEAg8McdMHPvxkw6nfahI1vANPee6IKxynauCVJUnBzxtI+8Rn0qWC5uba0SKUiBg0siIYyo2qoBG0gjptAH1OPRbG6i/syS2eyaRRHjDKuVyoGAMf3sDjj5vrQM0NJn+1uFktg0jbkmhuJCzqobBPzEYBxyDk+gBzXBeJ3aXxp4dW2slMUEV7K8e0xNlpbeJ27kEBjgntXcafbiCztXugPMZmZTcbAy5J+b7oxzuyf9zPOa5jWFa18W6IQ9zJDJDqKKqSKxJBt5NmCCMYQ5HcDjnigDo5GmWzCXcYWOYsEuZZMukgJ4G3GD1zz1c9cmuT8R6hc272WmaFYpc61qK+XaQkkLk5O5vlI2IAXPtx6CuinL22mW97PZ3CpIPMbdMoC7nVUOF4B+70JBqp8GpP7f8ZeI9dkhaOKxjTS7RWUKQQzee2BwMuirx2jFAjsPDHw90jRNDFhIJL2aRjPdTzH/AI+J2A3SMn3T04BBAAAHFPTwVb2Z8+ylQzrkhWsbUK3GNvyxqcH6119FAHM6bpuj30ZgvtHt471cs8VzbruGTyVOWyvI5ViB046Voah4d0y/jWOa2Cqu4jymMeCep4I59+vvWo0aM6syqWTO0kcj6U6gDz288L32jyT3Ojzz7Ej3eZEV83HOcLjDHodv3Wx/A3zH5h+NPhCfXLjVvElhZ28N/Yqr6rFbAiO4HB+1xDHQq8TsO3mA9Q1faurRTzaZdR2cnl3LRnym7BscZ9s9a8b0KKPVdYGnzm8jiuzNayTLLgm3lh8xIskHGdhBPX5QPTAB8W+H9c1LQL8XekXT28+NrYAZXGQdrKchhkDggivpvwt8czqOn2sfiLTZNFmiVd121o81rcY/vYG6MZOcgNzg9Mg9P8Fvh/ofhbxpf3selyrY6jDGunPqJjlkt50L+dCCOQ3AIJAJCt/d59/IBGCOPSgLngvh/UtI8QWF3rHhedrqzkkjku7eNx5+n3Kk5ki6ZHJOBwRjAIJSvS9K8VzC3AvrSa+27V+16bGZkcnsyD5kf1XBA9ax/HPw60S+uBq1jB/Zeubs/wBoafMtrPtHbBGyXoMq/UdxXLN4gs9OslvPFE+j6rAEMSavp93HZXShSQRJCXVtwIwQjtnHQUDOo1aa51rV4r24Eml2tuoigBG6U7nRiZAOFyyIAuSQMk/7OB8RTq+m41Qw2rmwvIblnMYRkgHEzjrkCJ3DqcDDZByvzZHh/Xh408Q3Nn4TvJpLWGJbm2N3d3cDS5BDj97FIpKk/iGz2NdPeaD4ofYr2dxIhDrIDLaThgyBGGCkWQRxgnnFAF+2hu4bVmW4gSN3VM+XI6k/Md2N/baMHPT86SVZ7mxhtzMViY7ixgaT5vvcgsSTjuO+Otc3aSz+AvBcEXinTtQay09VhNyIbd/PRRtiDqHLbsHBALfd46nG7oWv6VroGp6M1vcxrGJvJ8+N5FVcnHlhyIzgbQCByeT1FAx+FjR7eZEt2Mpm/eAtvIUdQNpAHHI4B5yelXpFub+VFiTFpGwa4imhMjhsJ93JAAOecd+ao3Ukai6zbxw20bO0saKJTnCjIAU4IH1xwavTmLzzbh03DoqsPlXGCATgDg9cng8UAY3wVUr4s+JO5txOrxt97OMwqcZwOmcV6xXlHwWSNPFvxIWBg8Y1aMAgAf8ALBfSvV6CQooooAKKKKACvP8A4/f8ka8Wf9eR/wDQhXoFef8Ax+/5I14s/wCvI/8AoQoAy7OWWOxtopI5LeZIIyskbMoQ7NzDcBgYI/MAHIPNeS2n8m4imsbG4kmmjI3SBVYEtuGMcYO49MHGaW1VTp8DXIYQBEgG8ljs24J2ZHy7mHOB+RFPtrm2trPK2k8ILRoSbSWMkqdxKIwJIIU9SF5NBQ6X7TBFFBJZwyzvIFG9DGhcuQSWCdNpzn27Zq1EFN1K8lj5ayTCJFJ3FirYBXIOTkZ7fLluuNtJ5VK25T7bdRiSIiVGLttBY4kQnI54IHOSDVwTG2Pm3kSLIsx2YiaWTGVH3+vQLg/UcYxQBW8a6ve6RoF5qEEcfkafY3F5iRdpLqj7Oi7SCSrY49fal8CabNY+H7LT1AlWC2topIhKGk3LGu7cDkKSzk8EH1HFY/xWDDwN4itxHtf+yp0BUliFwHO7gAZw3H+yK6e3h8qaaLzLpreORgkUZmYeWFUEBkPX7xwcn04ANMClq6zu0pu5WiZY13ZDAAqevBHHAYg8AgDo2KxZL29k1O10jRLNbjWLlRIivsVbaPOGklIHyp/ugFmyq9Ditquu/wBlaG+p3vySTJvSD+KaQ4Cx5PPmE4HIJBLZ5znv/hd4aXQdMnku2ll1yeQNqNww2rLLsTCp2McYwidhhsdTSJJ/CfgHS9DZby9A1XWyF8zULqMFhgYAjXpGoHQL+JJ5rrLiITQvGWdQ4xuRirD6EdKkqvfWVtfwiK8gjmjDBgHGcH1HvQBkahYTW0AlOoSHy2CqXIQDJHLbcAnPcAHnnNcT45+GWjeMPMHiOxE87AKt3Au25iBPDBwMMB6EY9VH3q6XWdBv0dDpcreRFh0gdvNB6gqA/KHBOCGAPQ461jJNqkVuLKFrkKWAWM9UIAJQbvYcISc4xlwSygHyb458C+KfhTdHUtH1C5l0gybPtUQKbCeiTx8jkdPvK3Y9q0/Cfx1vLR7dNcs1dwCsl/Blpm4xkozAHOACAV6nGOh+gNS1JFugLtBdaTMpMtpLGJQY8gSwY/i+8HUemwjljXzb8RfhLrVt8RU0rwz4c1SG11FybKG5aMhSFLsnmqxQ7QCeWzjGfUgH1H8NPGWj+PNHnvNKaI31soM0C43kAnb8uNyjIIH4jkYNZOuxtpD6hfQwS3OhXTCHUovOKSWk4bIcEglcE7gcdXHJBXHlHgv9mnxrb30V9L4gtNCuIsMktq8kkqNnkcbRxjqDj616XY+B/ip4VvLnVYPGWka9G8AiuoNXR4keJd2CXGSCNzfNn6kgUDPQvDvjW3GjwTa1OrQFR5WqwDzLW5XHDb0GEbsVbbznHFHiLVofE+lvpWgZuhc4Mt0UYRRxhgThiBvc4wFXPJycDrwHhabxp4ltDqGneBdA0VXPyXZ1WaAXIzjeBAu5lPUFuowRkV0v9ieOntyk1npLTEEFl8SagsePTbsz+tAiv4i0e41LRtUg1Jb9o5otqw2wBkhkDrh4gQAzBiCp4OVHXNP8G6ncat4WstSvZIhczpE5jLkssy8SLsJ+Q+YG4yOQFIHGSXQPHJcE2ulhMYCweILpSvTOC0BIGBj8vSsKfw/440e+uNU0zQDeXd0yy3UDavFNFK6qFLKGij2uVA+bkHA3A0Bc7eCK7ZJJLkxxSO7BCuZNmAeCCvUbug9c9qy21izTXGSGSLVdVCkNaWUTT4DbSFc7MRZGDhiBxWbrnjawRxDq1jqvh++mnVIrjVbV4razAU5kMqlonwQdozhiVyAMmvS/C9tpFho1rBoUlvJZMpdJIpBJ5x/ikLD77E8lu5NAHOvZeKtSjQWtrpXh+Fh8wlLXU3QgAqhRcYPQsw4puk/DPSodW1LVdZuLjV7/AFHyvtKzYS3YxKVTEK4XgE/e3V03ibW7bw9o81/dkkKQkcS8tLIxwqKBySTgcCszwHHrMenMdZaeRpCZTLdNiV3blsRjiKMdFXJbH3sHNAB/wr3waLhbgeFNCWdSCJFsIgwI6HO3rW/YWNrp9uILKCOCEEkIgwAas0U7tisFFFFIZyqeF7zT9TurzQtaltEuXMklnLbJJb7ic7gq7GB5wSG54zk806Kz8ZBmaXWtCYZ4RdLlAx9fPzmuoooAzNLl1fzWi1W2swuMrPbSsQTxwUYAjv3NadFFABRRRQAUUUUAc38S/wDknPir/sFXf/olq8u8A+GNK/4Qnw5cyeGNXd3023keeGVgHJiXlQk44Oc9M/09R+Jf/JOPFX/YJu//AES1R/Cz/kmXhL/sEWn/AKJWgDi49LFvaMkFl46iYrgLHeTGNOM8BpSSM+/86LN2sT5cniPV7AuxK/25YI2Mhf42ReOTwHPQnNeuUEZGDyKAPMIW1qCKS6c6LrakGMz2ty9rKTjPy7zJGTj0YZ596wPFusWBWxvDHPY6jpl3HcSWlwoUxQuDBI+c7HQLIHyhYDb2wa9NvfCWmySvcaeG0y7blpbMKoc+rxkFG+pUn3Fcf410VLzTzpHimwt722ulMUVzG5iR3I2hcHJhkweMEhuQOTtIO4mrQi98NJI1/EYUXdgOoVgh5BG7B4DqcEEZwMYFcr8BZDpl5o9nGimO+02KdpCDktJEJv5lu1bPgq2ng0pNC1C5SWa2dEa5LlRLCy/u7hCRxuBO4E/fVxyCK5H4UG8gv7K1uJ/LnsEOnP5ijakts0cUeMc4cI4PXiQn6gmfSNZGvawdNe0t7a2+16hduVhg8wRggY3MzHooyOxOWUAc1rLkqCwAbHIBziuL8P30fiDxrqV7LbKttYQrbWDyEEyZkfzZFHYFolA9QmehFAG14b8Qwa0buDZ9m1Gyk8q6tGlR2jJGQcqSCpHQ/UEAggbdYep+G9F1K4DTWkMd+mXS5tz5NxHn+IOuGGceuD3zWFa6Z43kubhE8Q2ttpqPstzd6cs106j+J2R1T6fLnGM85oA6vXJ5rbSLyW0VmuRGRCFGcueF/DJHJ4HevPtFm0KCScWdtda5qhYRvDpw8yNPLlZ4yZMiNGwV6uDwBitC68Ea5qd4ra/4qGpWK9LJ9ORIc+pUNh/o4Ye1NtPiV4XtZ7fR9NF/dyIhWIWmnSCOQIdpMZ2qjDP9zI9KAM2bwh4h1bWpdStYNL8MLcN5lxgC7uJZQUKSHaEUMpQdWccn1OeibwVPeNu1rxV4hvc9YobhbOM+2IVVsfVjUlv45tLxTJp+keILqBchpU050UEHBHz7SSCCOAehq9p3jDQL+eS3i1S3ivIhmS0uT5E8f+9G+GH1xigDltX+HHw80XTpdQ1Lw3bXMcRBeS4V7uQ5IA5csx5xVnStI8L+F0ju38N6NY6zcqTFaadYxm4KdoxtGWI43NwoPcAZrU1+4uNfMem+H54sRzxS3N6yeZFEEcPsGCAznA4B4HJ7A1k1LTdI1GfSNFuLe/8AEUm1rmS7ul3qT90ynr64jUdOgUc0ATahBeXn2fUPEV5baLp1lMtzFFFIPMBUf8tJT8oBBYFVHQkbiDW5p+uaZqGlSalZ3sUljHv3zE7Qm3727OMYxnntz0qpZeHYftK3usTNqmoKcrJMoEcJ/wCmUf3U+vLerGq2reFvt+vJeLePFYTbTf2OwFLpo+Y2J6gjgN/eCqDwKAHaNH/atwPEOpIY41VjYRTKV+zxEcyMD0dxzkgFVIXj5sweKPBXhXW5Fn1bSrX7dktFdwDyroMBnKSJh88Z4NW/FV/dIbXTdHjWbUrl1LKSAsUAI3yPnov8PqS3HQ4Gh0/w7aT61r99G08afvr+5wgRf7qDoi5OAo5PGdx5oA5PUNP17w3ZLcwPea9pMaFy+1V1KBdp5I2YmwMcEB/941o6FNaa1pUdxp95LJp8sIljuU27HXOOQwI6jlSPwHSp7LWtU8WTyNoEzaVpMeCt1c2Enn3HqUSQKqr2ydxPoBgmppvww0+zuNQlfWdfkW+uDdSxQ3ptY/MP3mCwBMZ6n357mgLmZ8H4vJ8ZfEmPBBXVYRyAD/x7p2HH5V6lXDWPwv8ADthcXNxYya3BcXMglmkj1m6DSOBgMx8zk4HerT+DrqFi2l+LfEVo3ULLNHdJ+ImRj+ooA6+iuPg0rxtbzbf+Eo0q6tznLXGkESL9CkyqfyqeTwzqOoJ5eueI76e2P3oLJBZq3sXQ+Zj2Dj3zQB1JIAySAPeobW7trtXNrcQzhGKOY3DbW9DjofaudsvAHhWzbdFoVk75zunTzmz9Xya6O1toLSBYbWGKCFfuxxoFUfQCgCWvP/j9/wAka8Wf9eR/mK9Arz/4/f8AJGvFn/Xkf/QhQBy2jyK2lxBfEGuF/IUqtroMbnaQBgf6MeeTxn862XuI4Pkn8TXyzPwTqmhqoOMDBPlRg9B364r0XSP+QTZf9cE/9BFW6APHLM37RxGB/C+u23ylRFIbCQEgdVHmpkhT1K9exFWYJLnTZjJqOk6vbWTN86JDBeqi5/vxuWCqQp+7ngd69E1Xw3o2rSCXUNMtZpwQVmMYEin1Dj5gfoaxLvwfdQow0fV5VQsrG21CMXUbANu27jiQD/gRphc53WYrDxXoWraZp+sxXTXVrLAYvljkiLqVAMZAYHPOCoqTwrGmo+HrOSB1SW+tUkQOFZSHRMlkQgsM+vuD0zUmu2VtqklnY+MNJhtb4MBa6ijZTzCcKsM6hWjY8YDYJ6DdWd4Btb7Q7q88Oald/bpLdpLmxvmiOZoZZCWDD+B0dtpAxw6EDtSKOJ8TRR32t2VlIWdLO0fUXjIYAsGjhjO1h6yO4ySQRnjOK+gPDlwlxo1sUaR/LUwMz9WZCUY/mprw6dWs/iLrEF2CoOjwypHjO1VvkYKOgyRIvfPPPavV/h/LONN8qaFwrhZQ/UByq71Pvuy2emGxnINBJ1lNkZljdkXewBIXOMn0p1FAHFah4o1OM/aNM077ZbtgeWD8ysFyV4z83seDxtyeKgfxDpPiFklsI2N6rJG0M6FPMUuAUbuCpZWB6rkEcbq66TSrWS6lnZMmaMxyp/DIPcVyXijwCl5qLapoU6WOpSNmfeCY5xjaQ2DwcZGec5PrQBg+PNOubuee4eL7JL+7mSCRCwMqEFWD7tuN3ljj+6uQOtVfF1m+qTW/iXw/DfQXl5BFfQ3MZ3fZ54h80csP8YKkBlHzYR9vPB9Dn0S41HSbrT9YuUuFkRDFMsYBjcIATg9fmBbnsxB4pmvaAk/hSawguDbSIocXQbYwYfecsO5XIJ5696AH+E/ESa/aQ3GYImmiDi3DFnRlO2QE9CAxXBHUEHoRUHjW2GqzaLo84Jsr27LXacYlijRn8s+zOEBHcZHQ1wfhopoGr6j9nuoLmPT/ACtTme1UCFopIvKmjjxxiNY4Hx9OBurqvGeomHxb4Je3dXtmuJppXX5gY2jEQORxjfPGc0AdyBjpUdy8kdvI8UfmyKpKpnG4+makooA5DxP8RPDvhnw0uuazeiC0cERxHHnSSA4aNUzncpGCO3fFfGfxY+N/iLxzqifYp5tI0i2lEttbW8hV9wPyu7Dkt7dB29a+lvFvgHw9rXxesrXW9BttQt9Rsprw3M1xPvRo2VWRQH2gEyoeAOhr5I+NOk2Hh/4peINM0a1S1sLWcJDCpLBRsU9WJJ5J6miwH0N8Df2grfW0g8PfEGWGK+ceXFqMgCxXHosvZWPr0PsevV/EDwNpt5em3+HLXGk+KJCkjy6ZL5VpArEfvZ1Hygld23aA5PtkjyT4CfC7T/GHgudNb8MXQubi6YprFwzRJFb7Ex5KhhvfO7GVKjOSTjafrHwx4f0vwvotvpWh2kdrZQDCovUn1Y9ST6mgDD8EeB08PJFc6pq2peINZVcG+1GZpNhI+bykJxGD7c+pNdjRRQAUUUUAFFFFABRRSIyuu5GDL6g5oAWiiigAooooAKKKKAOb+Jf/ACTjxV/2Cbv/ANEtUfws/wCSZeEv+wRaf+iVqT4l/wDJOPFX/YJu/wD0S1R/Cz/kmXhL/sEWn/olaAOoooooAKp6xp0GraXdWF2D5NxGUYqcMuehB7EHBB7EVcooA8h0/wAPw30ls0/mRapAZLe6NuJV8zB2yRl92AGKRyLkjhRx82Kx9Q0ZtH+IEkyNMkeu2ivGW/eFbqGJkckDPVXhkJHUI57V3euxNpnitjuMdvqA+0o+wsBKiqsi8ED5kEbc9kc8YzWZ4i0SbXAYLTyoLy0YT20yMfkmjDbG2g5MZDlWHIKyEZzzQBs3V5e3L6VbXOqG3tNZfEDw4jm2bHlKbuzEYXI/hQkYJyK3hDwjptnbX1rZC6tprDUiYJjMzyRgRrtGWJLJsbGGzwx6ZzXDeH9b1CfSH03V9O+06dFMLWW0ukWT7PKM5hLEfeU8qx6gI3Ckmt/T9OtrYST+FYdQ028dtsxsp0Czt8oUyRz5TdjC4OGHQErhqANzwFrWoS69qWgahEPM05C0zqDjc0rlCpOflZCCATkYxXeVwXhS7TQtX12LxTqtsupTyxSRzXIjtmmgEKBTgHaxVvMUleOOg4q3qXjV7otbeCdObxDeA7WmjlEVnD7vOQQT/spub2FAHYsAykHoRivF9NW8lvtW8IQ6xZWt1aStAI7qFZA9u3/HvvTAMh2YUYZMBAeSSa7PTdM8X6lGx17VI9MEgAkj05hIwGDlY2ZBsHPU7m4GCtYPjXwnoPhOxXxFogfT/EqyrFbXzStLJcySfJsmLljIh6kdQFyuCKAOs8DaR/Y1kllcRXX220gjgeeS4kmjnUDAdSxOM45HUe4wTH4o0vTvEWpxWP8AZ1hc3sC5kvZ7aOZrJG7LuB+dhnA6D7xHQHEtfFHjO3gsodR0GwuLjUJjBaTwTtCQOT5ssEmWVQo3EBmbGAQDwNqO28yZ/D1hcs3lgTareCQCYs/IXjozgHnjauAMZXAA/TYFktYdJ8NImn6HaZha4hUAvg8pD+Od0nrnGTkrpL4Y0IWi2x0fT3gX+CS3V8nuTkHJPcnk1qW8MVtBHBbxrHDEoREQYCqBgAD0qtY6lbXk0sMRkSeLBeKWNo3APQ4IGQcHkcUAc/4LEmm6n4i0ZmY6dYTxyWbO2fKikiVjHknOFYPjPRWUdBWD4k+KGnQQ3Mml6hp0Vlbttlv7mQFX7HyU3L5mDgE7gMkdRkjkYtGT4i6lq0cVxKtleXT3WqXfmuYo4APKghiTdsMrRIrszA7AwOMsMdBpeh/B3wdiS2XwxHPFhQ8s6XMwI9NxZs/SgDl/CvxBk+1Xs1kviDxWLhxI0tlprqWw/A3rGo2jB24YDa4yMlq9B8Kx6h4p1aPWvFGn3tkluS9hpk8QWO2OcCR88vNjoQNqAkDJyx0F+Inh5oHazbUrrYPlS30y5bfx/CfLCke+ce9dJpc93c2/m3lslqW5WMSb2x6kgYB6cDP1oAuUUUUAFFFFABRRRQAUUUUAFef/AB+/5I14s/68j/6EK9Arz/4/f8ka8Wf9eR/9CFAHa6P/AMgmy/64J/6CKt1U0f8A5BNl/wBcE/8AQRVugAooooAhvbWC+tJbW7iWW3lUq6MOCK89tdLFxeRLqEsh1DR53jM6ljKwYA5HYiSLZu/2l45WvSK4vxxHNYX9rqVtIYo7gx2s7KhYhlfdE2APUug95F6daBo8++JemLpraJ4gtvPDWipZX6yqN5t3dB5j47q/lE9sDg8c+m+AZSdOnjZssDHIo9FaJP8A2YOPqDVK/gt9csW0+8LNDcRussUkeWdCQrIRkdd+Dkcbh7VzvgLWrXS9Ou/DetPerqejhYWnTcGurRjmK5Ujkjs2M4csD1FAM9K1TUrfTIkkui4V22japbJ//Vk468HGasTmVoCbVo/MOCpfJUjPt7d/51hHU9JkshZ3U32i2cLHH5iuS44GSzfeYMMkjkcH3qKDwxcWkiJZatcxWgZm2EZZSc42np1JzkHPGecmgRoeGnvTZzpqV3HdTRzsoZUCOq8FVkA43gHkjgjBHWteuN0pL3QPEEcF9GtxHqOE+1QI4QOoJ5TnZnJ77fTH3a7KgAqGS7t47mO3knjWeX7kZYBm4J4HfgH8qZql9Bpmm3V9duEt7eNpZGJA4AyevFeeaDqGqar4okfMRvY1ZCMBxZpI6M6E56qkca47yO/UITQA/wAU2w8M+N9CvLBGt7HW7l7C5aJV2wzyRYSTacjLmOMHjGY1z1OYbHw7qWj+MbDTpr23fQ5rS8TT0SDBsmPkkRAMWDKNjMuemMdMAbXjfVtL1LwxrQsr2G4udHkiuZRC+5oZI5FkUcd/kI/MetT/ABI+2W9lpGp6YEN3Y6lBgP0KTN5D59cCbdj1UUAdcKKKKAPNfina6xceMfAh8M3ltZ6otzcgy3MZkj8jycyBkBBYHCDgjkjkVk+GPgnpw8Z6t4r8aG01vVryfzYoRAUt4MH7wRmbcTgYyTirHj+bX5PilpV14atba/Ph3S5ru5s5ZWRrgXDFFRCFbD4hJGRj881qeG/HWu6reXNtL4Qu7eaBsSwzX0CyQnvlcglD1V1yGGe4oA9DVVVQqAKoGAAMACszXtf0vQYEl1a8jtw5xGnLO5/2VGSfwHFVfsmvX3zXGoQ6ZG3/ACxs4hJIo95X+Un6Jx79as6fpWnaIk11n98y/v7y6kLyMB/edug9uAOwFAFjTNW0/VUdtOvLe5CY3+VIGK56ZA6fjV2uJ1D4iafGskmjaRr2vpHkPLpdiZI+Owdiqv8A8BJrW8H+LNO8Waet3pkd9GvIdLq1eFo2BwyNuGNwPYE/lQB0FFFFABRRWLrniG20yUWkMct/qsi7orC1AaVh6tkgIv8AtMQPx4oAs+IdQt9L0i4u7u+jsIowD58i7gDngberEnjaOTnA5xXIeGdY1uwN5Pqfh25h0aWUyxPA5lkRmPzt5GBIsbH5wMFgWYFcAGtnTdAuL7UodY8TmGa9iObSzjy0FlnuM/fl7GQgccKFGc9PQBBZXUF9aRXNpKssEq7kdehFT0CigAooooAKKKKAOb+Jf/JOPFX/AGCbv/0S1R/Cz/kmXhL/ALBFp/6JWpPiX/yTjxV/2Cbv/wBEtUfws/5Jl4S/7BFp/wCiVoA6iiiigAooooAy/EWlf2tp3lJIIrqGRZ7aYjPlyrypI7jsR3BI71yVhcQ3y/Y7rTbeCWMiGWABSLeVckgjPIC42nHzKw9cV6DXJ+MdHlMv9r6esrSrH5V3BCqs08Oc5UMCC6HkDuMr1IIAOD1HwhrXh7XZNd8LyTataXEf2e/0W6cDz4lz5ZjlzkSKOFLZ4wu4ACu68IXnhjxJH9t0m3iW8tX2TQTJsuLSQf8ALN0PKYx06dxnOa45JJdEvBc6XqEBsr4i8dWOYSzjOWUA7UZgSJFxtJIYMB8t/U9J03xJqTX0V3L4d8T2oKrexSIl0vosiY2zQ9CMkqR3BzQM9IvLK1vVVby2guFU7lEsYcA+oz3qZFWNAiKFRRgADAArzU+ONa8J+ZF4509b2zhPOsaLG0iAYzmW35ePvyu9fpVpfiho2s2MMvhTUNPuhP8AdmuJgip82CDF/rS2ASBtAPHIoEdzqN9babZyXV7KsUEY5Y9z2AHUkngAck8CsmwtLrULxtV1NZLfEbR2drwWt1I5duo80/iFHHds8lodjf694outRuLm4e40yDy7WW6iKQm4k5LLb5+QKiqBuO/EpJPStHxTrep6ctvbajf6ZYTX0hjghglIcqq5djM/CgDPIjJGQBkkGgCh9sll/sTUrPXo01u8821s7W/g8z7TD5rEMYl2urBQjO4wAE+YcVyuh6dbaj4n+H6X4jutRng1SfULiPMb3BR1UOxUg43k7QeB0HArpoLe00uzs5rC1WbxG24aenl7fObYUVsHLpbxqxAyQMZPLEZT4Y+HoxfW+tG4jnMEU2nQMQd/kxMsQI9A8iTSH3kX0oA9ItLSO0jVITLtUbR5krP3J6sSe9YPjkfYNC1nXIVQXVlpN2I5Odw+UP8AllB/nNdLVTV7GLU9JvbC4GYbqF4HHqrKQf50AeX/AAW8MG7+Hvh59atbf+y/7Oga20/76u7LuknmB4dnJGAchR7k16dZaVp1gSbGwtLY+sMKp/IV5T4L+KGgQ/Dfw/a2uoxSazDaRWJtERn8qZFCHzegjTI+8xAx3NT/ABP8ZeM/A3gh/Ejv4ZvY4/KVoY4JhlnYD5X8zkDOegzQB65RXy/8Mf2jNY8Ra/DpeoaBJf6jdM629vp0kcSHA3f8tDnIUHq+PavW7r4mzadG02s+B/F1lbL96dbWKdV9yIpGIHvigD0WisvRvEOk61b2dxpV/DdQ3kbywPEch1QgN9CCwBB5BrUoAKKKKACiiuS8X63qK39tonhm2F1q0uJp2Z9kVrCM4aRsHG5htAALEbiB8tAHW0Vyllb+M/JjjuLvQYmAAeUQyzMxwMtjcgyTnjtWxpVlqFu5fUdWe9YjGxYEijHuAMt+bUAadef/AB+/5I14s/68j/6EK9Arz/4/f8ka8Wf9eR/9CFAHa6P/AMgmy/64J/6CKt1U0f8A5BNl/wBcE/8AQRVugAooooAKralZQ6jp9xZ3K7oZ0KN6jPcehHUH1qzRQBxmlTSyJLbyqyaxBi1unDhd+0g71U8EMrB+mRux1riPi34e8UXdtDe6BZwalqWnTedaSRy+RN5bEeZCwGVdWUDHKHKg8kc+g+LtOaKVNatFlLwrsvIohkzQZzkLj5mQ/MO5G5f4q5TVdXv9DFjcW80dzpDs73DJGsgO5kMUqtnIwM8e4zjO4AyL4WP/AMJDozalo2otazpKI7qwuYiXhdcEpIhOVb0I4IOeM8es15He+Hy9/B4l8D6mn9vFcGaQs0F7GoA8ifAzgbT833lYdOSK7Dwj43s9cuP7Nv4JNI8Qom+XTLphvx0LxMOJY85wy/jg8UCOsIBorM1fXLHSnijupWa5myIbeJS8khHoo/n0rkvFGpajqGuaJpUE0lpHeGR57BQBK8axSMBLKCfKDMqgbeSN3PBAANPVY08Y3EmmwXEqaNayj7XNASpuJVYEQo/91SAXI74XP3sZuszeH9K8MaxokVxa+Holla2heGTyzJKUSTI2/Mxy4DYyTk880/XPFc3h7wy82naB9jhtYduLt1toInxxGoALPzwNi4PHPcR/B/w82l+H0utSuLbUNXkLCW8hhKpyxZkjJPK7iSWGAxyeeKAMnWtOi8WfD+G+8M26WV3DD9jurOOEgmEMpmgC/KdwxuQkDOR2c1p6/q174j07SLrTtOmh0RL+zu57m6IVpIllVgUjBJxnaxLbcAHjNdBrsU2kaj/btjE0sJAj1G3jUlpIx0lUDq6enVlyOSFFVluYtB26jp+2fwzefvpTB8wtmbnzVA6xNnLY+6fm6FsAHWU1GYlwyFQDgEkfMMDn+n4VHatG1skkMwmhceYsm7cGB5BB7jnj2rGur/8AtXU7O00mcyRQTiW8nhf5FVQcR7h1YtjK9gDnHGQDE8G3dqbnxn4oupFitpb94fOZhtENqgiJz6b1mP41z8vhfUPGqw3errqdndEtJDLJiB9OSRwxWJl+ZnCqqkNlcjuMg1Ph/YR+JPC2j6FcWbPb6dd3MmpPIW8vzFupCIgM4dyyhjnO1c9Cwrc8QeNIfEXixPA3hO7829YF9Wvbd+LC3GAwV+nmtkKMfdzk8igDyix8V+LrzVJvCnh7x/8Aari2cwGVrCOWVG814wjSH7+NgO/HIcGuh0jXDYkDXPD1xrd7blyLi+1WWcFlxlhHJHtj65xj5eRmux+IHhCLT7bRdS8M6TFt0gPC9pbRfM0DDnaBySGUZA5IZj16+ex6lNqF3PaaHDq091Mot8QRN84ZcPvLABVOFLEnAP6gHuHhjU7/AFyztdSB0+PT5k3KkReR/TBYhQCCCCNp6Vz/AMVrSKx8PXF/pV7Ppniacpa2FzbcyXE7ECOJ16SAng7gdoyeMZq/4E8KXPhvSPKa73XEsgmkj3ExRfJt2qON3qTxk84HSsTSNN0DUPiPLb6XKLq70GQ3uoTSuZpPtM4dUjDNnaFG9iq4AOwY4NAG/pmsaxp1nHZ6voGo3F5GMGezkSeKY/3lZ2Vl+jAY9T1pZLjxdqMn7jTbLSrUf897wPO/t8qMifm34V1lFAGALDXb5ANR1OCzjI+aPTojvPt5r5/RQfcVp6ZplnpkTx2MCxB23yN1aRv7zMeWPuSTVyigAooooAKKKKACiiigAooooA5v4l/8k48Vf9gm7/8ARLVH8LP+SZeEv+wRaf8Aolal+Jf/ACTnxV/2Crv/ANEtXD+BEjtfAPhNbCfULSV9Lti/2e4ZlVmiBzsdXjHPOTtHP4UAdPp/ii6sPEl7pPiUxRo1yRZ3KoUXY5/dK2eOeVDf3lIIBK7u0rg4IYbi5uItW1C4v2uoWtQ88KhfLJzgbYlU7iOc57Y61JZS6pp1oRpN1FLZxL/qdRV8RYGSom64wV6hvrxQFjuKK4WTXvEKXikHS5VwG+zxxSfOOTt80kYY44JXHIz1rrtJ1K11ayW6sZRJETg9mRh1Vh1DDuDQBcooooA47VtOfQbi6v8AToPM0+4yZ4Ywc27seZUABypzllweRuA+9nnvsZNosVnDHfafHiaNPMUSWwByJIJAQApGCozt5xlRxXqVcV4j8LPGxutHSSWHdul08SBRywYtFuyqkkcqRtPUbW5IBn6VrF9FFuBbV4IZCqq6LFeQnaDhkx855B42scgjd1rOsvDttdtc6x4HuofD+vyFVuzawh0mbJwtzbsBzktz8rDOc4JqK3nu5rqWfRbZl1K2ZRcwSnAZGGTHICAysCx2tjJBONykitD7VDq97ZwXUM9prCIwV42MVxt4OVZeJF/3Sy45IxxQM5LXfiL45+H89taeI/Cel/2ZNOsTa3aTyG3XcwBlkXBZepJDEE4ODXpNtoWr3tydRu/EMMPnxKp/suzjQMvJB8yTzGI57YHoKxoNXvLS5ktL+2n1GwkVz5skW2YL8ud0fRwCRnZz/snOai0eOWwt4rjwJdW66VuKtp0rO9ru5LLHxvhI56Aqf7goCx1liugeHoLiZbyASsgkuLm4uRJNKAuQWdjkjHQdBnis/wCD7zS/DXQZ7mBoJLiA3Gxjk4kYuCfchgcds1xnxR8X6IPBGqRaxpw0nWbuJLfZe26kuJGCOY5QCr4UsRg5+XoK9hgijghjihRUiRQqKowABwAKBD6z/EWpxaNoGpancELFZ20lwxPoqlv6VoV5z4uvJvFfijS/C1lbNNoPnGbV7vjy3EWGFsv97L7N+OADtzkkAA2/BenP4e+HOk2trp/m3cNjGZLdCsbSylQXyTgZLE8mvlD4y/Ebw/qOhax4Z0vw7q+i3jXUbvBOViSJlYl1MatjGcEcdSeQMCvtqvLfjZ8H9K+I2mSTxJFZeI4k/wBHvQv38dI5MdV9+o7dwQD4w+D/AIqsvBXxD0nxBqdvcXFrZmUtHb43ktGyDGSB1b1r7Z+HPxTg8dRm7tNEvtO0kByL3UJI41fYMtsUMSwHGW6D1zxXzl8MvgjdReIpT4rslv7uymCro1vOrBznh7mUZWOLvjl2HRSOv0l4e+HsxnmuvF2oRalvCLFplrAILG1jTlYlQcuoP944OASuQMAEvgqwsb/xnrfijSrN7awuYktoZB8sd64JMlwq9MNiNQ+Bu2Z5GDXfUigKAFAAAwAO1c9f+K7RLt7HSIJ9Y1FDteCywywtz/rZCQkfI6E7vQGgDoqK8l0nUfGXjbxTrtiNVtPDdlodwltLBaQLdyXDPGHyZJAAMBhjCdc9cCuw/wCEKtbuNk1/UdU1xGOfLvZgsXX/AJ5xKiEf7wNAC3/ihry7fTfCccWpX4yJbgkm0tP+ujj7zf8ATNcse+0c1saHpY0u0ZHme5u5W825uXADTSHqxA4AwAABwAAO1W7O1t7K2jtrOCK3t4xtSKJAiKPQAcCpqACiiigArz/4/f8AJGvFn/Xkf/QhXoFef/H7/kjXiz/ryP8A6EKAO10f/kE2X/XBP/QRXMWfiq7tPEF7p/iKG2ggF0Ybe4h3ABWG6MyZ6BgcbhxuVlOOM19E1nXrXR7MzWFtqEWxFWRJRbyY2jllO5T9QwB7Cq+trJqF6dQ1PT4kjWH7OsCyiTflwxMh4GMAgAZ+82euKB2PQqK4Dw/q1/pqmGCGbUtJVd0SF8XMA4+UFsCRQTgZIbgj5q1pvFcs8OdI0a/nkU/vPtsbWUcY56tIvJOMDAI9SBzQI6mis7QtWt9Z09bq2yrBjHLExBaGQfeRsEjI/I8EZBBrRoAK4LWrR/D1wFRUfSLt/LAdciIsW/cnnGxi52kg4Py9GUDvaiu7eG7tZba5jWWCVSjowyGU8EUAeV7bnwtdSS2l3m3DBJDKSq7uAElZj/dUKs3bhX3DBGvq1lofi+yaz1PT4JTaSNvif5Z7Q8EHcGDIxAYhlJHQjI6v1W1m0gGHU0lurTiK21AyAOATxHMxHB7B+jZweSd2PdaXPp0hEEU6xrkI6MJLi2TrtXn97HgEbPvAdM8YBnJav4N8ceELlb34f69Nrmnn57nSryWMXbrgEqtxjeRyMcggAda1fCnxc8B20hbxCJ/DWuwhhNZ6hDKZEY43MZMHzCcfeODjAx69Rb6ndNGLmW2ju4QNkt1pxR1QKRw0bbZF/h+XLN15pNRh0HxdZDTdd0uy1KOFVMlrNF5M0XUkqhAZAMryD0PXrkAzNbuofiPa3E3hyw1TU7G4s3tba8kdbayBYlWb5/3jc9Sq8hdvc56HwL4hXbfWOtzRWepWkaT3cU7mMozFtxUNgeSNqqrDggetc94d8LX/AIOsH/4QPV4LXS1JkfSNXLzwR5AZjHIMSR9TnO4d8c1rz3uuXNxE2veAdM1G4iX5Li1v4JcDPUCZUZRQI6S18aeGbuGOWDxBpTJIcJm7QFuSOAT7H61z9/4l8PeFJ57221zSjpkrGW5sVuYy6MfvSxKDk+rIBzyRzkNG+t3j3LJffDqbyH6uLmydiQMklTIOMd8mrSahqEDf8SnwTBZyuuQ11cwQjHv5W8/hQMvW9mY7VdR8ITWt3pdyDI1gXBgmB5LQsOEY88cqfRTk1m6r8SdF0iQaVa6fqk2vmMtBosFhIJm69Dt2BM9X3bR61TjsvE1veT61Bq+lQSFB5tha2rNbSHqGdi29n7blC9RkHGK1LvXNJv7eC18ZWJ0qVnAikuGKxeaM/wCqnGNrcHGdrHsCKBHi2gaprN34Yih1bVbhVnkluriwtyIFMks0kjI8ifOwLPCv3gMSHg8Gu4+AVjaRXnijVLcQLZwvFp8MqjYAkYZ2z2H+sBOKl1D4U3mmvFL4XvobiyhCGOwvBtICyrINsq9T8gAyv8K5PU1HoNve6H8Nbzw5qel31trWpXMsTLHbNLEwnm2AiRAU4iIJyRjBoA9lVgyhlIKkZBHQ0MQoJYgAckntXLWRHhCSKxnc/wBgSPstZnbP2NieIWJ/5Z/3G7cKf4c7eo6RZ6lLG18jzIg4haRvKb3ZM7W/EGgDjfiH4iW78OalbaAXuZ0XYbqKR1hikJ2Im5CC7lmUBAcc5bA68x8E7e1sviZ8RLKwaNoLOLTLbKY+8kLq27n724Hd75zzmr3jy81PxN4n0Twx4Te3tbCC4ka81HGfJeJB8sK9GdPMU5+6H2DqrAHws0qz0T4tfETTdMgWCzt4NLSNAc/8sZCSSeSSSSSeSSSaAPWqKKKACiiigAoooJx1oAKKKKACiiigAooooA5v4l/8k58Vf9gm7/8ARLVx/wAN2m/4Vr4dmjjlRDptsszlcDasY+bJOMYxz7Guw+Jf/JOfFX/YKu//AES1cN8OvB2sTeA/DF3a+N9atC+l2zJFHbWhRFMSkJzESwGSBkk+9AHVLeXICWk3meYyts8uNd7eoPU8nr0yDxyKN8rQW1iHZ5YkyGSHaqYIAGCc5weRn88Gqf8Awh3iiOJUi8aq+BtPn6LbsGHodu31p8+k+OVRozd+EtRhzkRz6dNAT36iRwDnB6UDuWXWZwbWdYpLtVKOyr8o+Q87R94gsOD1HToayptLRbsyWDHT7yNfLMlozI+5TlQ8fSRQOgO4bcjjirE83iqO1eK78HWFyGUKxsNRSQHA4YJMiD06ntVK98TWNnzr+h65pkSBSHm0vz4lK990JkAweRnGMdaAOw8M+II9WhEF0q2urRr+/tSwz/vJz8yHsR9Dg5Fbtec2mq6H4i09n0650fxAsOGaOMo0kbN1BB+ZfrwfyNXbC11HQ7xl0OP7TZtIwks3lARfQxknKHjkY2knt94gjuaKwP8AhKbKAD+1IbzTW4z9phOwZOMl1ygHHUkVuQyxzxLLDIkkbjKuhyCPUGgDM1vw/Y6uyyzo0V4ilY7qBtkqA543DqvJ+U5HtXK6npmp2+Y9bsY9a01WDrJZRlZEIXbnyt2Qcd4z3ztFegUUAeZWU9tKFtrLXrq3kYMBaXUiyNH6BknUyAcdj+VPurK/XzbpbexW/jQ/6ZayzWcm1Qcb1IZWAx/ESOnA4r0G+sLTUITDf2sFzEf4Jow6/kaxJfBulGLy7U3llHnIjt7p1jB/65klP0oC5xU2paxc6Y8Fzokes2csWyQIsEjuBu4MXmBX5BGfl78Ulhq2o6FEtvouoRJaRp8mm6/BPAYhgfIk+0lV64DeYB0BAxXYv4WZUzJr+olFHWSK1Yge5MP61jyy2yeZFY+ItZ1Sdjk/ZVtiisB1aXyggPTqc+1AEVt8Rblo/L1LwlqkhbKu+kTQ6lGvsfLbePxQVHZfEXRLe7FpaeHfFMc0cRWO1TQZV2KG+Yr8o4yVzzjgVat4XkUW+vQLe37wqskqQqNsm0HOTg8nOMdMelJ4KaKPxnfWaX0lw8FgheKQ72ty0rnYXydxxtPJLAbck5FAFW2+KFxrBkg8N+EdZuLpUD5v3hs4UBzgsxckfdY42k4GcVkeIv8AhOLq4sZdY1K0l0qSbF1pHh2Ty53i2n7s8hDuQ2AVQISDwc4FbfhKKLTNOG20SExPOjvFGoUyCd0Ysc5LE7T06d+RW9ahJLkwrCokyQd6dgeSDn+8OvU/lQOxzVrLoNjBaQaF4a8V2RhYbYbK0mtg3JJ3liqNzySSSe5Iqzf/ABP+x31lpknhLxIus3zmO1tHhiAkx1bzBIVCAck54qHUvEcFvdLpPhiBdT8USIrmzQBY4hx+9uGHESY45+Y8BRnmt/wT4R/sNpdR1W5Go+IbpAk95sCrGgORDCv8EQJOB1J5JJ6AmQyeGNS8QFJvFepzx255Ok6dKYoB7SSDEkvvyqn+7XUabp9npdlHZ6baw2lrEMJFCgRV+gFWqKAPNfhd/wAj78Tv+wtD/wCk6V6VXmvwu/5H34nf9haH/wBJ0r0qgAooooAKKKKACvP/AI/f8ka8Wf8AXkf/AEIV6BXn/wAfv+SNeLP+vI/+hCgCLTppZoxCiAKkMbtvysbL6A8cgAE+mSc81Z2CEGRIpI5QxCyxA7ZBv4PHDAZBPB7d6Wx0jxdNpli39s+HxiFdoOkSHaNowAfPpW0LxbEAYr/w3M5PzF9PnjyPQYnOPpigq4x1n25leVYAGLo6N8oIHyqVIYcnONpOcdOMSW1/NLPG8lyJUUESwtG+8bmxkZbIwc8EZx04FRGz8b2u/ZY+GrqIcLHFdTW5Yd/vI4Hfp61QF74jtIGTUPB+qqrMGL6be284j4AICsyE9P7vQ47UBcty20tjKbjSb17a+UKCBG8q3IOdquhPPsQQwOecHB63QNXXU4JI5lWHUrYhLq2zkxv6j1Q4yrdx7ggcRD4y0CC/S21PWpdMvJXGIdTsTZjCkYH7xQpOcYIPYelbF1pyyfZrpLhobmOWRra6gVEJU87FGT5iHPIIOTyOxoFY7SiuTh8RX+nz+RrdqlzGMA3enqzFSc43wcuAQM5UuPXArd07WdN1JA2n39rcAgHEcoJGfUdQfY0CLdxBFcwSQXMSSwyKVeORQysD1BB6iuG1Tw7qOhyveeH/AD72Futu8uZIQA2Nm7h1G4/K3PoTgLXe0UAeXyS2k1/HFJJdWWqzr8jRRvFck8nDqThx0I6gHPI5NStY3H2K2h1RrXV3iLTQi5aaOaPK55dA4U4HGAv616BqOnWWpweTqNpBdRA5CzRhwD6jPQ+9Ydx4QiCsumarqmnxlNnkxzCWLH+5IGA/DFAXOSP9uiP/AEVJZ7cx5WNpkmQAqD/rS0bqcN1Ibr7Yq4niTVYw8WoeFdbj3AjzrLZPjnOdwbJPbBA71rzaD4hhJNjqOjy/JtBubGQMee7LLzxkdO9Six8VyAb7rQYXBU70t5nzg5xzIMZx70BcxoNVu7/ybmz0PUbP72Z9Vm+zABuoCrvdgeOwHA6VNb22p7pZYtR0zLuTJbmzm8tmC9i0mfQ8DvS6zdajpjok2s6S92fljs4NOkllc44AHnZUf7RwAOpFWNFhuGsw9zLDbsFQzQW0atGkmcsQeCRnjOP4eKBmJP4z0rwvZJL4qf8AslJE2xTIk32aUpyNvy7o3wOQygt2LY44v4kSeKNYtbHW7aC6i0lLy3NrZysHlYs5/fSp/BwFATjaHYH5mIHY+Jkh1DW7PRsW93b208V/c7osCEJn7OGJJyWfHH91HJGCK6Mia50iWLV5TOQwYMqiH5QBnJ54yM569sUAeIeFfEOpadodsNFvrywvoomZ7Rm82I7RbpgxuSq5kkY/Lg9ea9c8BeKvEOr6X4TvNWh0x01u289xbrJE8OIy5O0lgwztHUfeFeTeMdCksJHutKBFxG853qR+9cTQqAFP8OYZGx7e1Q+GrbU/+Ee0bVYr3WLE2+kpYnyGCJnyyWVTg7MPCPu4OGPNAj6J8Q6/oemRtba1eWymZSptmHmPIpByPLALMMZzxXP6FdXovpNGhsNaOhyKyw3c0fkvaDAwm5m3Mp52tjcvAOeCOL0jQZrqyaHRrNFkmH72bHzMTBGQXk6k/vM5OT1r1CPTdQ0+zuDZXnmzMWMaSgeWCWYgnvgbsnHJxQBW0myhbxXNJaKkdlpVoLGGNB8qySESSfiFWH8zXNeB/wDkt/xO/wCuWl/+iXrc+FEvmeENrzm4uIr+9inmbG6SRbmQFjjjJwD+NYfgf/kt/wATv+uWl/8Aol6APTKKKKACiiigAooooAKKKKACiiigAooooA5v4l/8k48Vf9gm7/8ARLVH8LP+SZeEv+wRaf8Aolak+Jf/ACTjxV/2Cbv/ANEtUfws/wCSZeEv+wRaf+iVoA6iiiigAooooAwNd8HeHtdlM2qaRaTXPBFyqeXOMdMSrhx+BrEm8G6xYYfw74nudqDCWurwrex4xjb5nyyge5c13VFAHmser6/ojKPEnhm6ZFG03miEX0JHq0ZAmXt2fp171Bpc/hzWLiR9F1OO31DzAJYLNpLCUjPV4mwzNwOSPWvUayfEHhzRvEUAh1zTLS+RfumaIMyH1Vuqn3BFAGI1leQXEwsdf1JSFBVZtkwAyRkq6g4yrc554wajOra79oEFtqGm3GJPLZ20512nGRked3+lQXHgC6s4yvhfxVq+lpkkW10V1C3weo2zZYD6OKxL/Tfivp3z2U/g7XlVNv8ApFvNaykeg2uV7DqaANt9U1q4jVv7ZtUiPDSWenbsHB7tKwBBXH3T1qG5tJ9jvc65rDyGMM7C7WNR7gIFAB7HjpXGr4l+JcRKax4OisAp/wCXHT/t0fUkkbLpSfX7vekfxbcNHINR1i8sXbarovgm73DHu5cHuPQUDujtjo9hcW3myvHcuhIWS4kackhfSQuB3I6849MVPrdxb6NpaLqGox6eUkGHcxqsvHUKcZbgfKvsB1xXExa9pFwEluNf8favIGI8u20m4tEYn18mBGx/wLvWxpUmm2E7XXh74eeIG1En/XzW0UUj+5mnff8AnzTBMkl1nUdYu5LXRitjpsmNmoXaBZyhP/LCFgGJ7iRsKN2QGNWNPhsfDfiPQ7TT22P5ktrNa7xJLtlAYyN1dj5kaEyNngtk05l8Yaok8KeFrHT0ljMckuo6uXLg5z8kCk9z/EPwqx4L8J6/4UsBHb32kTAuWe0W1aNMcnCylmkzk9X3/hSFctX+h6xBrN+dJt9KNncyC5FxeMxMDlcOBGB8wyquDuXlm9q5fStH8beIjIW1a203R7gkpqMFqiXkkBwFWFRkRZClt7Eth1AGVzXWa54khuNC1Ownjm07WHt2jW1nIVmLgLujb7sgBYcqTjvg8V18EUdvBHDCoSKNQiKOgAGAKAMnwt4a0rwtpostFtVgjJ3ySElpJnPV5HPLsfUmtmiigAooooA81+F3/I+/E7/sLQ/+k6V6VXmvwu/5H34nf9haH/0nSvSqACiiigAooooAK8/+P3/JGvFn/Xkf/QhXoFef/H7/AJI14s/68j/6EKAOz0t0i0azeRlRFgQlmOABtFMstZ06+umt7S6jllVd2FzgjjJU9GHI6Z61gXTNqWmWunQ2UsskEUMvm/aFhCNsBBGcluCeqlc+4OMV9e1RNTvo3O62sogGv4oPNYE4ZkEpCxdNvRScjGCaAPSaZHLHIXEbq5RtrbTnafQ+h5FeTxeN9Y/sySQ+al1I5tooHjWR4ZMEF5nACqF2tw23LAjCquS7SfHEcVsmm6JNbzBXeSe/ZSyYBO7y8485y2cuSq53McKMUAep3sNtcWzw3scUtu42ukqhlbPGCDwa4i5+HXh5LuRPD0914f1DaJSNMnKJjJwWgOYyM5/h55rFtviciFr6/vrKK0uJhHbWxQhmwD8iE4LE5GXICjGACxIGzpGt3Men6ldpHbNeuPNkdiWWMgHLTMDiNFUcR5LYHPJIoAkjt/G2iu0rLpXiROBlc2NwQOMnO9GIHulYWteKdGZhB4s0KbR5uQ0usWgEJHYLcoHTr/tKR1+odf8AFEmopqdnFbXkYLxG2jvisQLfLEpym0ncVyMl8nkoOK6jw1beIltS2pvp13JcN/pEzTSMGwcFUj2KFUDIA5z1JJOaAK1hHdbIn8M65Lc2bdDJIt5ABzzuzv4wBtD96uR61rlvP5F1baXdyBfmaCaSI5zj7rIw6/7VN1H4c+F7yZriHS0069PIutMdrSUH13Rlcn65rJuPBviqxgkXRvGDX8fVLfXbUTDPYebEY3HPc7vxoGdAniS7DhZ/D+oDJAUxSwvk89i6t29KF8TTybRD4e1dmb7u7yEB4z1MvSuNv9T+IOnvGl94Gs9VhTGZtH1kxkY7hJVU/hn86wdV+LF1oyONQ+GPi+32naCqlo2Puy8d/egR6ZdavrkiMsFjYWBA3NJeTtLtH+6gx/4+KoNod9qfmHV9Qv7ljuAt47kQRAc7SVjCk5/2i2O9eeW/xiOqSA2reEtJKjH/ABNtfZT1zzEsWM/U5FaZ8VxagjSX3xX8KaUrACSPSGhZvwknd/XsgoGdnFpVvoVhNNbi3s4WXks4gjQdSWboSPXvjk9MYj+Ip/EkDW3hSyt3jMn7zV7jcLMP0HlDAM7k/wB0bPUn7pxAfhlDeR3OseLdI127TDxzaxrKXRQ55KoT5a8AdFBzW4fiV4KCwwS+JNOunWXKrA7T7QM7TlVbnpwMf4gGlpmhw6ZapbxorebuaaeR0ZpZHzvkLbcsx+UemAAAAMU+3nksJTcXMMSadDGEaUNuLYZeNoHPJOO5OMdaz18XwXcaDQ/DfiXWQI1CsLE2sZb18y4KY69s8VTutD8eeJEghl/s3wvYpIJSfON/dbguFPARAVPzDlhuwccYoA5Px3qdt4dtJXv5YhawMbeSbGwzlfM8xlGf4pLmYAdzC1bHwGZvEnwzTSdZgmsb2yvJJ2tpoyriGZ3ljYBh90h2API+U12Hhr4YeH9Hnt7y8jm1rVYEVEvdTYTMgBJGxcbE5Zj8oB+Y8nNaHi3w1LfXtvrehXP2HxFZIVjlxmO5j5P2eYfxRknOeqnkd8gjpLW3htYVit41jjUABVGOAMD9AKlPNZPhbWRr2iQXxt5LSYlo57WQgvBKjFXjJHBwwIyOowe9a1AHCzRP4N8XWslnFHH4a1qUQTwxR4FpeNnZKMcBZMBG4+/sP8RrN8D/APJb/id/1y0v/wBEvXa+LtJGueGdS03pJPCwibuko5jce6uFYe4rzX4OX8mq/EfxtqE+BNd6dos8gHQM1sxP6k0Aew0UUUAFFFFABRRRQAUUUUAFFFFABRRRQBh+OrO41HwR4hsbKMy3Vzp1xDFGCAXdomCjnjkkV514R8U+MtC8KaNpMvw01eWSwsobVpFvrYByiBSQN3Q4r2GigDzT/hPvGH/RL9Z/8D7b/wCKo/4T7xh/0S/Wf/A+2/8Aiq9LooA80/4T7xh/0S/Wf/A+2/8AiqP+E+8Yf9Ev1n/wPtv/AIqvS6KAPNP+E+8Yf9Ev1n/wPtv/AIqj/hPvGH/RL9Z/8D7b/wCKr0uigDzT/hPvGH/RL9Z/8D7b/wCKo/4T7xh/0S/Wf/A+2/8Aiq9LooA80/4T7xh/0S/Wf/A+2/8AiqP+E+8Yf9Ev1n/wPtv/AIqvS6KAPNP+E+8Yf9Ev1n/wPtv/AIqj/hPvGH/RL9Z/8D7b/wCKr0uigDzT/hPvGH/RL9Z/8D7b/wCKo/4T7xh/0S/Wf/A+2/8Aiq9LooA80/4T7xh/0S/Wf/A+2/8AiqP+E+8Yf9Ev1n/wPtv/AIqvS6KAPKr7xd4kv/J+2/CXUrjyJFmi827tW8t1OQy5bgj1FWv+E+8Yf9Ev1n/wPtv/AIqvS6KAPNP+E+8Yf9Ev1n/wPtv/AIqj/hPvGH/RL9Z/8D7b/wCKr0uigDzT/hPvGH/RL9Z/8D7b/wCKo/4T7xh/0S/Wf/A+2/8Aiq9LooA81+ENnrQ1jxnq2u6LPox1W/jnht55UkbasKoeUJHVa9KoooAKKKKACiiigArjfjFpN9rvwx8RaZpNu1zfXNqY4YlIBdsjjJIFdlRQB5H/AMJP4jltbaK9+EuoXLQxiMNLdWj4wMHGWq9F458WQxLHF8LNXSNRhVW+tgAPYbq9OooA8ql8XeJJnjeX4S6k7RuZELXdqSrHqw+bqfWpj448Vldp+FerFdpXH221xg9R97pXp9FAHlb+L/EjpIj/AAl1Jkkbc6m7tSHOc5I3cnPP1qaPxz4sjjEcfws1dIwMBVvrYAD6bq9OooA8vbxv4qZY1b4VasRGwZAb21+UjoR83BqX/hPvGH/RL9Z/8D7b/wCKr0uigDzT/hPvGH/RL9Z/8D7b/wCKo/4T7xh/0S/Wf/A+2/8Aiq9LooA80/4T7xh/0S/Wf/A+2/8AiqP+E+8Yf9Ev1n/wPtv/AIqvS6KAPLbjxn4nuVxc/CjVJh6SXlq382qjJrmqyY8z4MXDkcjdLZnH617BRQFjyaLxPr0QxF8H71B/s3FoP61bj8c+LIhiP4Waug9FvrYf+zV6dRQB5p/wn3jD/ol+s/8Agfbf/FUf8J94w/6JfrP/AIH23/xVel0UAeaf8J94w/6JfrP/AIH23/xVH/CfeMP+iX6z/wCB9t/8VXpdFAHmvw/13VpvGesW+t+Hb3QIdSRLu1iuZYpA8qAJNhkJ6r5RwfRj616VXNePLeUaXBqtpHvu9HnW+RQcF0UFZUHu0TSAe+K6KGVJ4Y5YmDxyKGVh0IIyDQA+vG/gNp2rrrfiXWdS0qWwsr+2sIrN3dGE6wxupcBTwDlTg4617ITgEk4Fcl8Ln2eEIdPeTzJ9Knm06Vj1JikZQT9VCt/wKgDraKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAFFFFABRRRQAUUUUAIyhlKsAVIwQe4rmvh35kHhtdMuGLTaVNJYEnukbYjP4xmM/jXRXE0dtbyzzuscMSl3djgKoGST7YrnvBulRxLd65LC8eo6xJ9pm3McqhAEaY6AhFQH3zQBu6hNHbWFzPPKIoo42dpDj5QByea4XSHuvDOsw6jqMYi0zxBFbtevgL9m1EoseWHZZAEXPZ1H97jvbm3huoxHcxrLGGV9rDIyDkH8CAa5f4hvHqWlv4btmMmp6kFVI0PzQxhhumb0VcZyepwByaAOtooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKyvFWqnRPDuoaiqeY9vEWVfVugz7ZIoAp6xFFr+oppTYksbZlnvQDw7A5jhP1I3MPQKDw1dDXEeHbuy0PQbzVdQnuLa2hkELwyqQyMWX5nQcmWRnDHqfnUD3nnTVvFtrDBNb3WiaRISbpZtoublMn90ApPlqw+8x+bBwAp5AAx21bxbdedpeqf2b4cXdGs9uoNxdsDgujHKpH1AOCT94Y+U1v6FoWn6HC6adBteU7pp5HMkszf3pJGJZj9TWjBDHbwRwwRpFDGoREQYVVAwAAOgFPoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACq2p2UWpadc2VxvEM8ZjYo21gCOoPY+hqzRQBzll4Tt4byO4vL6/wBQ8qQTpHcumwSjAEhCqu5hjgtnHGMYGOjoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After spontaneous expulsion to the scalpulae, external rotation of each thigh (A) combined with opposite rotation of the fetal pelvis results in flexion of the knee and delivery of each leg (B)",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gabbe, SG, Niebyl, JR, Simpson, JL (Eds). Obstetrics: Normal and Problem Pregnancies, 4th ed, Churchill Livingstone New York 2003. Copyright &copy; 2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_34_40484=[""].join("\n");
var outline_f39_34_40484=null;
var title_f39_34_40485="Estradiol (topical): Patient drug information";
var content_f39_34_40485=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Estradiol (topical): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/1/38935?source=see_link\">",
"     see \"Estradiol (topical): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8018309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Estrace&reg;;",
"     </li>",
"     <li>",
"      Estring&reg;;",
"     </li>",
"     <li>",
"      Vagifem&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8018310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Estrace&reg;;",
"     </li>",
"     <li>",
"      Estring&reg;;",
"     </li>",
"     <li>",
"      Vagifem&reg;;",
"     </li>",
"     <li>",
"      Vagifem&reg; 10",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10031033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700311",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Estrogens, when used in women after stopping periods (menopause), may raise the chance of uterine cancer. Progestins may lower this chance. A warning sign for cancer of the uterus is vaginal bleeding. Report any vaginal bleeding to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700259",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take estrogens to stop heart disease or dementia. Using estrogens may raise your chances of having a heart attack, a stroke, breast cancer, or a blood clot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3406344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use estrogens with or without progestin for the shortest time needed at the lowest useful dose.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10031035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat vaginal irritation and dryness caused by change of life.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10031034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to estradiol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Blood clots, breast cancer, liver disease, recent heart attack, recent stroke, tumor where estrogen makes it grow, or vaginal bleeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10031039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697661",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There may be a higher chance of endometrial or breast cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698554",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do monthly breast self-exams and have a gynecologic exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid cigarette smoking. People older than 35 years of age and/or smoking more than 15 cigarettes per day have more chance for heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10031040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaginal irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10031042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699053",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad vaginal irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698598",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A lump in the breast or breast soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10031037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705575",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Vaginal cream/tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696170",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use cream or tablet vaginally.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands and applicator after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705577",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Vaginal ring:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put into the vagina and leave in place for 90 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use as you have been told by your doctor or read the package insert.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695580",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out ring at the start of the 13th week.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695226",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put in a new ring.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To use, wash your hands and take ring from the pouch.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Press sides of ring at the same time between thumb and index finger and put folded ring into the vagina.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695506",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Perfect placement is not needed for the ring to work. The ring will not hurt.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696146",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To take off, hook your index finger around the rim or hold rim between index finger and middle finger and pull out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694778",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not throw the vaginal ring in the toilet.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10031038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10031043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10031044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11675 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-50DD9E1A11-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_34_40485=[""].join("\n");
var outline_f39_34_40485=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018309\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018310\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031033\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031035\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031034\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031039\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031040\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031042\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031037\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031038\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031043\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031044\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/25/14746?source=related_link\">",
"      Estradiol (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/58/38824?source=related_link\">",
"      Estradiol (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/35/35383?source=related_link\">",
"      Estradiol (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?38/1/38935?source=related_link\">",
"      Estradiol (topical): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_34_40486="Continuous postmenopausal hormone therapy";
var content_f39_34_40486=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Continuous postmenopausal hormone therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/34/40486/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/34/40486/contributors\">",
"     Laurence C Udoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/34/40486/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/34/40486/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/34/40486/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/34/40486/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/34/40486/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/34/40486/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial observational studies suggested that, in addition to improving menopausal symptoms and preventing postmenopausal bone loss, estrogen therapy also had a cardiovascular benefit. However, the Women's Health Initiative (WHI) and the Heart and",
"    <span class=\"nowrap\">",
"     Estrogen/Progestin",
"    </span>",
"    Replacement Study (HERS) trials found that continuous estrogen-progestin therapy (conjugated estrogen 0.625 mg and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    2.5 mg) is not cardioprotective and may slightly increase risk (in older women) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=see_link\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=see_link\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For most perimenopausal and postmenopausal women, short-term estrogen therapy is still a good option for treatment of menopausal symptoms. Patient compliance with continuous estrogen-progestin therapy, the ability of this regimen to minimize uterine bleeding (which provides the major rationale for its use), and its efficacy in relieving the vasomotor symptoms and bone loss induced by estrogen deficiency and in protecting against endometrial hyperplasia will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FREQUENCY OF ESTROGEN THERAPY USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even prior to the results of the WHI and HERS trials, estrogen therapy was not offered to many women, and many of those who began treatment did not continue it for very long. As an example, a 1993 North American Menopause Society-Gallup Poll questioned 833 women aged 45 to 60 years about estrogen therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      34 percent were currently taking estrogen",
"     </li>",
"     <li>",
"      8 percent had taken it in the past",
"     </li>",
"     <li>",
"      58 percent had never taken it",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In other surveys, only 10 to 30 percent of postmenopausal women were taking estrogen. In a 1987 study of women given prescriptions for estrogen, 20 to 30 percent never filled the prescription, 10 percent reported only intermittent use, and 20 percent discontinued treatment within nine months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The percentage of women taking postmenopausal hormone therapy declined dramatically after the initial publication of the WHI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reasons for not beginning treatment or discontinuing it include resumption of vaginal bleeding (caused by the addition of progestin therapy to decrease the risk of endometrial hyperplasia and uterine cancer if the woman has not had a hysterectomy), perceived lack of need, fear of breast or uterine cancer, and side effects, including breast tenderness, weight gain, and premenstrual-like symptoms such as irritability and fatigue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/6\">",
"     6",
"    </a>",
"    ]. In one study, more women clinicians were taking long-term estrogen therapy than women in general (41 versus 17 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In recognition of these barriers to acceptance of and compliance with cyclic estrogen-progestin therapy (cycles of estrogen and then estrogen plus progestin therapy), continuous daily estrogen and progestin therapy was introduced about 15 years ago. It was reasoned that continuous administration of a progestin would cause atrophy of the endometrium and amenorrhea. In addition, the frequency and severity of premenstrual-like symptoms (attributed to the progestin component of the regimen) could be reduced or eliminated because the daily administration of a progestin allows for the use of a lower dose to attain endometrial protection.",
"   </p>",
"   <p>",
"    One commonly used regimen for continuous therapy is 0.625 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/23/35184?source=see_link\">",
"     conjugated equine estrogens",
"    </a>",
"    (CEE) and 2.5 or 5 mg medroxyprogesterone daily. Other regimens include micronized estradiol, ethinyl estradiol, estradiol valerate, estriol or piperazine estrone sulfate as the estrogen, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/52/16199?source=see_link\">",
"     norethindrone acetate",
"    </a>",
"    , progesterone, norgestrel, dydrogesterone or megestrol as the progestin. A recent addition to these options is the combination of 17 beta-estradiol and drospirenone, a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    analogue with progestogenic, anti-aldosterone and anti-androgen properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition to oral estrogens and progestins, various other regimens have been tried, including transdermal estrogen and progestin delivery systems and progesterone-releasing intrauterine devices. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16218?source=see_link\">",
"     \"Preparations for postmenopausal hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COMPLIANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no large prospective studies of long-term compliance in women receiving continuous estrogen-progestin therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/9-25\">",
"     9-25",
"    </a>",
"    ]. A retrospective chart review of 104 women in a New Zealand clinic revealed that 86 percent of those for whom continuous estrogen-progestin therapy was prescribed were taking it one year later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/9\">",
"     9",
"    </a>",
"    ]. In clinical trials of 50 or more women followed for 12 to 36 months, approximately 80 percent (range 35 to 100 percent) were still taking continuous therapy at the end of the study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/11-25\">",
"     11-25",
"    </a>",
"    ]. Compliance was lowest in those women who switched from cyclic to continuous estrogen-progestin regimens. The usual reasons for drop-out were irregular uterine bleeding, breast tenderness, edema, weight gain, irritability, depression, and personal reasons.",
"   </p>",
"   <p>",
"    In another study with 10 years of follow-up, postmenopausal women were randomly assigned to continuous or cyclic estrogen therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/10\">",
"     10",
"    </a>",
"    ]. The women receiving continuous estrogen therapy were more likely to still be taking it at the end of the follow-up period (38 versus 22 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/10\">",
"     10",
"    </a>",
"    ]. This differs from the conclusions reached by a review of a California HMO prescription database. At the end of three years, patients receiving continuous estrogen-progestin therapy were less likely to be compliant (19 percent vs 24 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INDUCTION OF AMENORRHEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous estrogen-progestin therapy results in amenorrhea in",
"    <strong>",
"     50 to 94 percent",
"    </strong>",
"    of women treated for six months or longer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/12-16,19,24\">",
"     12-16,19,24",
"    </a>",
"    ]. However, irregular uterine bleeding is relatively common before six months, although its frequency varied widely among studies (0 to 93 percent).",
"   </p>",
"   <p>",
"    Comparison of the results of different studies is complicated by several factors: different doses and preparations of estrogen and progestin; fixed doses or changes in dose in attempts to decrease the incidence of uterine bleeding; and lack of information about whether the percentages given are for uterine bleeding at a certain time (eg, three months) or for bleeding during a time interval (eg, within the last three months). In addition, therapy was begun at various times after the menopause. In some studies, as an example, the incidence of uterine bleeding was higher in women starting treatment soon after their menses ceased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/11,21\">",
"     11,21",
"    </a>",
"    ]. Despite this variability, the likelihood of induction of amenorrhea with continuous therapy is clearly better than with cyclic therapy (75 versus 10 to 20 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16218?source=see_link\">",
"     \"Preparations for postmenopausal hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequency of uterine bleeding may also be influenced by the doses and types of estrogen and progestin and the delivery systems.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher estrogen doses (1.25 versus 0.625 mg of conjugated estrogens) may be associated with lower rates of amenorrhea when combined with 10 mg of medroxyprogesterone or 0.35 to 2.1 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/52/16199?source=see_link\">",
"       norethindrone",
"      </a>",
"      , respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/12,27\">",
"       12,27",
"      </a>",
"      ]. However, in women treated with estradiol valerate and chlormadinone, increasing the estrogen dose from 1 to 2",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      increased the incidence of amenorrhea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is a similar variability in findings with respect to the progestin component. Higher doses did not increase the frequency of amenorrhea in some studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/28-30\">",
"       28-30",
"      </a>",
"      ], but did in others [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/12,13,18,21,31,32\">",
"       12,13,18,21,31,32",
"      </a>",
"      ]. One study compared the response of conjugated estrogen (0.625",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      plus one of three different progestins: medroxyprogesterone, norgestrel and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/52/16199?source=see_link\">",
"       norethindrone",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/19\">",
"       19",
"      </a>",
"      ]. Amenorrhea occurred sooner in the women given norethindrone but, by eight months, the patterns of uterine bleeding were similar in all three groups.",
"     </li>",
"     <li>",
"      In one study, vaginal bleeding control with a combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/43/32442?source=see_link\">",
"       ethinyl estradiol-norethindrone",
"      </a>",
"      acetate (5 mcg and 1 mg) was significantly better than with conjugated estrogen and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      (0.625 mg and 2.5 mg) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings have led to several proposals to limit the incidence of irregular bleeding in women receiving continuous estrogen-progestin therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increase the dose of progestin until amenorrhea occurs. In one study using this type of regimen, postmenopausal women were treated with 0.625 mg of conjugated estrogens and 2.5 mg of medroxyprogesterone daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/13\">",
"       13",
"      </a>",
"      ]. Those women (&lt;50 percent) who reported bleeding at the three month follow-up visit underwent an endometrial biopsy. If the biopsy specimen did not show atypical hyperplasia or carcinoma, the dose of medroxyprogesterone was increased to 5.0 mg daily.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More than one-half of these women became amenorrheic in the next three months. The majority of the endometrial biopsies obtained from women with bleeding at three months showed proliferative endometrium, suggesting an inadequate progestin effect. At the six month follow-up, women with refractory bleeding underwent office hysteroscopy and endometrial ablation. Many of these women had endometrial pathology such as endometrial polyps or leiomyomata.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initiate treatment with a high dose of progestin (eg, 5 or 10 mg medroxyprogesterone) and then decrease it three or four months later.",
"     </li>",
"     <li>",
"      Use a progestin-containing intrauterine device to deliver progestin directly to the endometrium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. In studies evaluating this regimen, approximately 80 percent of women had amenorrhea within eight months after treatment was begun. Furthermore, the subjects studied were perimenopausal women in whom amenorrhea tends to occur slowly after initiation of continuous oral estrogen-progestin therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EFFICACY OF CONTINUOUS ESTROGEN-PROGESTIN THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous therapy diminishes vasomotor symptoms, prevents bone loss, and protects against endometrial hyperplasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Relief of vasomotor symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous estrogen-progestin therapy relieves hot flashes in nearly all women, based upon subjective reporting; objective biophysical monitoring has not been performed. In studies in which women were asked to record the incidence and severity of hot flashes, paresthesias, insomnia, nervousness, melancholy, vertigo, fatigue, arthralgias, myalgias, headaches, and palpitations (Kupperman score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/36\">",
"     36",
"    </a>",
"    ]), the scores declined significantly during treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/17,35,37-39\">",
"     17,35,37-39",
"    </a>",
"    ]. Continuous therapy also reduced the frequency and severity of hot flashes and other menopausal symptoms (eg, vaginal dryness and dyspareunia) in those studies in which the assessments were based upon diaries and interviews.",
"   </p>",
"   <p>",
"    Whether continuous therapy is superior to cyclic therapy in relieving vasomotor symptoms is unclear. In eight comparison studies, continuous therapy was more effective in three [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/15,19,40\">",
"     15,19,40",
"    </a>",
"    ], but not different in five [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/17,39,41-43\">",
"     17,39,41-43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Prevention of bone loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevention of osteoporosis and osteoporotic fractures in postmenopausal women, as confirmed by a reduction in osteoporotic fracture risk in the WHI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/1\">",
"     1",
"    </a>",
"    ], was one of the accepted indications for the use of long-term estrogen therapy. However, we no longer consider it to be a first-line drug for this indication, based upon the results of the WHI and HERS trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17831?source=see_link\">",
"     \"Postmenopausal hormone therapy in the prevention and treatment of osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prevention of endometrial hyperplasia and carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of postmenopausal women with unopposed estrogen can cause endometrial hyperplasia and cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/44\">",
"     44",
"    </a>",
"    ], with a relative risk of endometrial cancer with long-term estrogen between 3.1 and 15 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40486/abstract/45\">",
"     45",
"    </a>",
"    ]. Progestins prevent the increase in risk, and both cyclic and continuous combined hormone regimens are protective. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=see_link&amp;anchor=H256690677#H256690677\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\", section on 'Endometrial hyperplasia and carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prevention of cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen therapy has a favorable effect on cardiovascular risk factors, but does not appear to be cardioprotective. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=see_link\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H762621179\">",
"    <span class=\"h2\">",
"     Effect on breast cancer risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been a suggestion that progestin given continuously with estrogen may be associated with higher risk of breast cancer than regimens in which the progestin is given in a cyclic fashion, but this has not been reported in all studies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=see_link&amp;anchor=H150020558#H150020558\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\", section on 'Effect of progestins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous estrogen-progestin therapy is still indicated for treatment of menopausal symptoms, but is no longer indicated for prevention of chronic diseases given the results of the WHI and HERS trial. For those who choose to take HT, continuous estrogen-progestin therapy relieves hot flashes and other menopausal symptoms in most women, prevents bone loss, protects against endometrial hyperplasia and carcinoma, and produces a favorable change in serum lipids. Its main advantage over cyclic progestin therapy is the induction of amenorrhea in approximately 75 percent of women versus 10 to 20 percent with cyclic therapy. As a result, continuous therapy has been well accepted, with drop-out rates",
"    <strong>",
"     in clinical trials",
"    </strong>",
"    averaging only 20 percent, though the real-world experience has been variable.",
"   </p>",
"   <p>",
"    Based upon the evidence available, we use combined continuous therapy primarily in women who are postmenopausal two years or more and who will accept irregular uterine bleeding for at least the first six months. Counseling women about the likelihood of unscheduled bleeding and outlining a plan of management (eg, in-office endometrial biopsy, change in medication dose, ultrasound, hysteroscopy) greatly improves compliance. Women who are perimenopausal or early menopausal are started on a cyclic regimen and converted to a continuous regimen if the continuation of bleeding becomes an issue.",
"   </p>",
"   <p>",
"    The most commonly prescribed regimen is conjugated estrogens (0.625",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and medroxyprogesterone (2.5",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    although many other options are now available. Transdermal estradiol is recommended for women with a history of hypertriglyceridemia, glucose intolerance, gallbladder disease, or venous thromboembolism, because transdermal estradiol is expected to be less likely to cause these adverse events than oral estrogens.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/1\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/2\">",
"      Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/3\">",
"      Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/4\">",
"      Utian, WH, Schiff, I. NAMS-Gallup survey on women's knowledge, information sources, and attitudes to menopause and hormone replacement therapy. Menopause 1994; 1:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/5\">",
"      Ravnikar VA. Compliance with hormone therapy. Am J Obstet Gynecol 1987; 156:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/6\">",
"      Salamone LM, Pressman AR, Seeley DG, Cauley JA. Estrogen replacement therapy. A survey of older women's attitudes. Arch Intern Med 1996; 156:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/7\">",
"      Isaacs AJ, Britton AR, McPherson K. Utilisation of hormone replacement therapy by women doctors. BMJ 1995; 311:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/8\">",
"      Palacios S, Foidart JM, Genazzani AR. Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism. Maturitas 2006; 55:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/9\">",
"      Grey AB, Cundy TF, Reid IR. Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in post-menopausal osteoporosis. Clin Endocrinol (Oxf) 1994; 40:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/10\">",
"      Eiken P, Kolthoff N, Nielsen SP. Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women. Bone 1996; 19:191S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/11\">",
"      Staland B. Continuous treatment with a combination of estrogen and gestagen--a way of avoiding endometrial stimulation. Clinical experiences with Kliogest. Acta Obstet Gynecol Scand Suppl 1985; 130:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/12\">",
"      Magos AL, Brincat M, Studd JW, et al. Amenorrhea and endometrial atrophy with continuous oral estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 1985; 65:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/13\">",
"      Sporrong T, Hellgren M, Samsioe G, Mattsson LA. Comparison of four continuously administered progestogen plus oestradiol combinations for climacteric complaints. Br J Obstet Gynaecol 1988; 95:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/14\">",
"      Weinstein L, Bewtra C, Gallagher JC. Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient. Am J Obstet Gynecol 1990; 162:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/15\">",
"      Williams SR, Frenchek B, Speroff T, Speroff L. A study of combined continuous ethinyl estradiol and norethindrone acetate for postmenopausal hormone replacement. Am J Obstet Gynecol 1990; 162:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/16\">",
"      Hillard TC, Siddle NC, Whitehead MI, et al. Continuous combined conjugated equine estrogen-progestogen therapy: effects of medroxyprogesterone acetate and norethindrone acetate on bleeding patterns and endometrial histologic diagnosis. Am J Obstet Gynecol 1992; 167:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/17\">",
"      Obel EB, Munk-Jensen N, Svenstrup B, et al. A two-year double-blind controlled study of the clinical effect of combined and sequential postmenopausal replacement therapy and steroid metabolism during treatment. Maturitas 1993; 16:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/18\">",
"      Rauch U, Taubert HD. Continuous hormone replacement therapy with estradiol valerate and chlormadinone acetate in adjustable dosages. A preliminary study. Maturitas 1993; 17:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/19\">",
"      MacLennan AH, MacLennan A, Wenzel S, et al. Continuous low-dose oestrogen and progestogen hormone replacement therapy: a randomised trial. Med J Aust 1993; 159:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/20\">",
"      Marsh MS, Crook D, Whitcroft SI, et al. Effect of continuous combined estrogen and desogestrel hormone replacement therapy on serum lipids and lipoproteins. Obstet Gynecol 1994; 83:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/21\">",
"      Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol 1994; 83:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/22\">",
"      Munk-Jensen N, Ulrich LG, Obel EB, et al. Continuous combined and sequential estradiol and norethindrone acetate treatment of postmenopausal women: effect of plasma lipoproteins in a two-year placebo-controlled trial. Am J Obstet Gynecol 1994; 171:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/23\">",
"      Voetberg GA, Netelenbos JC, Kenemans P, et al. Estrogen replacement therapy continuously combined with four different dosages of dydrogesterone: effect on calcium and lipid metabolism. J Clin Endocrinol Metab 1994; 79:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/24\">",
"      Spaulding LB. Endometrial ablation for refractory postmenopausal bleeding with continuous hormone replacement therapy. Fertil Steril 1994; 62:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/25\">",
"      Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995; 273:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/26\">",
"      Ettinger, B, Li, DK, Klein, R. Continuation of postmenopausal hormone replacement therapy: comparison of cyclic versus continous combined schedules. Menopause 1996; 3:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/27\">",
"      Clisham PR, de Ziegler D, Lozano K, Judd HL. Comparison of continuous versus sequential estrogen and progestin therapy in postmenopausal women. Obstet Gynecol 1991; 77:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/28\">",
"      Luciano AA, De Souza MJ, Roy MP, et al. Evaluation of low-dose estrogen and progestin therapy in postmenopausal women. A double-blind, prospective study of sequential versus continuous therapy. J Reprod Med 1993; 38:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/29\">",
"      Weinstein L. Efficacy of a continuous estrogen-progestin regimen in the menopausal patient. Obstet Gynecol 1987; 69:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/30\">",
"      Kable WT, Gallagher JC, Nachtigall L, Goldgar D. Lipid changes after hormone replacement therapy for menopause. J Reprod Med 1990; 35:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/31\">",
"      Nand SL, Webster MA, Wren BG. Continuous combined piperazine oestrone sulphate and medroxyprogesterone acetate hormone replacement therapy--a study of bleeding pattern, endometrial response, serum lipid and bone density changes. Aust N Z J Obstet Gynaecol 1995; 35:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/32\">",
"      Yancey MK, Hannan CJ Jr, Plymate SR, et al. Serum lipids and lipoproteins in continuous or cyclic medroxyprogesterone acetate treatment in postmenopausal women treated with conjugated estrogens. Fertil Steril 1990; 54:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/33\">",
"      Simon JA, Liu JH, Speroff L, et al. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy. Am J Obstet Gynecol 2003; 188:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/34\">",
"      Andersson K, Mattsson LA, Rybo G, Stadberg E. Intrauterine release of levonorgestrel--a new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992; 79:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/35\">",
"      Raudaskoski TH, Lahti EI, Kauppila AJ, et al. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. Am J Obstet Gynecol 1995; 172:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/36\">",
"      KUPPERMAN HS, BLATT MH, WIESBADER H, FILLER W. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol Metab 1953; 13:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/37\">",
"      Marslew U, Riis BJ, Christiansen C. Bleeding patterns during continuous combined estrogen-progestogen therapy. Am J Obstet Gynecol 1991; 164:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/38\">",
"      Keller PJ, Hotz E, Imthurn B. A transdermal regimen for continuous combined hormone replacement therapy in the menopause. Maturitas 1992; 15:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/39\">",
"      Marslew U, Overgaard K, Riis BJ, Christiansen C. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. Obstet Gynecol 1992; 79:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/40\">",
"      Hargrove JT, Maxson WS, Wentz AC, Burnett LS. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet Gynecol 1989; 73:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/41\">",
"      Prough SG, Aksel S, Wiebe RH, Shepherd J. Continuous estrogen/progestin therapy in menopause. Am J Obstet Gynecol 1987; 157:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/42\">",
"      Luciano AA, Turksoy RN, Carleo J, Hendrix JW. Clinical and metabolic responses of menopausal women to sequential versus continuous estrogen and progestin replacement therapy. Obstet Gynecol 1988; 71:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/43\">",
"      Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol 1998; 92:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/44\">",
"      Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1996; 275:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40486/abstract/45\">",
"      Henderson BE. The cancer question: an overview of recent epidemiologic and retrospective data. Am J Obstet Gynecol 1989; 161:1859.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7451 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-77.94.48.4-84E1ECB1DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_34_40486=[""].join("\n");
var outline_f39_34_40486=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FREQUENCY OF ESTROGEN THERAPY USE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COMPLIANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INDUCTION OF AMENORRHEA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EFFICACY OF CONTINUOUS ESTROGEN-PROGESTIN THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Relief of vasomotor symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Prevention of bone loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prevention of endometrial hyperplasia and carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H762621179\">",
"      Effect on breast cancer risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=related_link\">",
"      Postmenopausal hormone therapy and the risk of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17831?source=related_link\">",
"      Postmenopausal hormone therapy in the prevention and treatment of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16218?source=related_link\">",
"      Preparations for postmenopausal hormone therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_34_40487="Third cranial nerve (oculomotor nerve) palsy in children";
var content_f39_34_40487=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Third cranial nerve (oculomotor nerve) palsy in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/34/40487/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/34/40487/contributors\">",
"     Andrew G Lee, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/34/40487/contributors\">",
"     Paul W Brazis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/34/40487/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/34/40487/contributors\">",
"     Evelyn A Paysse, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/34/40487/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/34/40487/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/34/40487/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/34/40487/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysfunction of the third cranial nerve (oculomotor nerve) can result from lesions anywhere along its path between the oculomotor nucleus in the midbrain and the extraocular muscles within the orbit. Third nerve palsy may herald a life-threatening intracranial process (eg, tumor, aneurysm). The diagnosis and management of third nerve palsy varies according to the age of the patient, characteristics of the third nerve palsy, and the presence of associated signs and symptoms.",
"   </p>",
"   <p>",
"    The manifestations and diagnosis of third nerve palsy will be reviewed here. Palsies of the fourth and sixth cranial nerves are considered separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/44/12999?source=see_link\">",
"     \"Fourth cranial nerve (trochlear nerve) palsy in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/2/43046?source=see_link\">",
"     \"Sixth cranial nerve (abducens nerve) palsy in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The third cranial nerve supplies the levator muscle of the eyelid and four extraocular muscles: the medial rectus, superior rectus, inferior rectus, and inferior oblique. The superior oblique muscle is innervated by cranial nerve IV and the lateral rectus muscle by cranial nerve VI (",
"    <a class=\"graphic graphic_table graphicRef72952 \" href=\"mobipreview.htm?37/58/38827\">",
"     table 1",
"    </a>",
"    ). In addition, the third cranial nerve constricts the pupil through its parasympathetic fibers that supply the smooth muscle of the ciliary body and the sphincter of the iris.",
"   </p>",
"   <p>",
"    The third nerve begins as a nucleus in the midbrain. It consists of several subnuclei that innervate the individual extraocular muscles, the eyelids, and the pupils. Each subnucleus, except the superior rectus subnucleus, supplies the ipsilateral muscle.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The superior rectus subnucleus innervates the contralateral superior rectus.",
"     </li>",
"     <li>",
"      The levator subnucleus is a single central caudate nucleus and innervates both eyelids.",
"     </li>",
"     <li>",
"      The parasympathetic pupil nucleus (Edinger-Westphal nuclei) controls pupil constriction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The third nerve fascicle leaves the nucleus and passes ventrally near important structures in the midbrain (eg, red nucleus, corticospinal tract). It then enters the subarachnoid space, passes into the lateral wall of the cavernous sinus, and finally divides into superior and inferior branches as it enters the superior orbital fissure in the orbit (",
"    <a class=\"graphic graphic_figure graphicRef76281 \" href=\"mobipreview.htm?6/60/7110\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acquired third nerve palsies usually complain of the sudden onset of binocular horizontal, vertical, or oblique diplopia and a droopy eyelid. Children with congenital third nerve palsies may not complain of diplopia because they ignore or suppress the second image or because they have superimposed amblyopia; often they are brought to medical attention by their parents, who have noticed ptosis or strabismus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/8/34951?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation and management of strabismus in children\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Eye examination",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     General findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;On physical examination, they may have a partial or complete ptosis (",
"    <a class=\"graphic graphic_picture graphicRef59305 \" href=\"mobipreview.htm?16/26/16805\">",
"     picture 1",
"    </a>",
"    ). The pupil may be of normal size and normally reactive, dilated and poorly reactive, or dilated and non-reactive to light and near stimulus. Deficits in ipsilateral adduction (medial rectus), elevation (superior rectus, inferior oblique),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    depression (inferior rectus) may be present.",
"   </p>",
"   <p>",
"    We consider third nerve palsies to be complete if impairment of the majority of function of all the somatic branches of the oculomotor nerve is present and ptosis is complete or almost complete.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the deficit of adduction is significant, a primary position exotropia (eye turned out) worse in gaze toward the paretic medial rectus muscle occurs.",
"     </li>",
"     <li>",
"      If the elevator muscles (eg, superior rectus or inferior oblique muscles) are involved, an ipsilateral hypotropia (eye is turned down) occurs (",
"      <a class=\"graphic graphic_picture graphicRef59305 \" href=\"mobipreview.htm?16/26/16805\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If the inferior rectus muscle is more involved, an ipsilateral hypertropia (eye is turned up) occurs.",
"     </li>",
"     <li>",
"      Complete third nerve palsies usually are associated with a large-angle exotropia and hypotropia (eye is down and out) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/34/40487/abstract/1-8\">",
"       1-8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The remainder of the clinical presentation varies depending upon the location and type of lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Nuclear lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesions of the third nerve nucleus are rare and usually are associated with other signs of mesencephalic (midbrain) involvement as described below. The levator palpebrae superioris muscles (which control the eyelids) are controlled by a single central subnucleus. Thus, in patients with nuclear lesions, they are affected either bilaterally or not at all. Nuclear lesions also can cause isolated muscle involvement of the extraocular muscles that are innervated by the third nerve.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most characteristic finding of a nuclear lesion is unilateral third nerve palsy with weakness of the ipsilateral and contralateral superior rectus (the superior rectus subnucleus is crossed) and bilateral incomplete ptosis (single central caudate subnucleus).",
"     </li>",
"     <li>",
"      Bilateral third nerve palsies with sparing of the eyelids (single levator subnucleus) and isolated bilateral ptosis with sparing of the extraocular muscles and pupils also can occur in nuclear lesions.",
"     </li>",
"     <li>",
"      Nuclear third nerve palsies can be associated occasionally with ipsilateral ptosis and contralateral eyelid retraction (plus-minus lid syndrome) if supranuclear inhibitory input to the third nerve is disrupted and ptosis from a fascicular lesion on the contralateral side occurs.",
"     </li>",
"     <li>",
"      Unilateral or bilateral isolated medial rectus paralysis is unlikely to be caused by a nuclear lesion; medial rectus neurons probably lie at three different locations within the oculomotor nucleus. For this reason, patients with presumed isolated medial rectus paresis should be evaluated for internuclear ophthalmoplegia (INO) caused by damage to the medial longitudinal fasciculus. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20246?source=see_link\">",
"       \"Internuclear ophthalmoplegia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nuclear lesions that are caused by infarction often are accompanied by lesions of the third nerve fascicle because both these structures are supplied by the paramedian branches of the basilar artery. Rarely does a fascicular third nerve lesion occur in isolation without other neurologic signs or symptoms. Nuclear and fascicular lesions are \"defined by the company they keep\"; the involvement of other midbrain structures identifies the midbrain location of the lesion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Contralateral ataxia will be present if the red",
"      <span class=\"nowrap\">",
"       nucleus/superior",
"      </span>",
"      cerebellar peduncle is involved.",
"     </li>",
"     <li>",
"      Cerebellar tremor may be present in Claude syndrome (ipsilateral third nerve palsy and contralateral cerebellar signs).",
"     </li>",
"     <li>",
"      Contralateral hemiparesis may be present in a cerebral peduncle lesion (Weber syndrome).",
"     </li>",
"     <li>",
"      Contralateral choreiform movements or tremor are present when red",
"      <span class=\"nowrap\">",
"       nucleus/substantia",
"      </span>",
"      nigra involvement occurs (Benedikt syndrome).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Extra-axial lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, extra-axial third nerve palsies usually are caused by ischemia. In contrast, ischemia is a rare cause for third nerve palsy in children; trauma and congenital third nerve palsies are more common.",
"   </p>",
"   <p>",
"    Other extra-axial causes include uncal herniation; aneurysms of the internal carotid-posterior communicating, superior cerebellar, basilar, or posterior cerebral arteries; infection, inflammation, and neoplastic invasion of the meninges; and trauma (including neurosurgical procedures).",
"   </p>",
"   <p>",
"    Ischemic lesions typically present with intact pupillary function, probably because of the lack of damage to the superficial periphery of the third nerve (where the majority of pupillomotor fibers are thought to pass) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40487/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]. In contrast, aneurysmal compression of the superficial pupil fibers of the third nerve as it passes through the subarachnoid space usually results in a dilated and unresponsive pupil. This important differentiating feature affects the choice of imaging procedure as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cavernous sinus lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesions of the third nerve in the cavernous sinus and superior orbital fissure often involve other cranial nerves and have the following clinical manifestations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fourth cranial nerve &mdash; vertical diplopia",
"     </li>",
"     <li>",
"      Sixth cranial nerve &mdash; horizontal diplopia; esotropia (inward deviation)",
"     </li>",
"     <li>",
"      First (ophthalmic) branch of the trigeminal nerve &mdash; pain or numbness",
"     </li>",
"     <li>",
"      Oculosympathetic fibers &mdash; Horner's syndrome (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/32/32262?source=see_link\">",
"       \"Horner's syndrome\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Orbital lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesions within the orbit that produce third nerve dysfunction usually produce other orbital signs, including optic neuropathy, chemosis, conjunctival injection or chemosis, and proptosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Third nerve palsy is uncommon in children. A population-based study in Minnesota identified 36 cases over a 15-year period; the age- and sex-adjusted annual incidence was 1.7 per 100,000 county residents under the age of 18 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40487/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Third nerve palsy in children often is congenital (intrauterine or birth-related events) but may occur after postnatal trauma, infection, inflammation, tumor, or childhood migraine (",
"    <a class=\"graphic graphic_table graphicRef71965 \" href=\"mobipreview.htm?2/36/2636\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40487/abstract/10-15\">",
"     10-15",
"    </a>",
"    ]. Aneurysms are rare, but certain children are at increased risk (eg, those with polycystic kidney disease, coarctation of the aorta, or Ehlers Danlos syndrome) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40487/abstract/12\">",
"     12",
"    </a>",
"    ]. Traumatic third nerve palsy usually arises only from severe blows to the head [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40487/abstract/12,16\">",
"     12,16",
"    </a>",
"    ]. Thus, third nerve palsy associated with mild head trauma should prompt evaluation for associated pathology. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One review at the Wilmer Eye Institute identified 41 children younger than eight years of age with third nerve palsy. The most frequent causes were congenital (39 percent), traumatic (37 percent), and neoplastic (17 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/34/40487/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study of 49 children with 53 affected eyes, the palsy was congenital in 20 eyes and caused by postnatal trauma in 17 eyes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/34/40487/abstract/10\">",
"       10",
"      </a>",
"      ]. Tumor (6), vascular problems (6), and infection (3) were responsible for the remainder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several conditions can mimic the extraocular dysfunction of third nerve palsy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intracranial lesion (eg, compressive lesion, aneurysm)",
"     </li>",
"     <li>",
"      Orbital disease (including orbital fracture, tumor, and inflammation) can affect the extraocular muscles. Forced ductions (passive rotation of the eyes with ophthalmic forceps) might confirm the restrictive nature of the ophthalmoplegia caused by these problems.",
"     </li>",
"     <li>",
"      Congenital fibrosis of the extraocular muscles can mimic third nerve palsy. This condition is inherited in an autosomal dominant pattern and may be associated with absence of the superior division of the third cranial nerve [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/34/40487/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Myasthenia gravis can mimic any painless, pupil-spared, non-proptotic ophthalmoplegia and should be considered in every patient with a pupil-spared complete or incomplete third nerve palsy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/34/40487/abstract/18\">",
"       18",
"      </a>",
"      ]. Other signs of myasthenia gravis, such as ptosis, variability, and fatigue, usually are present. The \"ice test\" (a two-minute application of ice to the eyelid with ptosis) may help to differentiate myasthenia from other causes of ptosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/34/40487/abstract/19-22\">",
"       19-22",
"      </a>",
"      ]. A positive test (&ge;2 mm improvement in ptosis) was 80 percent sensitive and 100 percent specific in one study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/34/40487/abstract/19\">",
"       19",
"      </a>",
"      ], although some authors have questioned the pathophysiologic basis of the test as perhaps simply an augmented rest test. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17206?source=see_link\">",
"       \"Clinical manifestations of myasthenia gravis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Skew deviation is a vertical misalignment caused by disruption of the vestibulo-ocular connections and can result in hypertropia. Usually, it is associated with other posterior fossa signs (eg, other cranial neuropathies, hemisensory loss, or hemiparesis). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28806?source=see_link&amp;anchor=H10#H10\">",
"       \"Supranuclear disorders of gaze in children\", section on 'Skew deviation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ophthalmoplegic migraine, a diagnosis of exclusion, can cause recurrent third nerve palsy in children. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/21/42327?source=see_link&amp;anchor=H21#H21\">",
"       \"Classification of migraine in children\", section on 'Ophthalmoplegic migraine'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of children with third nerve palsy is centered on determining the underlying etiology, because the treatment varies depending upon the cause (",
"    <a class=\"graphic graphic_table graphicRef71965 \" href=\"mobipreview.htm?2/36/2636\">",
"     table 2",
"    </a>",
"    ). Historical features may help to distinguish congenital, traumatic, or infectious conditions. Inflammatory, neoplastic, and vascular conditions may be more insidious. Although aneurysms are rare in children, certain clinical features should increase suspicion for aneurysm:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lack of vasculopathic risk factors or alternative etiology (eg, diabetes mellitus, hypertension, increased cholesterol).",
"     </li>",
"     <li>",
"      History of polycystic kidney disease, coarctation of the aorta, Ehlers Danlos syndrome.",
"     </li>",
"     <li>",
"      Severe headache or other signs of subarachnoid hemorrhage (eg, loss of consciousness, seizure, nausea, vomiting, meningismus). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38522?source=see_link&amp;anchor=H12#H12\">",
"       \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neuroimaging almost always is necessary. Lumbar puncture should be performed if signs or symptoms of meningeal inflammation or infection are present and in children who have pupillary involvement and negative radiologic evaluation. In addition, evaluation for myasthenia gravis and consultation with a neurologist, ophthalmologist, or neuro-ophthalmologist may be indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/1/25625?source=see_link\">",
"     \"Lumbar puncture: Indications, contraindications, technique, and complications in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RADIOLOGIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomographic (CT) scan, magnetic resonance imaging (MRI), MR angiography (MRA), and carotid angiography all can provide useful information in the evaluation of children with third nerve dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/40/23178?source=see_link&amp;anchor=H17#H17\">",
"     \"Approach to neuroimaging in children\", section on 'Vascular disease and hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CT scanning is the least sensitive of the imaging modalities for detection of aneurysms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/34/40487/abstract/23\">",
"       23",
"      </a>",
"      ], but it is better than MRI in detecting subarachnoid hemorrhage.",
"     </li>",
"     <li>",
"      At most centers, CT angiography (CTA) has emerged as the first-line non-catheter angiography study for the evaluation of possible aneurysm in third nerve palsy. In many institutions, CTA has surpassed MRA in sensitivity and specificity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/34/40487/abstract/24-27\">",
"       24-27",
"      </a>",
"      ]. It is rapidly supplanting catheter angiography in aneurysm evaluation, particularly in children in whom the risk of aneurysm is presumably lower than in adult patients with pupil-involved third nerve palsy.",
"     </li>",
"     <li>",
"      MR angiography is noninvasive and more sensitive than is MRI.",
"     </li>",
"     <li>",
"      CTA and MRA have been evolving each year. Each technique has advantages and disadvantages, and although catheter angiography arguably remains the \"gold standard\" for detection of aneurysms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/34/40487/abstract/23,28-30\">",
"       23,28-30",
"      </a>",
"      ], it is associated with a 1 to 2 percent risk of neurologic (principally stroke) and systemic complications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many institutions consider CT-CTA to be the first-line imaging study for third nerve palsy in adults. There is insufficient literature on children with third nerve palsy to make a strong evidence-based recommendation for CTA over MRI and MRA as a first-line study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Overview of imaging strategy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of diagnostic imaging technique for a particular patient is dependent upon the age of the patient and the clinical circumstances. The optimal imaging strategy permits the detection of significant intracranial pathology (eg, tumor, aneurysm) and minimizes the potential hazards (eg, radiation, sedation, neurologic compromise).",
"   </p>",
"   <p>",
"    Third nerve palsies can be divided into those that are isolated and those that are accompanied by other contributory neurologic findings (\"non-isolated\"), as well as by the degree of involvement of the extraocular muscles and pupil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40487/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a non-isolated third nerve palsy require imaging directed at the topographical localization.",
"     </li>",
"     <li>",
"      Patients with isolated pupil-involved third nerve palsies should undergo neuroimaging and some type of angiography study to exclude aneurysm, even though aneurysm is uncommon in children. CTA is typically the first-line study, but in some cases, catheter angiography may still be required.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients with a moderate or uncertain risk of aneurysm, the combination of MR and MRA (or CTA) may not be sufficient to exclude aneurysm. In these cases, catheter angiography should be considered, even in a child.",
"     </li>",
"     <li>",
"      If the risk of aneurysm is low, or the risk of angiography is high (eg, high risk of renal failure, anaphylactic reaction, risk of stroke), MRI and MRA (or CTA) alone may be reasonable, provided that the clinician is confident in the capability, availability, and reliability of the neuroradiologist and the imaging technology.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with a low risk of aneurysm (ie, isolated, pupil-spared, otherwise complete third nerve palsy) and a high risk of angiography, catheter angiogram may be deferred.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Isolated third nerve palsies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Congenital or long-standing third nerve palsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital or long-standing third nerve palsies may not require neuroimaging if they are static. Patients with progressive disease, new neurologic findings, or with uncertain etiology may require neuroimaging (usually with MR).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Complete third nerve palsy with pupillary sparing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and young adults who have isolated complete third nerve palsies and normal pupillary function, particularly those without vasculopathic risk factors (diabetes mellitus, hypertension, and increased cholesterol), should have neuroimaging (usually MR scan of the brain and orbit) to rule out intracranial mass lesions or developmental brain anomaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40487/abstract/32\">",
"     32",
"    </a>",
"    ]. These patients generally do not need angiography.",
"   </p>",
"   <p>",
"    Neuroimaging may be deferred in adult patients who have ischemic third nerve palsies. In children, however, ischemia is an uncommon etiology for third nerve palsy, and neuroimaging is recommended. All patients should be examined at 24- to 48-hour intervals for one week, because some patients with aneurysms develop delayed pupil involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Partial third nerve palsy and pupillary sparing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with incomplete motor third nerve palsy with pupillary sparing require an MR scan to rule out a mass lesion. Aneurysm is an extremely uncommon cause for a third nerve palsy in children. MR imaging and MR angiography or CTA probably are sufficient to exclude aneurysm in patients with low suspicion of intracranial aneurysm. As a general rule, these patients do not require catheter angiography unless they are at high risk for intracranial aneurysms (eg, polycystic kidney disease, coarctation of the aorta, or Ehlers Danlos syndrome) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40487/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Catheter angiography should be considered in all patients, including children, if the clinical findings are highly suggestive of aneurysm (eg, severe headache or other signs of subarachnoid hemorrhage) and the MR scan is normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Third nerve palsy with impaired pupillary function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Third nerve palsies with complete pupilloparesis are often due to compressive lesions (eg, aneurysm) or meningeal inflammation. Aneurysm is an uncommon cause of third nerve palsy in children, but the diagnosis must be pursued in all children with otherwise unexplained pupillary involvement.",
"   </p>",
"   <p>",
"    Some type of angiography (CTA versus catheter angiography) should still be considered in all patients with complete pupil involvement or other clinical evidence for aneurysm (eg, severe headache or other signs of subarachnoid hemorrhage). The risk of catheter angiography must be weighed against the risk of observation. At selected institutions, the use of CTA may be sufficient if the quality of the study and interpretation are adequate to exclude aneurysm and the clinical suspicion is low.",
"   </p>",
"   <p>",
"    Children with these findings also should undergo neuroimaging, usually with MR. CT imaging may be preferred if there are signs or symptoms of subarachnoid hemorrhage, because noncontrast CT scan is better able to detect hemorrhage. In addition, CT may be more readily available than MRI and can be combined with a CTA. MRI, however, is better for imaging the course of the third cranial nerve and for detecting non-aneurysmal etiologies for third nerve palsy. Consultation with a neuroradiologist may be helpful in determining the optimal imaging modalities and the order of imaging",
"    <span class=\"nowrap\">",
"     (CT/CTA",
"    </span>",
"    first versus",
"    <span class=\"nowrap\">",
"     MRI/MRA",
"    </span>",
"    first) in children with a third nerve palsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Non-isolated third nerve palsies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with non-isolated third nerve palsies should undergo neuroimaging (preferably MRI with contrast) with attention to the topographic areas suggested by the associated neurologic signs and symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy should be directed at the underlying etiology of the third nerve palsy. The goal is to maximize visual function, including alignment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with infectious, inflammatory, or neoplastic lesions should receive appropriate therapy.",
"     </li>",
"     <li>",
"      Patients with known vasculopathic risk factors and acute isolated pupil-spared nerve palsies may be observed for improvement; their vasculopathic risk factors should be controlled. The majority of ischemic third nerve palsies, including those related to migraine headaches, usually improve with time.",
"     </li>",
"     <li>",
"      Children who have traumatic third nerve palsies, particularly those who have partial palsies, may experience spontaneous resolution. Improvement usually occurs within the first several months after trauma.",
"     </li>",
"     <li>",
"      Prism therapy may be employed for small, comitant, long-standing deviations. \"Comitant\" deviations are those in which the distance between the double images is little affected by the direction of gaze.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A temporary press-on (Fresnel) prism of sufficient power to align the eyes is placed on the spectacle lens of the affected child. Permanent prisms can be ground into the spectacle lens if the patient is happy with the result and the deviation fails to improve spontaneously.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Strabismus surgery may be helpful in patients who fail prism therapy. However, this surgery is difficult to perform, particularly in children who have complete third nerve palsies, because multiple muscles are involved; ocular alignment may occur at the expense of more severe ophthalmoplegia. Ocular alignment can ultimately be achieved, but multiple procedures may be necessary, and binocular function often remains impaired [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/34/40487/abstract/10,33\">",
"       10,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Amblyopia therapy may be effective in maintaining visual function in children who have congenital disease. Improvement in visual acuity is difficult to achieve, and visual outcome usually is poor in children younger than eight years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/34/40487/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ptosis surgery may be necessary in some patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of amblyopia is the major complication of third nerve palsy in children. It occurs in as many as 50 to 75 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40487/abstract/10\">",
"     10",
"    </a>",
"    ] and is caused by ptosis (deprivation amblyopia), loss of accommodation, and strabismus (ocular misalignment). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/61/8153?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of amblyopia\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aberrant regeneration of the third nerve causes lid-gaze or pupil gaze synkinesia and is another complication of third nerve palsy in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40487/abstract/12\">",
"     12",
"    </a>",
"    ]. In one study, it was present in 9 of 20 patients (45 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/34/40487/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The third cranial nerve (oculomotor nerve) supplies the levator muscle of the eyelid and four extraocular muscles (",
"      <a class=\"graphic graphic_table graphicRef72952 \" href=\"mobipreview.htm?37/58/38827\">",
"       table 1",
"      </a>",
"      ). It also constricts the pupil. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with acquired third nerve palsies usually complain of the sudden onset of binocular horizontal, vertical, or oblique diplopia and a droopy eyelid. Children may present with parental complaints of ptosis or strabismus. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Examination findings may include partial or complete ptosis (",
"      <a class=\"graphic graphic_picture graphicRef59305 \" href=\"mobipreview.htm?16/26/16805\">",
"       picture 1",
"      </a>",
"      ); deficits in ipsilateral adduction, elevation,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      depression; and pupillary abnormalities. Other findings vary depending upon the location of the lesions. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Eye examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis includes: intracranial lesions (compressive lesions, and, less likely, aneurysm), orbital disease (fracture, tumor, inflammation), congenital fibrosis of the extraocular muscles, myasthenia gravis, skew deviation, and ophthalmoplegic migraine. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation of children with third nerve palsy is centered on determining the underlying etiology (",
"      <a class=\"graphic graphic_table graphicRef71965 \" href=\"mobipreview.htm?2/36/2636\">",
"       table 2",
"      </a>",
"      ), which affects treatment. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neuroimaging is almost always necessary. The approach to neuroimaging varies depending upon the age of the child and the clinical circumstances (eg, whether the third nerve palsy is isolated or associated with other neurologic findings and the degree of involvement of the extraocular muscles and pupil). Consultation with a neuroradiologist may be helpful in determining the optimal imaging modalities and the order of imaging, particularly when aneurysm is a consideration. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Radiologic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Amblyopia is the major complication of third nerve palsy in children. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Complications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/61/8153?source=see_link\">",
"       \"Overview of amblyopia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/1\">",
"      Jacobson DM, McCanna TD, Layde PM. Risk factors for ischemic ocular motor nerve palsies. Arch Ophthalmol 1994; 112:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/2\">",
"      Jacobson DM. Pupil involvement in patients with diabetes-associated oculomotor nerve palsy. Arch Ophthalmol 1998; 116:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/3\">",
"      Nadeau SE, Trobe JD. Pupil sparing in oculomotor palsy: a brief review. Ann Neurol 1983; 13:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/4\">",
"      Richards BW, Jones FR Jr, Younge BR. Causes and prognosis in 4,278 cases of paralysis of the oculomotor, trochlear, and abducens cranial nerves. Am J Ophthalmol 1992; 113:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/5\">",
"      RUCKER CW. Paralysis of the third, fourth and sixth cranial nerves. Am J Ophthalmol 1958; 46:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/6\">",
"      Rucker CW. The causes of paralysis of the third, fourth and sixth cranial nerves. Am J Ophthalmol 1966; 61:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/7\">",
"      Rush JA, Younge BR. Paralysis of cranial nerves III, IV, and VI. Cause and prognosis in 1,000 cases. Arch Ophthalmol 1981; 99:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/8\">",
"      Teuscher AU, Meienberg O. Ischaemic oculomotor nerve palsy. Clinical features and vascular risk factors in 23 patients. J Neurol 1985; 232:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/9\">",
"      Holmes JM, Mutyala S, Maus TL, et al. Pediatric third, fourth, and sixth nerve palsies: a population-based study. Am J Ophthalmol 1999; 127:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/10\">",
"      Schumacher-Feero LA, Yoo KW, Solari FM, Biglan AW. Third cranial nerve palsy in children. Am J Ophthalmol 1999; 128:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/11\">",
"      Harley RD. Paralytic strabismus in children. Etiologic incidence and management of the third, fourth, and sixth nerve palsies. Ophthalmology 1980; 87:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/12\">",
"      Ing EB, Sullivan TJ, Clarke MP, Buncic JR. Oculomotor nerve palsies in children. J Pediatr Ophthalmol Strabismus 1992; 29:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/13\">",
"      Mizen TR, Burde RM, Klingele TG. Cryptogenic oculomotor nerve palsies in children. Am J Ophthalmol 1985; 100:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/14\">",
"      Kodsi SR, Younge BR. Acquired oculomotor, trochlear, and abducent cranial nerve palsies in pediatric patients. Am J Ophthalmol 1992; 114:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/15\">",
"      Mudgil AV, Repka MX. Ophthalmologic outcome after third cranial nerve palsy or paresis in childhood. J AAPOS 1999; 3:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/16\">",
"      Eyster EF, Hoyt WF, Wilson CB. Oculomotor palsy from minor head trauma. An initial sign of basal intracranial tumor. JAMA 1972; 220:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/17\">",
"      Engle EC, Goumnerov BC, McKeown CA, et al. Oculomotor nerve and muscle abnormalities in congenital fibrosis of the extraocular muscles. Ann Neurol 1997; 41:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/18\">",
"      Kim JH, Hwang JM, Hwang YS, et al. Childhood ocular myasthenia gravis. Ophthalmology 2003; 110:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/19\">",
"      Golnik KC, Pena R, Lee AG, Eggenberger ER. An ice test for the diagnosis of myasthenia gravis. Ophthalmology 1999; 106:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/20\">",
"      Sethi KD, Rivner MH, Swift TR. Ice pack test for myasthenia gravis. Neurology 1987; 37:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/21\">",
"      Ellis FD, Hoyt CS, Ellis FJ, et al. Extraocular muscle responses to orbital cooling (ice test) for ocular myasthenia gravis diagnosis. J AAPOS 2000; 4:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/22\">",
"      Chatzistefanou KI, Kouris T, Iliakis E, et al. The ice pack test in the differential diagnosis of myasthenic diplopia. Ophthalmology 2009; 116:2236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/23\">",
"      Bartleson JD, Trautmann JC, Sundt TM Jr. Minimal oculomotor nerve paresis secondary to unruptured intracranial aneurysm. Arch Neurol 1986; 43:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/24\">",
"      White PM, Wardlaw JM, Easton V. Can noninvasive imaging accurately depict intracranial aneurysms? A systematic review. Radiology 2000; 217:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/25\">",
"      Hashimoto H, Iida J, Hironaka Y, et al. Use of spiral computerized tomography angiography in patients with subarachnoid hemorrhage in whom subtraction angiography did not reveal cerebral aneurysms. J Neurosurg 2000; 92:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/26\">",
"      Korogi Y, Takahashi M, Katada K, et al. Intracranial aneurysms: detection with three-dimensional CT angiography with volume rendering--comparison with conventional angiographic and surgical findings. Radiology 1999; 211:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/27\">",
"      Zouaoui A, Sahel M, Marro B, et al. Three-dimensional computed tomographic angiography in detection of cerebral aneurysms in acute subarachnoid hemorrhage. Neurosurgery 1997; 41:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/28\">",
"      Jacobson DM, Trobe JD. The emerging role of magnetic resonance angiography in the management of patients with third cranial nerve palsy. Am J Ophthalmol 1999; 128:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/29\">",
"      Heiserman JE, Dean BL, Hodak JA, et al. Neurologic complications of cerebral angiography. AJNR Am J Neuroradiol 1994; 15:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/30\">",
"      Dion JE, Gates PC, Fox AJ, et al. Clinical events following neuroangiography: a prospective study. Stroke 1987; 18:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/31\">",
"      Lee AG, Onan HW, Brazis PW, Prager TC. An imaging guide to the evaluation of third cranial nerve palsies. Strabismus 1999; 7:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/32\">",
"      Good WV, Barkovich AJ, Nickel BL, Hoyt CS. Bilateral congenital oculomotor nerve palsy in a child with brain anomalies. Am J Ophthalmol 1991; 111:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/34/40487/abstract/33\">",
"      Gottlob I, Catalano RA, Reinecke RD. Surgical management of oculomotor nerve palsy. Am J Ophthalmol 1991; 111:71.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6258 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-201.211.0.116-EBA5E762DA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_34_40487=[""].join("\n");
var outline_f39_34_40487=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Eye examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - General findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Nuclear lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Extra-axial lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cavernous sinus lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Orbital lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RADIOLOGIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Overview of imaging strategy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Isolated third nerve palsies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Congenital or long-standing third nerve palsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Complete third nerve palsy with pupillary sparing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Partial third nerve palsy and pupillary sparing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Third nerve palsy with impaired pupillary function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Non-isolated third nerve palsies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6258\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6258|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/60/7110\" title=\"figure 1\">",
"      Third nerve anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6258|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/26/16805\" title=\"picture 1\">",
"      Ptosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6258|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/58/38827\" title=\"table 1\">",
"      Actions extraocular muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/36/2636\" title=\"table 2\">",
"      Etiology third nerve palsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/40/23178?source=related_link\">",
"      Approach to neuroimaging in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/21/42327?source=related_link\">",
"      Classification of migraine in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17206?source=related_link\">",
"      Clinical manifestations of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/8/34951?source=related_link\">",
"      Evaluation and management of strabismus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/44/12999?source=related_link\">",
"      Fourth cranial nerve (trochlear nerve) palsy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/32/32262?source=related_link\">",
"      Horner's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20246?source=related_link\">",
"      Internuclear ophthalmoplegia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/1/25625?source=related_link\">",
"      Lumbar puncture: Indications, contraindications, technique, and complications in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/61/8153?source=related_link\">",
"      Overview of amblyopia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/2/43046?source=related_link\">",
"      Sixth cranial nerve (abducens nerve) palsy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28806?source=related_link\">",
"      Supranuclear disorders of gaze in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_34_40488="Erythema induratum of Bazin";
var content_f39_34_40488=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76526%7EDERM%2F53596%7EDERM%2F64335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76526%7EDERM%2F53596%7EDERM%2F64335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema induratum of Bazin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An ulcerated nodule and multiple scars are present on the lower legs of this patient with erythema nodosum of Bazin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dr. M Ramam, New Delhi.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Erythema induratum (nodular vasculitis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple nodules are present on the posterior lower legs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema induratum (nodular vasculitis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple nodules are present on the posterior lower legs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_34_40488=[""].join("\n");
var outline_f39_34_40488=null;
var title_f39_34_40489="Heparin: Drug information";
var content_f39_34_40489=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Heparin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/20/325?source=see_link\">",
"    see \"Heparin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/39/7801?source=see_link\">",
"    see \"Heparin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F15793684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Heparin Product Label Change",
"     </span>",
"     <span class=\"collapsible-date\">",
"      December 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The Food and Drug Administration (FDA) has issued a notice about changes to some heparin product labels to reduce the risk of miscalculations that may result in medication errors. Effective May 1, 2013, manufacturers of Heparin Lock Flush Solution, USP and Heparin Sodium Injection, USP will be required to clearly state the strength of the entire container of heparin followed, in parentheses, by the amount of the medication contained in 1 mL. Heparin carton labeling will also be revised to comply with the new format. As the labeling is transitioned to the new requirements, users should be aware that both current and revised heparin container labels will be available. The FDA suggests users separate heparin stock according to &ldquo;current&rdquo; and &ldquo;revised&rdquo; labeling and use all &ldquo;current&rdquo; labeling supplies before transitioning to the &ldquo;revised&rdquo; labeling supply.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information can be found at",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm330695.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm330695.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F11443864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F178752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hep-Lock;",
"     </li>",
"     <li>",
"      HepFlush&reg;-10",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F178753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hepalean&reg;;",
"     </li>",
"     <li>",
"      Hepalean&reg; Leo;",
"     </li>",
"     <li>",
"      Hepalean&reg;-LOK",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F178797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticoagulant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F178757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Many concentrations of heparin are available ranging from 1 unit/mL to 20,000 units/mL. Carefully examine each prefilled syringe or vial prior to use ensuring that the correct concentration is chosen. Heparin lock flush solution is intended only to maintain patency of I.V. devices and is not to be used for anticoagulant therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute coronary syndromes:",
"     </b>",
"     I.V. infusion (weight-based dosing per institutional nomogram recommended):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      STEMI:",
"     </i>",
"     Adjunct to fibrinolysis (full-dose alteplase, reteplase, or tenecteplase) (Antman, 2008): Initial bolus of 60 units/kg (maximum: 4000 units), then 12 units/kg/hour (maximum: 1000 units/hour) as continuous infusion. Check aPTT every 4-6 hours; adjust to target of 1.5-2 times the upper limit of control (50-70 seconds). Duration of heparin therapy depends on concurrent therapy and the specific patient risks for systemic or venous thromboembolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI) (Anderson, 2007):",
"     </i>",
"     Initial bolus of 60 units/kg (maximum: 4000 units), followed by an initial infusion of 12 units/kg/hour (maximum: 1000 units/hour). Check aPTT every 4-6 hours; adjust to target of 1.5-2 times the upper limit of control (50-70 seconds). Continue for 48 hours in low risk patients managed with a conservative strategy (ie, no diagnostic angiography or PCI) (Jneid, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Percutaneous coronary intervention (Levine, 2011):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     No prior anticoagulant therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      If no GPIIb/IIIa inhibitor use planned:",
"     </i>",
"     Initial bolus of 70-100 units/kg (target ACT 250-300 seconds for HemoTec&reg;, 300-350 seconds for Hemochron&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      If planning GPIIb/IIIa inhibitor use:",
"     </i>",
"     Initial bolus of 50-70 units/kg (target ACT 200-250 seconds regardless of device)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prior anticoagulant therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      If no GPIIb/IIIa inhibitor use planned:",
"     </i>",
"     Additional heparin as needed (eg, 2000-5000 units) (target ACT 250-300 seconds for HemoTec&reg;, 300-350 seconds for Hemochron&reg; )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      If planning GPIIb/IIIa inhibitor use:",
"     </i>",
"     Additional heparin as needed (eg, 2000-5000 units) (target ACT 200-250 seconds regardless of device)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Thromboprophylaxis (low-dose heparin):",
"     </b>",
"     SubQ: 5000 units every 8-12 hours.",
"     <b>",
"      Note:",
"     </b>",
"     The American College of Chest Physicians recommends a minimum of 10-14 days for patients undergoing total hip arthroplasty, total knee arthroplasty, or hip fracture surgery (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of venous thromboembolism:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Start warfarin on the first or second treatment day and continue heparin until INR is &ge;2 for at least 24 hours (usually 5-7 days) (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DVT/PE (unlabeled dosing): I.V.: 80 units/kg (or alternatively 5000 units) I.V. push followed by continuous infusion of 18 units/kg/hour (or alternatively 1000 units/hour) (Guyatt, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DVT/PE (unlabeled dosing): SubQ:",
"     <i>",
"      Unmonitored dosing regimen:",
"     </i>",
"     Initial: 333 units/kg then 250 units/kg every 12 hours (Guyatt, 2012; Kearon, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intermittent I.V. Anticoagulation:",
"     </b>",
"     Intermittent I.V.: Initial: 10,000 units, then 50-70 units/kg (5000-10,000 units) every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Maintenance of line patency (line flushing):",
"     </b>",
"     When using daily flushes of heparin to maintain patency of single and double lumen central catheters, 10 units/mL is commonly used for younger infants (eg, &lt;10 kg) while 100 units/mL is used for older infants, children, and adults. Capped PVC catheters and peripheral heparin locks require flushing more frequently (eg, every 6-8 hours). Volume of heparin flush is usually similar to volume of catheter (or slightly greater). Additional flushes should be given when stagnant blood is observed in catheter, after catheter is used for drug or blood administration, and after blood withdrawal from catheter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Parenteral nutrition:",
"     </b>",
"     Addition of heparin (0.5-3 unit/mL) to peripheral and central parenteral nutrition has not been shown to decrease catheter-related thrombosis. The final concentration of heparin used for TPN solutions may need to be decreased to 0.5 units/mL in small infants receiving larger amounts of volume in order to avoid approaching therapeutic amounts. Arterial lines are heparinized with a final concentration of 1 unit/mL.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F178776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/39/7801?source=see_link\">",
"      see \"Heparin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Many concentrations of heparin are available ranging from 1 unit/mL to 20,000 units/mL. Carefully examine each prefilled syringe or vial prior to use ensuring that the correct concentration is chosen. Heparin lock flush solution is intended only to maintain patency of I.V. devices and is not to be used for anticoagulant therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prophylaxis for cardiac catheterization (arterial approach)",
"     </b>",
"     : I.V.: Bolus: 100 units/kg (Freed, 1974; Monagle, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Systemic heparinization:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intermittent I.V.: Initial: 50-100 units/kg, then 50-100 units/kg every 4 hours (",
"     <b>",
"      Note:",
"     </b>",
"     Continuous I.V. infusion is preferred)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. infusion: Initial loading dose: 75 units/kg given over 10 minutes, then initial maintenance dose: 20 units/kg/hour; adjust dose to maintain aPTT of 60-85 seconds (assuming this reflects an antifactor Xa level of 0.35-0.7 units/mL); see table.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Pediatric Protocol For Systemic Heparin Adjustment",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     To be used after initial loading dose and maintenance I.V. infusion dose (see usual dosage listed above) to maintain aPTT of 60-85 seconds (assuming this reflects antifactor Xa level of 0.35-0.7 units/mL).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Obtain blood for aPTT 4 hours after heparin loading dose and 4 hours after every infusion rate change.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Obtain daily CBC and aPTT after aPTT is therapeutic.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <col align=\"center\" width=\"80\">",
"     </col>",
"     <col align=\"center\" width=\"220\">",
"     </col>",
"     <col align=\"center\" width=\"200\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         aPTT",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (seconds)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dosage Adjustment",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Time to Repeat aPTT",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"top\">",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         Modified from Andrew M, et al, &ldquo;Heparin Therapy in Pediatric Patients: A Prospective Cohort Study,&rdquo;",
"         <i>",
"          Pediatr Research",
"         </i>",
"         , 1994, 35(1):78-83.",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Note:",
"         </b>",
"         The aPTT range of 60-85 seconds corresponds to an anti-Xa level of 0.35-0.7 units/mL.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;50",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Give 50 units/kg bolus and increase infusion rate by 10%",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 h after rate change",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50-59",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Increase infusion rate by 10%",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 h after rate change",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         60-85",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Keep rate the same",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Next day",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         86-95",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Decrease infusion rate by 10%",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 h after rate change",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         96-120",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Hold infusion for 30 minutes and decrease infusion rate by 10%",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 h after rate change",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;120",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Hold infusion for 60 minutes and decrease infusion rate by 15%",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 h after rate change",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Refer to adult dosing for notes on line flushing and TPN.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F178758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients &gt;60 years of age may have higher serum levels and clinical response (longer aPTTs) as compared to younger patients receiving similar dosages. Lower dosages may be required.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F11256164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment required; adjust therapeutic heparin according to aPTT or anti-Xa activity.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F11256165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment required; adjust therapeutic heparin according to aPTT or anti-Xa activity.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F178727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in 1/2 NS, as sodium [porcine intestinal mucosa source]: 25,000 units (250 mL, 500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W, as sodium [porcine intestinal mucosa source]: 10,000 units (250 mL); 12,500 units (250 mL); 20,000 units (500 mL); 25,000 units (250 mL, 500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in NS, as sodium [porcine intestinal mucosa source]: 1000 units (500 mL); 2000 units (1000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in NS, as sodium [porcine intestinal mucosa source, preservative free]: 1000 units (500 mL); 2000 units (1000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium [lock flush preparation; porcine intestinal mucosa source]: 10 units/mL (1 mL, 2 mL, 3 mL, 5 mL, 10 mL); 100 units/mL (1 mL, 2 mL, 3 mL, 5 mL, 10 mL, 30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hep-Lock: 100 units/mL (1 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium [lock flush preparation; porcine intestinal mucosa source, preservative free]: 1 units/mL (2 mL, 3 mL, 5 mL); 2 units/mL (3 mL); 10 units/mL (1 mL, 2 mL, 2.5 mL, 3 mL, 5 mL, 6 mL, 10 mL); 100 units/mL (1 mL, 2 mL, 2.5 mL, 3 mL, 5 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HepFlush&reg;-10: 10 units/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium [porcine intestinal mucosa source]: 1000 units/mL (1 mL, 10 mL, 30 mL); 5000 units/mL (1 mL, 10 mL); 10,000 units/mL (1 mL, 4 mL, 5 mL); 20,000 units/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium [porcine intestinal mucosa source, preservative free]: 1000 units/mL (2 mL); 5000 units/mL (0.5 mL); 10,000 units/mL (0.5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F178711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F178732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SubQ: Inject in subcutaneous tissue only (not muscle tissue). Injection sites should be rotated (usually left and right portions of the abdomen, above iliac crest).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     I.M.: Do not administer I.M. due to pain, irritation, and hematoma formation; central venous catheters must be flushed with heparin solution when newly inserted, daily (at the time of tubing change), after blood withdrawal or transfusion, and after an intermittent infusion through an injectable cap. A volume of at least 10 mL of blood should be removed and discarded from a heparinized line before blood samples are sent for coagulation testing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Continuous I.V. infusion: Infuse via infusion pump. If preparing solution, mix thoroughly prior to administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Heparin lock: Inject via injection cap using positive pressure flushing technique. Heparin lock flush solution is intended only to maintain patency of I.V. devices and is",
"     <b>",
"      not",
"     </b>",
"     to be used for anticoagulant therapy.",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14472657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     25,000 units in 250 mL (concentration: 100 units/mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, or NS",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14472658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     100 units/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F178803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      25",
"     </sub>",
"     W, fat emulsion 10%,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS, Ringer's injection;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, peritoneal dialysis solutions, TPN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acetaminophen, acyclovir, alcohol (ethyl), allopurinol, amifostine, aminophylline, ampicillin, ampicillin/sulbactam, anidulafungin, atracurium, atropine, aztreonam, betamethasone sodium phosphate, bivalirudin, bleomycin, caffeine citrate, calcium gluconate, cefazolin, cefotaxime, cefotetan, ceftazidime, chlorpromazine, cimetidine, cisplatin, cladribine, clindamycin, cyanocobalamin, cyclophosphamide, cytarabine, daptomycin, dexamethasone sodium phosphate, dexmedetomidine, digoxin, docetaxel, dopamine, doripenem, doxorubicin liposome, edrophonium, enalaprilat, epinephrine, eptifibatide, ertapenem, esmolol, estrogens (conjugated), ethacrynate, etoposide phosphate, famotidine, fenoldopam, fentanyl, fluconazole, fludarabine, fluorouracil, foscarnet, furosemide, gallium nitrate, gemcitabine, gold sodium thiosulfate, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), hydralazine, hydrocortisone sodium succinate, insulin (regular), isoproterenol, kanamycin, leucovorin calcium, lidocaine, linezolid, lorazepam, magnesium sulfate, melphalan, meperidine, meropenem, methotrexate, methyldopate, methylergonovine, metoclopramide, metronidazole, micafungin, midazolam, milrinone, minocycline, mitomycin, morphine, nafcillin, neostigmine, nitroprusside, norepinephrine, ondansetron, oxacillin, oxaliplatin, oxytocin, paclitaxel, palonosetron, pancuronium, pemetrexed, penicillin G potassium, pentazocine, phytonadione, piperacillin, piperacillin/tazobactam, potassium chloride, procainamide, prochlorperazine edisylate, propofol, propranolol, pyridostigmine, ranitidine, remifentanil, sargramostim, scopolamine, sodium bicarbonate, tacrolimus, teniposide, terbutaline, theophylline, thiotepa, ticarcillin/clavulanate, tigecycline, tirofiban, trimethobenzamide, vasopressin, vecuronium, vinblastine, vincristine, warfarin, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Alteplase, amiodarone, amphotericin B cholesteryl sulfate complex, amsacrine, caspofungin, diazepam, doxycycline, ergotamine, filgrastim,  haloperidol, idarubicin, levofloxacin, methotrimeprazine, nesiritide, phenytoin, reteplase.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Aldesleukin, amikacin, antithymocyte globulin (rabbit), ceftriaxone, ciprofloxacin, cisatracurium, dacarbazine, diltiazem, diphenhydramine, dobutamine, doxapram, doxorubicin HCl, droperidol, drotrecogin alfa, erythromycin lactobionate, fentanyl, gentamicin, hydromorphone, labetalol, methylprednisolone sodium succinate, metoprolol, nicardipine, nitroglycerin, pantoprazole, promethazine, quinidine gluconate, succinylcholine, telavancin, tenecteplase, thiopental, tobramycin, TPN, vancomycin, vinorelbine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Aminophylline, amphotericin B, ampicillin, atropine, bleomycin, buprenorphine, caffeine citrate, cefazolin, cefotaxime, cefoxitin, chloramphenicol, cisplatin, clindamycin, clonidine, cyclophosphamide, digoxin, dobutamine, dopamine, epinephrine, etomidate, fentanyl, fluorouracil, furosemide, hyaluronidase, iohexol, iopamidol, iothalamate meglumine 60%, ioxaglate meglumine 39.3% and ioxaglate sodium 19.6%, leucovorin calcium, lidocaine, lincomycin, methotrexate, metoclopramide, mitomycin, nafcillin, naloxone, neostigmine, nitroglycerin, nitroprusside, pancuronium, phenobarbital, piperacillin, ranitidine, succinylcholine, sulfamethoxazole/trimethoprim, verapamil, vincristine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amiodarone, diazepam, doxorubicin hydrochloride, droperidol, erythromycin lactobionate, gentamicin, haloperidol, hydromorphone, kanamycin, levofloxacin, meperidine, methotrimeprazine, midazolam, pantoprazole, pentazocine, promethazine, streptomycin, tobramycin, vancomycin, warfarin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Amikacin, ceftriaxone, chlorpromazine, cimetidine, dimenhydrinate, morphine, vinblastine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F178731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis and treatment of thromboembolic disorders; as an anticoagulant for extracorporeal and dialysis procedures",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Heparin lock flush solution is intended only to maintain patency of I.V. devices and is",
"     <b>",
"      not",
"     </b>",
"     to be used for systemic anticoagulant therapy.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F1962621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     ST-elevation myocardial infarction (STEMI) as an adjunct to thrombolysis; unstable angina/non-STEMI (UA/NSTEMI); anticoagulant used during percutaneous coronary intervention (PCI)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F178805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Heparin may be confused with Hespan&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      National Patient Safety Goals:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Joint Commission (TJC) requires healthcare organizations that provide anticoagulant therapy to have a process in place to reduce the risk of anticoagulant-associated patient harm. Patients receiving anticoagulants should receive individualized care through a defined process that includes standardized ordering, dispensing, administration, monitoring and education. This does not apply to routine short-term use of anticoagulants for prevention of venous thromboembolism when the expectation is that the patient&rsquo;s laboratory values will remain within or close to normal values (NPSG.03.05.01).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The 100 unit/mL concentration should not be used to flush heparin locks, I.V. lines, or intra-arterial lines in neonates or infants &lt;10 kg (systemic anticoagulation may occur). The 10 unit/mL flush concentration may inadvertently cause systemic anticoagulation in infants &lt;1 kg who receive frequent flushes.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Heparin sodium injection 10,000 units/mL and  Hep-Lock U/P 10 units/mL have been confused with each other. Fatal medication errors have occurred between the two whose labels are both blue.",
"       <b>",
"        Never rely on color as a sole indicator to differentiate product identity.",
"       </b>",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Heparin lock flush solution is intended only to maintain patency of I.V. devices and is",
"       <b>",
"        not",
"       </b>",
"       to be used for anticoagulant therapy.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F178795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Thrombocytopenia has been reported to occur at an incidence between 0% and 30%. It is often of no clinical significance. However, immunologically mediated heparin-induced thrombocytopenia (HIT) has been estimated to occur in 1% to 2% of patients, and is marked by a progressive fall in platelet counts and, in some cases, thromboembolic complications (skin necrosis, pulmonary embolism, gangrene of the extremities, stroke, or MI).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Allergic vasospastic reaction (possibly related to thrombosis), chest pain, hemorrhagic shock, shock, thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia (delayed, transient), bruising (unexplained), cutaneous necrosis, dysesthesia pedis, erythematous plaques (case reports), eczema, urticaria, purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Adrenal hemorrhage, hyperkalemia (suppression of aldosterone synthesis), ovarian hemorrhage, rebound hyperlipidemia on discontinuation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, hematemesis, nausea, tarry stools, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Frequent or persistent erection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Bleeding from gums, epistaxis, hemorrhage, ovarian hemorrhage, retroperitoneal hemorrhage, thrombocytopenia (see note)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Irritation, erythema, pain, hematoma, and ulceration have been rarely reported with deep SubQ injections; I.M. injection (not recommended) is associated with a high incidence of these effects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy, osteoporosis (chronic therapy effect)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctivitis (allergic reaction), lacrimation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, bronchospasm (case reports), hemoptysis, pulmonary hemorrhage, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, anaphylactoid reactions, heparin resistance, hypersensitivity (including chills, fever, and urticaria)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F178735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to heparin or any component of the formulation (unless a life-threatening situation necessitates use and use of an alternative anticoagulant is not possible); severe thrombocytopenia; uncontrolled active bleeding except when due to disseminated intravascular coagulation (DIC); not for use when appropriate blood coagulation tests cannot be obtained at appropriate intervals (applies to full-dose heparin only)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Some products contain benzyl alcohol as a preservative; their use in neonates, infants, or pregnant or nursing mothers is contraindicated by some manufacturers.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F178715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding:  Monitor patient closely for signs or symptoms of bleeding. Certain patients are at increased risk of bleeding; risk factors include subacute bacterial endocarditis; congenital or acquired bleeding disorders; active ulcerative or angiodysplastic GI diseases; continuous GI tube drainage; severe uncontrolled hypertension; history of hemorrhagic stroke; or use shortly after brain, spinal, or ophthalmologic surgery or other invasive procedures including spinal tap or spinal anesthesia; concomitant treatment with platelet inhibitors; recent GI bleeding; thrombocytopenia or platelet defects; severe liver disease; hypertensive or diabetic retinopathy; renal failure; or in patients (especially women) &gt;60 years of age. Discontinue if bleeding occurs; severe hemorrhage or overdosage may require protamine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heparin-induced thrombocytopenia (HIT): May cause thrombocytopenia; monitor platelet count closely. Patients who develop HIT may be at risk of developing a new thrombus (heparin-induced thrombocytopenia and thrombosis [HITT]). Discontinue therapy and consider alternatives if platelets are &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and/or thrombosis develops.  HIT or HITT may be delayed and can occur up to several weeks after discontinuation of heparin. Use with extreme caution (for a limited duration) or avoid in patients with history of HIT, especially if administered within 100 days of HIT episode (Dager, 2007; Warkentin, 2001); monitor platelet count closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heparin resistance: Dose requirements &gt;35,000 units/24 hours to maintain a therapeutic aPTT may occur in patients with antithrombin deficiency, increased heparin clearance, elevations in heparin-binding proteins, elevations in factor VIII and/or fibrinogen; frequently encountered in patients with fever, thrombosis, thrombophlebitis, infections with thrombosing tendencies, MI, cancer, and in postsurgical patients; measurement of anticoagulant effects using antifactor Xa levels may be of benefit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: Monitor for hyperkalemia; can cause hyperkalemia by suppressing aldosterone production.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: May occur; only in life-threatening situations when use of an alternative anticoagulant is not possible should heparin be cautiously used in patients with a documented hypersensitivity reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteoporosis: May occur with prolonged use (&gt;6 months) due to a reduction in bone mineral density.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in patients &gt;60 years of age, particularly women; they are also more sensitive to the dose and a higher incidence of bleeding has been reported in these patients. May require lower doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol:",
"     <b>",
"      [U.S. Boxed Warning]: Some products contain benzyl alcohol as a preservative; use of these products is contraindicated in neonates.",
"     </b>",
"     In neonates, large amounts of benzyl alcohol (&gt;100 mg/kg/day) have been associated with fatal toxicity (gasping syndrome). Use in neonates, infants, or pregnant or nursing mothers is contraindicated by some manufacturers; the use of preservative-free heparin is, therefore, recommended in these populations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfites: Some preparations contain sulfite which may cause allergic reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fatal medications errors: Many concentrations of heparin are available ranging from 1 unit/mL to 20,000 units/mL. Clinicians",
"     <b>",
"      must",
"     </b>",
"     carefully examine each prefilled syringe or vial prior to use ensuring that the correct concentration is chosen; fatal hemorrhages have occurred related to heparin overdose especially in pediatric patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F178720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     5-ASA Derivatives: May enhance the adverse/toxic effect of Heparin. Specifically, the risk for bleeding/bruising may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: May enhance the anticoagulant effect of other Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: May enhance the anticoagulant effect of Heparin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Heparin may enhance the adverse/toxic effect of Corticorelin. Significant hypotension and bradycardia have been previously attributed to this combination.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Heparin may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: Potential benefits of therapeutic heparin doses should be weighed against an increased risk of bleeding in patients who receive drotrecogin alfa.  In patients receiving prophylactic heparin doses consider continuing this during drotrecogin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroglycerin: May diminish the anticoagulant effect of Heparin. Nitroglycerin may decrease the serum concentration of Heparin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Palifermin: Heparin may increase the serum concentration of Palifermin.  Management: Avoid coadministration of heparin with palifermin, and flush any heparin-maintained intravenous line with saline prior to administration of palifermin via that line.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the anticoagulant effect of Heparin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Anticoagulants may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the anticoagulant effect of Anticoagulants. Vitamin E may also increase the overall risk for bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F178748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Herb/Nutraceutical: Avoid cat's claw, dong quai, evening primrose, feverfew, red clover, horse chestnut, garlic, green tea, ginseng, ginkgo (all have additional antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F178723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6481836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increased resorptions were observed in some animal reproduction studies. Heparin does not cross the placenta. Heparin may be used for the prevention and treatment of thromboembolism in pregnant women; however the use of low molecular weight heparin (LMWH) is preferred. Twice-daily heparin should be discontinued prior to induction of labor or a planned cesarean delivery. In pregnant women with mechanical heart valves, adjusted-dose LMWH or adjusted-dose heparin may be used throughout pregnancy or until week 13 of gestation when therapy can be changed to warfarin. LMWH or heparin should be resumed close to delivery. In women who are at a very high risk for thromboembolism (older generation prosthesis in mitral position or history of thromboembolism), warfarin can be used throughout pregnancy and replaced with LMWH or heparin near term; the use of low-dose aspirin is also recommended. When choosing therapy, fetal outcomes (ie, pregnancy loss, malformations), maternal outcomes (ie, VTE, hemorrhage), burden of therapy, and maternal preference should be considered (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Some products contain benzyl alcohol as a preservative; their use in pregnant women is contraindicated by some manufacturers; use of a preservative free formulation is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F178762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Does not enter breast milk",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11443865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heparin is not excreted into breast milk and can be used in breast-feeding women (Guyatt, 2012). Some products contain benzyl alcohol as a preservative; their use in breast-feeding women is contraindicated by some manufacturers due to the association of gasping syndrome in premature infants.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Heparin (Porcine) in NaCl Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 unit/mL 0.9% (500 mL): $4.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 unit/mL 0.45% (250 mL): $7.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 unit/mL 0.45% (250 mL): $8.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Heparin Lock Flush Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 units/mL (5 mL): $0.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 units/mL (10 mL): $1.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Heparin Sod (Porcine) in D5W Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 units/mL (250 mL): $9.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Heparin Sodium (Porcine) Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 units/mL (10 mL): $3.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2500 units/mL (10 mL): $9.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5000 units/mL (1 mL): $3.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10000 units/mL (1 mL): $4.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20000 units/mL (1 mL): $12.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Heparin Sodium (Porcine) Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2000 units/mL (5 mL): $4.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Heparin Sodium Lock Flush Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 units/mL (5 mL): $3.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Monoject PreFill Adv Heparin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 units/mL (5 mL): $3.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 units/mL (3 mL): $3.05",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F178725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemoglobin, hematocrit, signs of bleeding; fecal occult blood test; aPTT (or antifactor Xa activity levels) or ACT depending upon indication",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Platelet counts should be routinely monitored (eg, every 2-3 days on days 4-14 of heparin therapy) when the risk of HIT is &gt;1% (eg, receiving therapeutic dose heparin, postoperative antithrombotic prophylaxis), if the patient has received heparin or low molecular weight heparin (eg, enoxaparin) within the past 100 days, if pre-exposure history is uncertain, or if anaphylactoid reaction to heparin occurs. When the risk of HIT is &lt;1% (eg, medical/obstetrical patients receiving heparin flushes), routine platelet count monitoring is not recommended (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     For intermittent I.V. injections, aPTT is measured 3.5-4 hours after I.V. injection.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Continuous I.V. infusion is preferred over I.V. intermittent injections. For full-dose heparin (ie, nonlow-dose), the dose should be titrated according to aPTT results. For anticoagulation, an aPTT 1.5-2.5 times normal is usually desired. Because of variation among hospitals in the control aPTT values, nomograms should be established at each institution, designed to achieve aPTT values in the target range (eg, for a control aPTT of 30 seconds, the target range [1.5-2.5 times control] would be 45-75 seconds). Measurements should be made prior to heparin therapy, 6 hours (pediatric: 4 hours) after initiation, and 6 hours (pediatric: 4 hours) after any dosage change, and should be used to adjust the heparin infusion until the aPTT exhibits a therapeutic level. When two consecutive aPTT values are therapeutic, subsequent  measurements may be made every 24 hours, and if necessary, dose adjustment carried out. In addition, a significant change in the patient's clinical condition (eg, recurrent ischemia, bleeding, hypotension) should prompt an immediate aPTT determination, followed by dose adjustment if necessary. In general, may increase or decrease infusion by 2-4 units/kg/hour dependent upon aPTT.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Heparin infusion dose adjustment: A number of dose-adjustment nomograms have been developed which target an aPTT range of 1.5-2.5 times control (Cruickshank, 1991; Flaker, 1994; Hull, 1992; Raschke, 1993). However, institution-specific and indication-specific nomograms should be consulted for dose adjustment.",
"     <b>",
"      Note:",
"     </b>",
"     aPTT values vary throughout the day with maximum values occurring during the night (Decousus, 1985).",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F178728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Venous thromboembolism: Heparin: 0.3-0.7 unit/mL (children: 0.35-0.7 unit/mL) anti-Xa activity (by chromogenic assay) or 0.2-0.4 unit/mL (by protamine titration); aPTT: 1.5-2.5 times control (usually reflects an aPTT of 60-85 seconds) (Garcia, 2012; Monagle, 2012)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     When used with thrombolytic therapy in patients with acute MI, a lower therapeutic range corresponding to an aPTT of 1.5-2 times control (or approximately an aPTT of 50-70 seconds) is recommended (Antman, 2004).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F178738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Agglutek (TW);",
"     </li>",
"     <li>",
"      Caprin (IN);",
"     </li>",
"     <li>",
"      Coaparin (PL);",
"     </li>",
"     <li>",
"      Hemastat (PH);",
"     </li>",
"     <li>",
"      Hemonor (PE);",
"     </li>",
"     <li>",
"      Hepaflex (FI, NO);",
"     </li>",
"     <li>",
"      Heparin (AT, BF, BG, BJ, CH, CI, CZ, DE, ET, FI, GB, GH, GM, GN, GR, HN, IL, KE, LR, MA, ML, MR, MU, MW, NE, NG, NO, SC, SD, SE, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Heparin Injection B.P. (AU);",
"     </li>",
"     <li>",
"      Heparin Leo (DK, HK, ID, MY, PH, TW);",
"     </li>",
"     <li>",
"      Heparin Novo (TW);",
"     </li>",
"     <li>",
"      Heparin Sodium B Braun (ID, MY);",
"     </li>",
"     <li>",
"      Heparine (BE, NL);",
"     </li>",
"     <li>",
"      Heparine Choay (FR);",
"     </li>",
"     <li>",
"      Heparine Novo (BE, NL);",
"     </li>",
"     <li>",
"      Heprin (PH);",
"     </li>",
"     <li>",
"      Hepsal (SG);",
"     </li>",
"     <li>",
"      Heptin (PH);",
"     </li>",
"     <li>",
"      Inviclot (ID);",
"     </li>",
"     <li>",
"      Lioton (RU);",
"     </li>",
"     <li>",
"      Liquemin (DE, IT);",
"     </li>",
"     <li>",
"      Liquemine (BE, BR, TR, UY, VE);",
"     </li>",
"     <li>",
"      Meparin (PH);",
"     </li>",
"     <li>",
"      Multiparin (NZ, PK);",
"     </li>",
"     <li>",
"      Nuparin (PH);",
"     </li>",
"     <li>",
"      Parinix (AR);",
"     </li>",
"     <li>",
"      Proparin (MX);",
"     </li>",
"     <li>",
"      Thrombophob (DE);",
"     </li>",
"     <li>",
"      Thromboreduct (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F178714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potentiates the action of antithrombin III and thereby inactivates thrombin (as well as activated coagulation factors IX, X, XI, XII, and plasmin) and prevents the conversion of fibrinogen to fibrin; heparin also stimulates release of lipoprotein lipase (lipoprotein lipase hydrolyzes triglycerides to glycerol and free fatty acids)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F178734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Anticoagulation: I.V.: Immediate; SubQ: ~20-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral, rectal: Erratic at best from these routes of administration; SubQ absorption is also erratic, but considered acceptable for prophylactic use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; may be partially metabolized in the reticuloendothelial system",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dose-dependent:  I.V. bolus: 25 units/kg: 30 minutes; 100 units/kg: 60 minutes; 400 units/kg: 150 minutes (Hirsh, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mean: 1.5 hours; Range: 1-2 hours; affected by obesity, renal function, malignancy, presence of pulmonary embolism, and infections",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     At therapeutic doses, elimination occurs rapidly via nonrenal mechanisms. With very high doses, renal elimination may play more of a role; however, dosage adjustment remains unnecessary for patients with renal impairment (Hirsh, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (small amounts as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Andrew M, Marzinotto V, Massicotte P, et al, &ldquo;Heparin Therapy in Pediatric Patients: A Prospective Cohort Study,&rdquo;",
"      <i>",
"       Pediatr Research",
"      </i>",
"      , 1994, 35(1):78-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/8134203/pubmed\" id=\"8134203\" target=\"_blank\">",
"        8134203",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, The Society of Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 116(7):e148-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/17679616/pubmed\" id=\"17679616\" target=\"_blank\">",
"        17679616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe DT, Armstrong PW, et al,&ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(9):e82-292.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/15339869/pubmed\" id=\"15339869\" target=\"_blank\">",
"        15339869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Broderick J, Connolly S, Feldmann E, et al, &ldquo;Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2007, 38(6):2001-23. Available at  file://stroke.ahajournals.org/cgi/content/short/STROKEAHA.107.183689",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/17478736/pubmed\" id=\"17478736\" target=\"_blank\">",
"        17478736",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cruickshank MK, Levine MN, Hirsh J, et al, &ldquo;A Standard Heparin Nomogram for the Management of Heparin Therapy,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1991, 151(2):333-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/1789820/pubmed\" id=\"1789820\" target=\"_blank\">",
"        1789820",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dager WE and White RH, &ldquo;Pharmacotherapy of Heparin-Induced Thrombocytopenia,&rdquo;",
"      <i>",
"       Expert Opin Pharmacother",
"      </i>",
"      , 2003, 4(6):919-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/12783589/pubmed\" id=\"12783589\" target=\"_blank\">",
"        12783589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dager WE, Dougherty JA, Nguyen PH, et al, &ldquo;Heparin-Induced Thrombocytopenia: Treatment Options and Special Considerations,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2007, 27(4):564-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/17381384/pubmed\" id=\"17381384\" target=\"_blank\">",
"        17381384",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Decousus HA, Croze M, Levi FA, et al, &ldquo;Circadian Changes in Anticoagulant Effect of Heparin Infused at a Constant Rate,&rdquo;",
"      <i>",
"       Br Med J (Clin Res Ed)",
"      </i>",
"      , 1985, 290(6465):341-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/3917812/pubmed\" id=\"3917812\" target=\"_blank\">",
"        3917812",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flaherty ML, &ldquo;Anticoagulant-Associated Intracerebral Hemorrhage,&rdquo;",
"      <i>",
"       Semin Neuro",
"      </i>",
"      , 2010, 30(5):565-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/21207349/pubmed\" id=\"21207349\" target=\"_blank\">",
"        21207349",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flaker GC, Bartolozzi J, Davis V, et al, &ldquo;Use of a Standardized Heparin Nomogram to Achieve Therapeutic Anticoagulation after Thrombolytic Therapy in Myocardial Infarction. TIMI 4 investigators. Thrombolysis in Myocardial Infarction,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1994, 154(13):1492-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/8018004/pubmed\" id=\"8018004\" target=\"_blank\">",
"        8018004",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Francis JL, Groce JB 3rd, and the Heparin Consensus Group, &ldquo;Challenges in Variation and Response of Unfractionated Heparin,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2004, 24(8 Pt 2), 108-19.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/15334856/pubmed\" id=\"15334856\" target=\"_blank\">",
"        15334856",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Freed MD, Keane JF, and Rosenthal A, &ldquo;The Use of Heparinization to Prevent Arterial Thrombosis After Percutaneous Cardiac Catheterization in Children,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1974, 50(3):565-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/4607271/pubmed\" id=\"4607271\" target=\"_blank\">",
"        4607271",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garcia DA, Baglin TP, Weitz JI, et al, &ldquo;Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):24-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/22315264/pubmed\" id=\"22315264\" target=\"_blank\">",
"        22315264",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greinacher A, Janssens U, Berg G, et al, &ldquo;Lepirudin (Recombinant Hirudin) for Parenteral Anticoagulation in Patients With Heparin-Induced Thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) Investigators,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 100(6):587-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/10441094/pubmed\" id=\"10441094\" target=\"_blank\">",
"        10441094",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greinacher A, Volpel H, Janssens U, et al, &ldquo;Recombinant Hirudin (Lepirudin) Provides Safe and Effective Anticoagulation in Patients With Heparin-Induced Thrombocytopenia: A Prospective Study,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 99(1):73-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/9884382/pubmed\" id=\"9884382\" target=\"_blank\">",
"        9884382",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):7-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/22315257/pubmed\" id=\"22315257\" target=\"_blank\">",
"        22315257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hull RD, Raskob GE, Rosenbloom D, et al, &ldquo;Optimal Therapeutic Level of Heparin Therapy in Patients with Venous Thromboembolism,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1992, 152(8):1589-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/1497392/pubmed\" id=\"1497392\" target=\"_blank\">",
"        1497392",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network, &ldquo;Standard Concentrations of Neonatal Drug Infusions,&rdquo; 2011.  Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jaff MR, McMurtry MS, Archer SL, et al, &ldquo;Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension: A Scientific Statement from the American Heart Association,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(16):1788-830.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/21422387/pubmed\" id=\"21422387\" target=\"_blank\">",
"        21422387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jauch EC, Saver JL, Adams HP Jr, et al, &ldquo;Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2013 [epub ahead of print].",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/23370205/pubmed\" id=\"23370205\" target=\"_blank\">",
"        23370205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jneid H, Anderson JL, Wright RS, et al, &ldquo;2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(7):875-910.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/22800849/pubmed\" id=\"22800849\" target=\"_blank\">",
"        22800849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kearon C, Ginsberg JS, Julian JA, et al, &ldquo;Comparison of Fixed-Dose Weight Adjusted Unfractionated Heparin and Low-Molecular-Weight Heparin for Acute Treatment of Venous Thromboembolism,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2006, 296(8):935-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/16926353/pubmed\" id=\"16926353\" target=\"_blank\">",
"        16926353",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klerk CP, Smorenburg SM, and Buller HR, &ldquo;Thrombosis Prophylaxis in Patient Populations With a Central Venous Catheter: A Systematic Review,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2003, 163(16):1913-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/12963564/pubmed\" id=\"12963564\" target=\"_blank\">",
"        12963564",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):e574-651.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/22064601/pubmed\" id=\"22064601\" target=\"_blank\">",
"        22064601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Monagle P, Chan A, Goldenberg NA, et al, \"Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition),\"",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):e737-801.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/22315277/pubmed\" id=\"22315277\" target=\"_blank\">",
"        22315277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al, \"2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 127(4):e362-425.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/3247304/pubmed\" id=\"3247304\" target=\"_blank\">",
"        3247304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raschke RA, Reilly BM, Guidry JR, et al, &ldquo;The Weight-Based Heparin Dosing Nomogram Compared With a &ldquo;Standard Care&rdquo; Nomogram: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1993, 119(9):874-81.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Savi P, Chong BH, Greinacher A, et al, &ldquo;Effect of Fondaparinux on Platelet Activation in the Presence of Heparin-Dependent Antibodies: A Blinded Comparative Multicenter Study With Unfractionated Heparin,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2005, 105(1):139-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/15388575/pubmed\" id=\"15388575\" target=\"_blank\">",
"        15388575",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sinnaeve PR, Alexander JH, Bogaerts K, et al,&ldquo;Efficacy of Tenecteplase in Combination With Enoxaparin, Abciximab, or Unfractionated Heparin: One-Year Follow-Up Results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) Randomized Trial in Acute Myocardial Infarction,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 2004, 147(6):993-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Verma AK, Levine M, Shalansky SJ, et al, &ldquo;Frequency of Heparin-Induced Thrombocytopenia in Critical Care Patients,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(6):745-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/12820817/pubmed\" id=\"12820817\" target=\"_blank\">",
"        12820817",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Warkentin TE and Kelton JG, &ldquo;Temporal Aspects of Heparin-Induced Thrombocytopenia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 344(17):1286-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/11320387/pubmed\" id=\"11320387\" target=\"_blank\">",
"        11320387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Warkentin TE, \"Heparin-Induced Thrombocytopenia: A Clinicopathologic Syndrome,\"",
"      <i>",
"       Thromb Haemost",
"      </i>",
"      , 1999, 82(2):439-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/10605735/pubmed\" id=\"10605735\" target=\"_blank\">",
"        10605735",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Warkentin TE, Levine MN, Hirsch J, et al, &ldquo;Heparin-Induced Thrombocytopenia in Patients Treated With Low-Molecular Weight Heparin or Unfractionated Heparin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 332(20):1330-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/34/40489/abstract-text/7715641/pubmed\" id=\"7715641\" target=\"_blank\">",
"        7715641",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8518 Version 54.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-D2DE38DEA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_34_40489=[""].join("\n");
var outline_f39_34_40489=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15793684\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443864\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178752\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178753\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178797\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178757\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178776\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178758\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11256164\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11256165\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178727\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178711\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178732\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472657\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472658\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178803\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178731\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1962621\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178805\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178795\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178735\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178715\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299438\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178720\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178748\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178723\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6481836\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178762\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443865\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524629\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178725\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178728\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178738\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178714\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178734\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8518\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8518|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/20/325?source=related_link\">",
"      Heparin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/39/7801?source=related_link\">",
"      Heparin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_34_40490="Wireless motility capsule studies";
var content_f39_34_40490=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77372&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77372&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 830px\">",
"   <div class=\"ttl\">",
"    Wireless motility capsule studies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 810px; height: 813px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Representative results of wireless motility capsule studies in patients with (A) normal intestinal transit, (B) delayed gastric emptying, and (C) delayed colonic transit.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Braden Kuo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_34_40490=[""].join("\n");
var outline_f39_34_40490=null;
var title_f39_34_40491="Perioperative anaphylaxis vs general";
var content_f39_34_40491=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F51806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F51806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differences between perioperative/perianesthesia anaphylaxis and anaphylaxis in other settings",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Other settings",
"       </td>",
"       <td class=\"subtitle1\">",
"        Perioperative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin",
"       </td>",
"       <td>",
"        Flushing, itching, or urticaria are present in &gt;90 percent of cases",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Signs and symptoms are more likely to be absent",
"         </li>",
"         <li>",
"          Patient cannot report itching",
"         </li>",
"         <li>",
"          May be present but hidden by surgical drapes",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Upper respiratory tract",
"       </td>",
"       <td>",
"        Laryngeal edema can present as throat tightness, deepening of voice",
"       </td>",
"       <td>",
"        Severe laryngeal edema may present as difficulty with intubation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Lower respiratory tract",
"       </td>",
"       <td rowspan=\"4\">",
"        Shortness of breath, wheezing, persistent cough are typical",
"       </td>",
"       <td class=\"sublist1_start\">",
"        May present as sudden:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Increase in ventilatory pressure needed to inflate lungs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Increase in end-tidal CO",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Decrease in arterial oxygen saturation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiovascular system",
"       </td>",
"       <td>",
"        Dizziness or tunnel vision may signal onset of hypotension (collapse without warning symptoms is not typical)",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Cardiovascular collapse is the first detected manifestation in one-half of cases",
"         </li>",
"         <li>",
"          Arrhythmias and cardiac arrest more common",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_34_40491=[""].join("\n");
var outline_f39_34_40491=null;
var title_f39_34_40492="Risk classific exercise class B";
var content_f39_34_40492=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk classification for exercise training: class B: presence of known, stable cardiovascular disease with low risk for complications with vigorous exercise, but slightly greater than for apparently healthy individuals",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        This classification includes individuals with any of the following diagnoses:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Coronary artery disease (myocardial infarction, bypass surgery, angioplasty, angina pectoris, abnormal exercise test, and abnormal coronary angiograms) whose condition is stable and who have the clinical characteristics outlined below.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Valvular heart disease, excluding severe valvular stenosis or regurgitation with the clinical characteristics as outlined below.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Congenital heart disease; risk stratification for patients with congenital heart disease should be guided by the 36th Bethesda Conference recommendations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Cardiomyopathy: ejection fraction &le;30 percent; includes stable patients with heart failure with clinical characteristics as outlined below but not hypertrophic cardiomyopathy or recent myocarditis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        5. Exercise test abnormalities that do not meet any of the high risk criteria outlined in class C below.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical characteristics (must include all of the following)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. New York Heart Association class 1 or 2.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Exercise capacity &le;6 METs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. No evidence of heart failure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        4. No evidence of myocardial ischemia or angina at rest or on the exercise test at or below 6 METs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Appropriate rise in systolic blood pressure during exercise.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Absence of sustained or nonsustained ventricular tachycardia at rest or with exercise.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Ability to satisfactorily self-monitor intensity of activity.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Activity guidelines:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Activity should be individualized, with exercise prescription provided by qualified individuals and approved by primary healthcare provider.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Supervision required:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Medical supervision during initial prescription session is beneficial.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Supervision by appropriate trained nonmedical personnel for other exercise sessions should occur until the individual understands how to monitor his or her activity.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Medical personnel should be trained and certified in Advanced Cardiac Life Support. Nonmedical personnel should be trained and certified in Basic Life Support (which includes cardiopulmonary resuscitation).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        ECG and blood pressure monitoring:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Useful during the early prescription phase of training, usually 6 to 12 sessions.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fletcher GF, Balady GJ, Amsterdam EA, et al. Circulation 2001; 104:1694. Copyright &copy; 2001 Lippincott Williams and Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_34_40492=[""].join("\n");
var outline_f39_34_40492=null;
var title_f39_34_40493="Repeated exercise challenge";
var content_f39_34_40493=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Refractoriness to repeated exercise-induced bronchoconstriction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 318px; background-image: url(data:image/gif;base64,R0lGODlh6AE+AeYAAP///yBzOYCAgBA5HAAAAP+AgMDAwEBAQP8AAAAzmf/AwICZzP9AQMDN5kBms/Dz+RBAn6Cz2TBZrNDZ7GCAv/8QENDQ0KCgoP/w8P/g4FBzuf+wsBAQEP8wMCAgIJC5nODg4FBQUP8gIP9wcHCNxiBNpvDw8LDA3//Q0ODm8zAwMP9gYGBgYP9QUP+QkJCm07CwsHBwcMjczliWa/+goEpK/y58RZCQkIaG/6zLtcPD/w0N/9bl2/L3857CqWafdzyFUpaW//Hx/0qNXnSohCsr/9LS/7S0/4KwkGho/+Tu57rUwggcDu8DCY8mUxAmU4OQ5s8JHCA8lUBNZo+WwoBAQGN22D8mclBTme+zub88VlBZbK+AoI8WQoAwMO8yOc96jU8jab8MJn8gIF9fn+/j6ZOd7IAQEAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADoAT4BAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7LQy7++ZPDM57fb3+I0B+/uZSh8y8gkcmG8fPAA+PvRAqBBAjhkzfAj6kIPHBwA9fED08S9gDyQQL/b4MOPHEoIoU3Lb94EiABkBiOQIIBFJACQ/aAIIYKPfjJtIbMC8CMTGByRAAAwxOiQAD5VQo0rjF2CGIB88fwiyAaRl1Z1DBPGIKUjJUAA2bBD5oGTsjA9E/wJclEq3LrJ+hJTsq7eza8t6X1/KHXSWxw8gPGe+bRnQruPHv1i2xLh0ho2nOQHmuBgYrY0lS4acpSfjJ4+0OWT44Au5tetaVAMAiCujh40hPXoQ6Wl0p1WxOaueDQ6knuF9QE6+Xs68ufPn0KNLn069uvXr2LNrL2VAgPfv4MOLD29gu/nzjQQwGcC+vfv38NszEYC+vn1CAgbE3s9//wD69wV4Xn79FcjffwImqB2BBja4D4IKRlgdgw4aCKGEGEJHYYX9XZjhh8ttyKF/AIJoYmsijkiVhye2SFeKKj5Yoos0QgVjjCzWqKNAN6qY445AttPjiD8GaSQ6Q3JY5P+RTI6TZIVLNimlN086GOWUWGZTZYNXZuklNVtaOOOXZF4TZoFdlqnmMmd2OOaacDrT5oFvxmlnMnOSeOeebOoXo558BmpMnrGlKeihthC6Yp2INoqLovwY6uikrUAqI6WY3mJpAJJmyqcFBoDAyqademqnBRwQwCgppK5q6qEqEKDqqH7+ueirmQrAQQyzrtIqrpRaQAAMAvQqSHfkgfIrsI4WK6usJSL73QGuWrIss4iCYIABLBDAgqiIeKdsrbZeiu2kxboq7ifXnovtup606y6w8A6ywQaYyDvvq/UKskEFDGRgLbnllrovn/0KUoYWFbhQib4H57oqF1F0gML/JBBHTGnChJzgRBMjYBBJxho3W+0DZIghAr6PkFwyohwbskAYTbQgcHoE22rwy2vGbEgDUnTRMM7l3sqzxI884MAVFV+siMtHI1ytzBA4UUHIiUAd9Z0+J9JACVh8sXK4Of+589Zedp3IAxqUAEYFNhuiNdpwqq3ICwlQscLQ+JWN49R09wx4IhOUoEEWIjDgNABzB16m3YuwXcIEBSBQgMiNO/4l5Izg/UIGDIigQOaaZ8k5I4U78AANFZzht4+Dl2567Iw8QAEEDWBQxetE0i67lKc7EgEEC5D+e5PBOzKBBE/wrqTvxx+ZvCMPbOE8lNBHH+T0jhiv/fbZE120/7nfCz7u+OSX/3j4jHivfo3ciz/+2e+3GH/711vJfv0m3r+I+/w7kf+elj8u7S+AGRpg1gooJgSm7YALRB+nIOhABSmQbBKkXwUldMFDAHCDHKSgBxmIJi/cDITSE6HcSNihMVSgAChM4fnQ9x8UdKADCoghkDq4wgwCyAVXE5kOacTDQlwrAy2oAMuGKEAVGpGFdCrEBhJ3QiYm0Il9y+AUHlAIDIzghVb8UBGzSMMnlKABhrAhDsMYwhnOTwAvIN4hgIg1NgpojIP41fJUZ4gMdKACNMihHe2DR0Esy3a4M4QCRhA6BABsBQXYgAKEOEjrFJJxUASUIIa3AEVkQP8BLigAAzqAAAQwoAUFcIECqlhJ5lxSXnvkoiMwoAAaFKAFDKgAAjrAgAIUQAGLa6VjXpnJQr0JkSewhAI2UIAVNDJxkJSkMKNCTB8i4gQQIAEnUKAAX47SkacsQCApOU0hYTGPxTTaIVIgAQmkIBSfDCUuS8nLVK6ynOVAFrXcWLQrkQACETgFLZnpTF1Cc4n45IY+z2nIdEZqahFIwARcoYBuAoyVCdVGNWkIuOFN9BVe5FtGt7HRNwoPAh99hQJuGMyRWqOk/YydR2VRgCC6KwOhdAE5EYECBtBAEYxkBANGAAAaKI6kDMWkNR/xz3fGAnRjwxYDSrlLRijAcor/mCojTAmAyglSS0k1HgUkIMtY/CtuwNoABjAgAgSsMpKMhCEAMODMFmCVEApw5gp6ioANtKAFF8uAM4cqMq56da6ibAG+urkBZ7IMBX/1pcAEy4C9AgOmBYPeWMsKi5A6DFtt/WQpc4mAn5JyBCu4qyCu2gFRihIBIiClCACggF6mdgUAMKxbAfDHApASBZUDWCkzkIEKvHCqq6xAa4172bA6NH2P2CwtFBDblmbKBQgg6lVhuAHLoQABuN0uIex6M9AhQBCkFAQNnMlV3QLTlM203GFH4NbK/dSr2IUkcn+BWZ2FTwNkrUXl6pgp+uKWtljdrnjFOwitNvi8ANAq/31HcFUG5NbCXq2wL395WK92uL7g3TBGc9Ffs4XvARLQgC2g+tVJ2VUEvqxogi2HgQqIjr5yFUR+u/laQWh1qhugQXsxvFvjBtIFttytV7vbgtq69bsdkOQIrEti5y51EiimwC1Y14KdHoqqpfzljGHIOlOqVhAFaKsSHaxVFOhyqhZ2LwAgW8qVfTiH9FXubjdAyl2O+FFW5qglsnwLuooUn6rkMwK83Fx+ZvYShL4FdY+Kz7buEqHDKPHfMJGCbOaicpdz6TE0DbtMTACguWCxqItB6t5p4tQBzQUQu7xqYbT6eZuAtS4wkMTP1toXt8YeJyaQgFjnYtJ//nUtgv+tv05ENKW4wAColb0LZhvQEzPdRU9FR21AO9q/n8j2LoC4AkZHiJsbTre6183udrv73S02h7UbGG6U9oLXgEzQQJtJ2sSN4N0AD7jA1R1vXlzgAiYIAQtYFWiTgqKpvkD2dj5py3nuspeqTDY+PHCDbhHgBqOYN5qSKgjp3hvH00G3KEkJMFSOEzIEMIAKDhCDA4S84TEdhcl7YUNuu2aZBWBkW6EZyYK7hgPpEoDNRSFyN5Fi572go7nzQcuKk7aev6Tyc3gVcxUsnOk4fzQpAMxZXiBRifmIpyinakpUZvw8JrgBDEwgAAvc/NsmLgWKVRyMKQbMHBUFZdAb+cj/ok99OzGIwSmaHkW9S0DLwQhpjqvBzVr6kpEMYPvFKxtjoyuIBUsvBeM1SYpIB0ONng/GJ4HuzczrEraZR2XnJ2mkGyDdOxe4O7ueO0FUmD4YUt914DeMy0aCM/MbluQ91XSAZxEg9MoKO7hR0WltDgN0Lxy49re/7sH22ZSZ/7c4K6r1PYFqWwawO9jxvulU6JoYGxA/9+c/cFVWdF4mqLkFQgAD3ceL9xpUCe/Xbb8QArLCLSHgf53wQZcwgATICx93AN0BfewifXnHCsRmbA+oC8MigQeQgOu3e1e2Cs+2gbvAAhzAAR5AALkXgv83giRobyaICwlHALvCcOxX/2qvIG4zSAsWAC4/qICcwICbwIM9GAv7xDgUGC8W2H6wAHFHCAsWcAAqeABUuIQL2IQ6GAtQF4WrYADOZ4P954ILCIAkNwld6IWqEAMtKHpa6Gq0kIZqCA2jZ0y2QHZzmAox13zPgoVD+Ia4Vgt7l4eocAAWUHNWSHNCuAlECAq/R4jNUIfqJIiPB4kMFx5tGH05CIe38IiW2AlhKCt+KAgmQCx1Zwjnty0mEC6AKGy5UH2fCAroN4vqFy7OVx6EwIcHyIqbGIi54IA80wDQJgkT4AAaeAgR4AATUIzHGAyhAgDdMibNdwOqyIsiKGi7AIwRMwELkAAOkAjeuAgNkP8AnaQI3dgA41iOg6ICHgAug9B8M5eJRtSKzcYL2rgvDpAA4SgIJ6ABDkABDRBRJbAATiUIKUACDqABJzCOJICQ5YiQ/zhR55iOm+QADvACgrAAEfAC/8hFtuMAC7AAaPQAC5CQycQKB+ABHlCLghADAhADqTKG0uIdSfiC2GiPxRaM+xhRGrAAPUkCCQAByjgIDwABxEMBDjCO3ggBOTmQ/1QCADCR5AgAQEkCGpAAGKmPElACCaBlEpAAJEABUykBxPOVw4gKYOiH6XIs4VGTZQiDujA8GFky4/iNAIA3EqCRgrCPg4A3sZYCFHkCU9kACMmUUZkA6DiVEDCQ3fj/jeH4AN44jlqWjsQGkmKpjprALbiICAonALGycGBIHx6QeKmymfPYi67oC6cGeRFTl4NQkvqoTXyZkYg5CBSZjoKpkF95mInZSQnAmHq5j5E5mORYlyEpkp0gLM/HkviRKt6yiqEJAAZIAB4gj/hBj9cGDCgWYPsyAXjZAA/wAiQQkAmgYr/ZAAVJbBIQkBpwm+TYjQtwAlzJmxR5lSIZAb5pl94ImWcElJ1klBHQAC/QjJnQHdbJiNhJb9o5VmcJLPmoj4gpn/qoAVzUjRLVMV9ZnMS5ACj2m/MplZ2ESEGZn3v5jcPjjVM5AVf5myfJCSDAnEyImvUoDAuQSN0W/6ANcJUtynSjqAmS+FDFEFEE6lJi+ZuYyQkXkIhW6AE9mgk/Cl3BcGrWF4sjE4pNmi8JOnLHwE4USqWRcAAqgH6gt4g+aobIoDTu5KWPcAGKJwhsSqZOaqbJcDsNqqaw8KS9pwzDM6R2KggdZ5o4eI0OpwwNIEd96kGywnHuSIZDKKfLUDgUUHalA5jI+QsWgIKyEgKAGqOCmnPNsJ2SejQNcAI++ZVCOZ7DAAMreKWXgKcBmAsUMDkv8wACWpJcWQIgGaCh6gsgcAMr+Hxwmi+O6gxxtKPAMgENsABIqY//GJ91KgwGoIsct4qMyojD6gx7aioBWapB6QAk8ALoSf+HNsgCMKqJnSp20bCaiAKY4ukATJliGolG1gADCIcKrnqGsoBifAQnE0Cqy+qNFCCSz0oN3QEAFmB3BxesrXqt0MA2EjCwO0Kr+OkAtwqS4LqrJEUAAGCFG8uq1pKlTmcN/wSxIEKr7fquPbmQ6lAsHduy1VqmcCkNQkoj2+quACuSBSkkqqKSAsCkCjswMSsNUpohKUCqAJYA8HoCOcsjVvqzD8Ow1LA8XWofJrusQhmvdTGTuOe0lNCIw4CmGCsdNcuU/3ixraEtqXCv3UCn1FG03Jq0S+saLMuxbiij2ckN2cocVZuPVxug1DG3Houldqug3IBNc+kYYwuwZov/HYBrCmr7DZAaFW57tHBbH87ifIHbtSDbeN8AqvggBDpwBDhgBXybq/J6R037snEatNpgO7JqDkagA0GAA0lQA0WwAztQAzWAA2YAnqbyuOJQo6erDaArujigu7hbBDWQBDgQBDpgBPMCvOKQt9IQu7Nbu7ebu7uLA0egA0JwNNIrDuqaDMWLA8dbA8m7vM37vLITvuLATvvqC9ZLu7aLu7prvt37verjvuLgsHEbC8i6AFCAvDugvMzrvNALQvw7DiPrCrTqrzaLqyQABflrRws8DjNbCoCJn/6olRYbrvh0weNQqEdqaslakqaakPEattMkwuOwPJFaCaO6AAhZ/7EBq7Im6MLj4LmRs63++K4gKbB5qMPkwLaDwK4l+aAqDK7/O8SbS3rtEEc13K037LuHakhPbIf5cALjObxXLDdZPIlf/CJhDKRjbBdEfMb4kMZqbA9s3Mbs8MZwvLJlDKVzPBByfMfnkMd6LA4LNbha2scC8cfnOn2CjMd1nKeHzCOJ/KqLjFSAHLKPvMaNjK+TLCeVfMmUHMmcq8lxnMmebE6cDMWhjCSgXMp0PMpajMrpwMesbCan/MryFsuyTA6uXMvTcMu4HA26vMvP0Mu+HIm0HMxUMszEzA3AfMx4YszKDFaqLMbNrFHMHM0vNc3UDCbWfM3SkMzabGvZ3P/Nv/zN4CzMz2zG41zN5WzH50yH4rzOy5zOiuzO29zO8jwo9FzPxMDN+OxthXyB+xzO8OzI/6wp9zzQ/FXQBt0L+pzQsrDQDH2nCP3QVRbQlizRjhvRFp0oGJ3RtODQHK0KHv3R9rrRIg3RFF3StWABNyAA9Zo1JI3SnoC5T/PSMI2kAAACsjLTJ13TsmAAvDIjWmuF4zHURD3UB7Ae8ZHUSc0E1FLUTv3UUB3VUj3VVF3VVn3VWJ3VWr3VXN3VT72p1pCkBNCmbMnVQu3VWX3WaH3Var3WVN3Wbi3VcB3XUD3XdO3Udn3XRO2W2tB8YN2qFZ0egd0+g63TJn3Yr3D/SSNT2D2tAi8pK4vqo4zt0g092R5k2WAcC4oNCZvdMpjtCiAQK9Q5hllY2aaN2K7Q2d3z2dep2azNy6+dR7GNxa5d26hdKbOt2pBs27c9Krn927yd2rPtDNvS03+tCsUNC8n9CsvtCs3dCs/NCtHN09Rd3dbtGhbgHeWaCshC2tI9i849i5GdCtl9A+N9CqBSCNpCraew3oPQ3dxdi7N43PcAA9S5gt6N3M7H2mHoCmH42RdAnSl43qMAAheQKoNQirFC352g4DF3LPttCtkNrILQ3yoRKwdLACoA2uUR4Jkb0zE33aeAfqlyoKaQKiYQ4F9nr8/y3s/C4JwAhrt4/9MdTuGkwIehd4Aijg85DQA97goXEAIckN96+HyaCgsB7gH+TQAmkJas8OOC4NepIOWDEORDPuI2LopHrhI9DuWsEAMqwAEmbgohIADdwgEEfgorOOal0C0eECsfvgleTuWnQOcAAOZijuWhV+Znnub2gOImYIOy4OUo+eCtkOSvkOLeYSxFXgh2XgqP7uMaawpO7uiGjhLRWCwr7itlboBKLt2OfebsrQomUOLMbQAHjuaqoC0HKCpNHis3sN2e8OofZ3cC0OnUKeE3oOEG8OpmboOjPhA1SAAhEOypoKqiKOukENqyogLKzioafqeZ+uzKEuEyLoqULtPIvpymoP+LMcfsGk7t1z3u5F7u5n7u6J7u6r7u7N7uX5KK22IBSSruljCFbO7utODtz9cdfp4JICAAMI7vsQAq3cIC6cfvAHABAgADNGcCoKd+BhACDY8I3QEDIVDsSpd7/97hC3/x9C7wadsrxVIezaeSNljyAGDfIcArICg3NhgrHBDmBMDq9FHysfLpIN/RIv/gzQcA0dnzBugdK2iL5QGsI//zkx4rOb9sO0/yGov0G6sq30H0Pm5zRz8rPR/1S6/zADLyWg/1u66pMLBwu26aXm/0IY71k571W6/ZTf/1am9Iv5qAIYDzhvTgaL8tca/1bb8Med734gACLQ/4hF/4hn8M+Iif+Iq/+IyvOYEAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Exercise-induced bronchoconstriction (as measured by a fall in FEV1) is attenuated when a second exercise challenge is performed one hour after an initial challenge.",
"    <div class=\"footnotes\">",
"     FEV1: forced expiratory volume in&nbsp;one second.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_34_40493=[""].join("\n");
var outline_f39_34_40493=null;
var title_f39_34_40494="Fourth metacarpal oblique shaft fracture";
var content_f39_34_40494=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fourth metacarpal oblique shaft fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This lateral radiograph shows a long oblique fracture of 4th metacarpal shaft. Although minimally displaced, this fracture is at high risk for subsequent proximal displacement (ie, shortening)&nbsp;of the distal fragment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Josh Bloom, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_34_40494=[""].join("\n");
var outline_f39_34_40494=null;
var title_f39_34_40495="Inspiratory Arteriogram Celiac Artery Compression Syndrome";
var content_f39_34_40495=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inspiratory Arteriogram Celiac Artery Compression Syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 287px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A lateral arteriogram with widely patent origins of the celiac artery (most superior vessel) and SMA (inferior vessel). This image was taken upon end-inspiration in a patient suspected of having celiac axis syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Sherry Scovell, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_34_40495=[""].join("\n");
var outline_f39_34_40495=null;
